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Summary 
Cancer is increasingly being viewed as a metabolic disease. Research shows the 
importance of metabolism to cancerous traits such as metastasis, invasion, drug 
resistance, growth, evasion of apoptosis or immune system. Therefore, 
understanding how metabolism adapts to support the growth of tumours could 
lead towards the optimization of current therapeutic approaches and the 
development of new treatment options, which would help to overcome multi-drug 
resistance traits. 
In this study we represent a systems biology approach to identify biomarkers and 
therapeutic options of breast cancer through the analysis of breast cancer 
metabolism. The metabolism of breast cancer was explored in the context of 
personalized genome scale metabolic models (GSMNs) by combing gene 
expression data with currently the most comprehensive GSMN Recon2 by using 
the GEBRA algorithm. GEBRA algorithm ensures maximum congruency between 
gene expression data and metabolic genes present in the GSMN while satisfying 
various constraints (stoichiometry, mass balance, thermodynamic) to generate 
metabolic landscapes. 
We performed analysis using microarray data derived from the Metabric study, 
consisting of 2,000 individual breast tumours and 131 matched normal breast 
tissue samples. In addition, this study was complemented with publicly available 
gene expression datasets of breast cancer cell lines (MCF-7, MDA-MB-231, and 
MCF-10a), and breast cancer stem cells. 
The performed metabolic analysis of the Metabric Discovery set (997 patients) 
identified a novel poor prognosis group, which was reproduced in the validation 
set (995 samples). We further explored the hypothetical metabolic adaptations 
elicited by the poor prognosis tumours and established serotonin production to 
be an important trait of the poor prognosis group. In addition, the analysis of 
breast cancer stem cells suggested the prostaglandin synthesis pathway to play a 
major role in breast cancer stem cell maintenance and development.  
Our data supports the reconsideration of the synergistic use of selective serotonin 
uptake inhibitors (SSRIs) and prostaglandin synthase inhibitors along with the 
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chemotherapeutic regimens used to treat breast cancers.  
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 1 
1 Introduction 
1.1 Mammary gland and cancer 
1.1.1 General introduction 
Breast cancer is a group of diseases, described as the most prevalent female cancer 
type world-wide; solely in the UK accounting for 31% of diagnosed cancer cases 
[9, 10]. The improved diagnosis and treatment of breast cancer have increased 
mean survival and relapse free time, such that 85% of breast cancer diagnosed 
women survive the next 5 years [11-13]. However, the main problem impeding 
the successful treatment of an individual is the development of multi drug 
resistance (MDR) to the currently used therapeutics. It is estimated that 25-40% 
of patients develop a metastatic cancer that is relatively incurable due to the 
development of resistance [14]. Therefore, despite improved treatment, diagnosis 
and screening programs, breast cancer remains a leading cause of death. The 
heterogeneity of breast cancer tumours and the multifactorial systems involved in 
the maintenance of tumour traits are the main reasons impeding the development 
of new therapeutic approaches. A vast repertoire of factors can contribute to the 
MDR phenotype such as efflux transporters, metabolism (Warburg or reverse 
Warburg), the progenitor cancer cell, molecular type, microRNA levels and other 
factors. Therefore, the traditional reductionist approach is not efficient enough to 
explain the molecular and biochemical mechanisms involved in breast tumour 
development. This study employed a systems biology approach to overcome the 
complexity in order to better understand metabolism in breast tumours and offer 
potential molecular targets capable of improving treatment.  
1.1.2 Breast tissue architecture, development and aetiology of the disease 
The mammary gland (breast) is a glandular, fibrous organ that produces milk to 
suckle young. It undergoes a number of growth and regression phases associated 
with the developmental changes occurring over the course of puberty, pregnancy, 
lactation or involution [6, 15, 16]. Figure 1 shows the anatomical structure of the 
female breast, consisting of several types of specialized cells and tissues that form 
a branching ductal structure in order to accommodate its biological functions. The 
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ductal system consists of the inner luminal cells lining the ducts and milk 
producing cells, and the outer layer cells that touch the basement membrane and 
contract in response to oxytocin [8]. Due to this contractile function, the outer 
layer cells resemble smooth muscle cells and, therefore, are named 
myoepithelium.  
The mammary gland undergoes cycles of growth and regression; therefore, it 
must contain undifferentiated cells with unrestricted proliferative abilities. Fully 
mature mammary gland cells (luminal and myoepithelial) arise from these breast 
tissue stem cells in a hierarchical manner. Several lineages of pluripotent breast 
cells have been identified and have been shown to be capable of forming the entire 
mammary gland [17]. In addition, it has been shown that these lineages arise from 
a single progenitor cell population [6]. Cell division, during the cycles of growth 
and regression, increases the likelihood of spontaneous DNA mutations being 
fixed into the cell lineage leading to the development of cancer. Figure 2 details 
the proposed scheme of normal breast tissue development, and how this may be 
reprogrammed during breast cancer development. As can be seen, the 
differentiation of breast cells from their progenitor stem cells occurs in stages, 
with cancerous cells potentially arising at any developmental stage or during 
transition between the phases. Consequently, several defined breast cancer 
classes can be seen as emerging from different points in this hierarchical 
development. Such a speciation of breast cancer would be consistent with the 
identified molecular classes and also consistent with general cancer stem cell 
theory [18].  
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  A) 
B) 
Figure 1 – Structure of the mammary glands 
A) The anatomy of the female breast. Breast tissue consists of vast network of ducts that branch through fatty 
tissue. Hormonal stimulation drives growth and regression of ducts and milk secreting cells during the various 
cycles of puberty, pregnancy etc. Mammary glands contain at least 3 lineages of pluripotent cells – myoepithelial, 
ductal and milk producing [6]. Historically, breast cancers were named after their morphology, such as ductal or 
lobular. However, it was shown that regardless of histological types, the majority of breast cancers originate from 
the terminal duct lobular units. Lymph nodes are examined to confirm the presence of metastasis and help to 
indicate the aggressiveness of cancer and treatment options. Image adapted from Dontou et al [6]. B) Picture 
shows a haematoxylin and eosin –stained portion of a mature adult breast [8]. Image adapted from Gortesou et 
al [8]. 
 4 
 
  
Figure 2 - Development of mammary gland cells and process of carcinogenesis. 
Breast tissue contains stem cells that give rise to all the differentiated cells. However, sometimes 
these cells acquire genetic mutations leading to the development of cancer. This figure shows a 
simplified version of cancer development, based upon the 5-6 different molecular classes of cancer 
currently defined (6). Image adapted from Dontu et al [3, 4]. 
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1.1.2.1 Introduction to the aetiology of the breast cancer  
Even though the ductal system of the mammary gland is comprised of two cell 
types, the process of differentiation creates a hierarchical epithelial structure [8]. 
It is widely accepted that, with rare exceptions, breast cancers occur in the 
terminal tubules from luminal and myoepithelial cells and hence, depending on 
the majority cell type, are named luminal or basal [8]. However, it is important to 
note that for classification purposes, the majority of cells present in the tumour 
decide the breast cancer type, with tumour heterogeneity ignored. Hence, it is 
possible to have a basal tumour with a large percentage of luminal cells, and vice 
versa. In addition, it is not clear whether breast cancers develop from terminally 
differentiated cells, differentiating cells or stem cells. The current evidence 
supporting the development of breast cancer is not conclusive. 
In addition to classification by the major cell component, several additional 
classifications have been proposed based upon the molecular signature within 
breast cancer cells (classification is discussed further in section 1.2). 
To add further complexity, breast tumours can also be hereditary. Such tumours 
are associated with germ-line mutations in genes such as BRCA1 and BRCA2, and 
account for 5-10% of breast cancer cases, with the other 90% due to de novo 
mutations [19]. The majority of BRCA1- and BRCA2-associated cancers exhibit an 
aggressive phenotype with poor prognosis, and is associated with the basal 
molecular class [20-22]. 
In summary, the mammary gland contains stem cells that divide and differentiate 
to populate the entire tissue. Differentiation of breast tissue cells occurs in 
transitional stages during normal developmental and, possibly, cancerous 
transformation. Such hierarchical carcinogenesis would explain the existence of 
several diverse molecular cancer classes, which contribute to the heterogeneity of 
breast cancers. Two theories explain the establishment and progression of cancer 
(clonal evolution theory and hierarchical development, discussed further in the 
next section), and it is possible for both theories to act simultaneously.  
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1.1.3 Progression of cancer and tumour heterogeneity 
The development of cancer is a dynamic process, which starts with benign 
tumours that, due to Darwinian evolution, progressively become metastatic, drug 
resistant, immune reaction invisible entities. Two of the greatest challenges in 
treating breast cancer are tumour heterogeneity and the development of multi 
drug resistance. Heterogeneity of tumours may limit the potential therapeutic 
efficacy of any drug, and often require a mixture of chemotherapy agents to be 
used for a successful response [23]. In addition, this heterogeneity may drive the 
development of drug resistance with therapies effectively selecting for those cells 
that they cannot kill. The development of drug resistance will be described in more 
detail in section 1.4. 
Spatial and temporal heterogeneity terms are used to define cancer development 
in general and heterogeneity has been an observed phenomenon for many years. 
Intratumoural heterogeneity is a dynamic process that changes spatially and over 
time, due to molecular cancer evolution and in response to environmental factors 
such as immune reaction response, lack of oxygen or presence of xenobiotics [24]. 
Spatial heterogeneity describes the existence of genetically different cancer cells 
regions within the tumour and differences between initial tumour and metastatic 
sites. For example, a standard classification for breast tumours relies on the 
different Oestrogen (ER), Progesterone (PGR) and HER2 receptor expression 
levels in tumour sections [25]. However, the true extent of spatial molecular 
heterogeneity has only been recently demonstrated, through the use of high 
throughput techniques, which identified a high-level of previously unknown 
genetic heterogeneity within distinct tumour regions [26]. In comparison, 
temporal heterogeneity is an evolution of cancer cells during the progress of the 
disease from in situ to metastatic. For instance, unrestricted growth rate is a 
primary trait of cancer cells, which favours the fastest growing clones under the 
lack of environmental pressures (nutrients, drugs, space); in contrast the slower 
growing clones gain the advantage when resources (oxygen, glucose) are depleted 
or xenobiotics are introduced [27]. In an additional example, cancer cells lacking 
a specific tumour antigen may survive the immune reaction response and as a 
result outgrow the other clones within the tumour. To summarize, tumours 
consist of heterogeneously different cells containing different proliferative and 
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metastatic abilities, resistance to chemotherapy, metabolic types, as well as 
stromal cells that are present in the tumour microenvironment to support cancer 
growth [28].  
The heterogeneity can be explained by the clonal evolution theory, stating that 
acquisition of genomic abnormalities leads to the co-existence of different cancer 
cell clones within a tumour [29]. However, clonal evolution theory is challenged 
by the hierarchical clonal evolution model (or cancer stem cell model), stating that 
tumour heterogeneity is controlled by stem cells in a similar fashion to the normal 
breast tissue cells (Figure 2) [30]. Figure 3 summarizes clonal evolution and 
cancer stem cell theories. An accumulating amount of evidence dictates cancer 
stem cells to be a driving force of tumours; however, it is not clear if sporadic 
mutations must occur at the stem cell level, or if differentiated cells can revert to 
the stem cell phenotype. As a result, both theories are discussed without a clear 
consensus [31]. Also, it is important to emphasize that each cancer cell is subjected 
to acquire mutations, hence is affected by clonal evolution theory. Therefore, 
clonal evolution and CSCs theories could coexist together.  
1.1.3.1 Clonal evolution theory  
Clonal evolution theory is the oldest theory of cancer development, first suggested 
by Peter Nowel in 1976 [29]. Clonal evolution theory states that cancer develops 
from single cells and heterogeneity is established due to genetic instability and 
environmental pressure, eventually resulting in an aggressive disease. This theory 
is at least partially right, as it is clear that cancer can develop only from cells 
already exerting a proliferative trait (without terminal differentiation) and such 
cells would resemble or could retain a potential to revert to stem like cells [32]. 
Additionally, stochastic mutations would explain clonal similarities between 
initial and metastatic tumours; however, so would the existence of stem cell-like 
cancer cells (explained further in Figure 3 ).  
1.1.3.2 Hierarchical evolution or cancer stem cell model 
The cancer stem cell model states that tumour cells divide in a similar hierarchical 
organization as healthy breast cells and tumours are maintained by breast cancer 
stem cells (BCSCs). BCSCs are tumour propagators that further undergo slow 
asymmetrical division and, as a result, give rise to faster dividing cells. These cells 
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in turn divide in a symmetrical fashion and undergo cellular differentiation, 
creating heterogeneous cancer cells (Figure 3). The origin of BCSCs is not clear, as 
BCSCs can develop abnormal stem cells or revert back to progenitor cells that have 
not lost proliferative ability. Evidence has demonstrated that basal type breast 
cancer cells can revert back to stem cell phenotypes, suggesting that cancerous 
transformation may not be a unidirectional process [33]. However, it should be 
noted that basal type cells already resemble stem cells in many of their traits; it is 
not clear if more differentiated cancer cells retain the ability to dedifferentiate to 
a stem cell-like phenotype. A great amount of evidence shows the importance of 
BCSCs, however, the development of BCSCs has not been definitively proven. For 
example, it is possible that stochastic events revert partially differentiated cells 
back to stem cell-like phenotype, rather than stem cells being the progenitor cell. 
Despite this caveat, over the last decade a compiling amount of evidence has 
emerged supporting the importance of BCSCs for the development of tumours, 
metastasis and drug resistance.   
1.1.3.3 Micro-environment co-evolution theory 
In recent years, a third theory explaining tumour heterogeneity has been 
proposed: tumour co-evolution with the extracellular environment [34]. This 
theory is based upon the premise that cancer cells are capable of transforming the 
stroma surrounding them from a hostile to a supportive environment for growth. 
This change is possible because cancer cells can secrete molecules that either 
modify the extracellular environment directly, or act as chemo attractants for 
different cells (e.g. fibroblasts, mast cells), which in turn promote the development 
of cancer by secreting various signalling molecules. For example, highly 
tumorigenic cancer cells (stem cells) have been shown to overexpress hyaluronan 
synthase (HAS2), which promotes interaction with tumour-associated 
macrophages; these, in turn, secrete signalling molecules such as PDGF-BB, to 
promote cancer cell self-renewal and activate other stromal cells [35]. 
Furthermore, breast tumour-associated mast cells were shown to secrete 
tryptase, which increases invasiveness, migration and proliferation rate of cancer 
cells [36]. This secretion of tryptase is likely to be due to stimulation by tumour 
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cells, as breast tumours contain higher proportions of tryptase-secreting mast 
cells over benign tumours [37, 38].   
The relationship between tumour and stroma cells is not unidirectional, with 
evidence supporting the impact of stromal cells on tumour cell phenotype as well. 
For example, cancer-associated fibroblasts, which have previously been attracted 
by breast cancer cells, secrete IL-6. This results in the down regulation of ER 
expression in breast cancer cells and, hence, drug resistance to ER targeting agents 
such as tamoxifen [39]. Similar stroma-cancer cell interactions have been 
documented for some melanoma cancers, where alterations granting drug 
resistance have been identified in the environment, but not cancer cells 
themselves [40]. Cancer cells shape the extracellular environment to attract cells 
supporting growth and in return stroma cells are able to affect gene expression of 
cancer cells creating heterogeneous populations. 
1.1.3.4 Conclusions of tumour heterogeneity  
The truth of breast cancer heterogeneity lies between all three of the above-
mentioned theories. In fact, it is the most likely that all three theories occur at the 
same time, each contributing towards the phenotypic development of a tumour. 
However, the weight of evidence supports cancer stem cells as taking the largest 
role in the establishment and development of breast tumours, as well as creating 
intratumoural heterogeneity. Hence, the field of breast cancer stem cells will be 
discussed in more detail in the next section. 
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1.1.4 Brest cancer stem cells (BCSCs) 
The theory of cancer stem cells is relatively new and not only does it provide a 
compelling explanation for intratumoural heterogeneity, but also for tumour 
relapse, development of metastasis and development of drug resistance. Despite 
breast tumours being inhabited with a large number of highly proliferating cells, 
Figure 3 – Comparison of clonal and cancer stem cell (CSC) models.  
The CSC model states that stem-cell like cancer cells drive tumours. The mutation within a cancer stem cell 
changes its phenotype and as a result impacts further differentiation processes. The mutated stem cell becomes 
a cancer stem cell, and further asymmetrical division creates a heterogeneous population of cancer cells, as 
well as a persistent population of cancer stem cells. The newly formed cancer stem cells and cancer cells are 
further subjected to acquiring additional sporadic mutations. In comparison, the clonal evolution theory states 
that tumour heterogeneity is driven by sporadic mutations, which can occur to any cell within a mammary 
gland. The acquisition of sporadic mutations is the key mechanism responsible for the heterogeneous nature 
of cancer cells within a tumour. However, both models could occur simultaneously. 
 11 
research has shown that only a small fraction of these cells are capable of initiating 
new tumours. The initial study demonstrated that as little as 100 cells, isolated 
from breast cancer patients, were capable of establishing tumours in 
immunocompromised mice [41]. Importantly, these cells had a very specific 
phenotype, whilst thousands of other cell phenotypes failed to initiate tumours. 
Therefore, these cells were termed breast cancer stem cells. It is of note that the 
heterogeneity of cancer cells in newly formed tumours has been shown to be 
similar to the heterogeneity of original site, suggesting that heterogeneity is at 
least determined by the initial metastatic cells [42]. 
For a long time it was thought that the ability to establish tumours (both locally 
and at remote sites) and then to proliferate was innate to every cell within a 
tumour. However, this theory was disproven by demonstrating that only a subset 
of cells (cancer stem cells; CSC) were able to retain the ability to establish tumours 
at distant sites in low numbers, while non CSCs fail to do so. To clarify, BCSCs is 
used to emphasize cancer stem cells strictly originating from the breast tumours, 
whereas CSCs is used to define stem cells of other tumours. Whilst cancer stem 
cells of different tumours retain similar features, there might be slight molecular 
differences that have not been discussed in the literature.  
The term phenotypic plasticity is used to describe the ability of cells to establish a 
tumour at a distant site even when its phenotype is distinct from the cells at this 
remote site [43]. Evidence strongly suggests that BCSCs or cancer stem-like cells 
are the major drivers of breast cancer plasticity and underlie the preponderance 
for breast tumours to metastasize successfully. In support of this, a growing body 
of evidence describes different plasticity levels between CSCs, non-CSCs and 
different types of BCSCs [35, 41].  
1.1.4.1 BCSCs types 
Research revealed two functional types of breast cancer stem cells and has shown 
that cells may transition between the two functional states [5]. Epithelial-like 
BCSCs (also called mesenchymal to epithelial transition, MET) are characterized 
by the cell surface markers, CD44+/CD24-/low , and expression of aldehyde 
dehydrogenase (ALDH) [5]. They are typically centrally located within the 
tumours and contain higher proliferative and tumour initiating abilities [5].  
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Mesenchymal-like BCSCs (also known as epithelial to mesenchymal transition, 
EMT) are defined by the CD44+/CD24-/low phenotype. These mesenchymal-like 
BCSCs tend to be localized at the edge of the tumour, close to stromal cells, and are 
quiescent (Figure 4). As noted above, BCSCs can transition between these two 
functional states, which is proposed to determine the metastatic potential of 
tumours, as mesenchymal-like BCSCs are capable of metastasizing and 
establishing new tumours at distant sites [5]. During the EMT, epithelial-like stem 
cells undergo morphological transformation to become mesenchymal-like 
through cytoskeletal reorganization and subsequent loss of polarity, morphology 
and cell-cell contact [44]. Research shows that the transition between the 
epithelial and mesenchymal type cancer stem cells is a reversible process, with 
the balance being dependent upon the tumour microenvironment [5]. 
1.1.4.2 BCSCs and metastasis 
In addition to their role in metastasis, BCSCs have also been implicated in the 
development of the overall tumour prognosis phenotype. As discussed above, the 
transition of BCSC from epithelial-like to mesenchymal-like is mediated by 
stromal cell interactions, and facilitates metastasis of BCSCs. Due to this; 
metastatic breast cancer lesions are enriched with BCSCs, providing them with a 
high phenotypic plasticity. Tumours that exert poor prognosis phenotypes have 
been shown to be enriched with BCSCs and CSCs [41]. For example, the aggressive 
phenotype of triple negative breast cancer is directly associated with the presence 
and number of BCSCs [41]. Supportive of this hypothesis, it is not surprising that 
the gene expression profiles of highly aggressive tumours overlap with that of 
stem cells. However, it should be noted that it is unclear the exact causal 
relationship for these similar expression profiles (e.g. do the stem cells drive the 
overall tumour gene expression profile, or vice versa). Cancer stem cells are 
similar to normal stem cells, and accordingly contain mechanisms associated with 
resistance to drugs and radiation. Therefore, BCSCs are naturally highly resistant 
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to current therapeutics, in addition to slow growth and quiescent phase, holding 
a higher chance of surviving general cytotoxic therapeutic regiments, 
subsequently causing a relapse.  
  
Figure 4 Summary of BCSCs.   
BCSCs exists in two functional states (Epithelial like and Mesenchymal like, also called MET and EMT, respectively). 
MET and EMT type cells exert abilities of self-renewal, differentiation and plasticity to transition between the states. 
The EMT cells exert lower proliferative rates, but are invasive, metastatic and upon establishing tumour at a distinct 
site are able to revert to MET phenotype. In contrast, MET type BCSCs are centrally located and exert higher proliferative 
rates, contributing to the tumour growth [5].  
BCSCs resemble normal stem cells and therefore exert a resistance to the drugs. Theory states those BCSCs that survive 
chemotherapy and re-establish tumours with cells contain multi-drug resistance trait. More importantly, research has 
demonstrated that relapsed tumours, as well as aggressive tumours and invasive breast cancer cells, contain higher 
number of BCSCs.  
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1.1.4.3 BCSCs and resistance to drugs and radiation 
A number of studies have linked BCSCs with the development of multiple drug 
resistance phenotype, consistent with their association with poor prognosis 
tumours [45]. Research has demonstrated that BCSCs isolated from breast cancer 
cell lines, primary mouse tumour models and patient-derived xenografts all retain 
an innate multiple drug resistance phenotype, plus resistance to ionizing radiation 
[1, 46]. Additionally, research has demonstrated that tumours treated with 
neoadjuvant chemotherapy became enriched with BSCSs, and that these BCSCs 
exerted a higher mammosphere forming ability [47]. Breast cancer lesions were 
enriched with BCSCs after neoadjuvant and endocrine therapies. The residual cells 
demonstrated mesenchymal profiles, increased invasiveness, mammosphere 
formation capabilities and possible drug resistance, as these cells have survived 
chemotherapy. In addition, a great number of studies confirmed that BCSCs exert 
enhanced invasiveness, intrinsic drug resistance, high efflux transporter activity, 
boosted DNA damage repair mechanisms and anti-oxidant activity [46]. Such data 
suggests that not only do BCSCs possess a resistant phenotype, but that 
chemotherapeutic treatment may actually select for them, increasing the overall 
drug resistance capacity of the tumour.  
While it is not evident if breast tumours arise from mutated stem cells or 
differentiated cells that have reverted to a stem cells phenotype, it is becoming 
increasingly clear that CSCs drive and sustain tumours. In addition, there is 
increasing evidence that CSCs are responsible for tumour heterogeneity, 
metastasis, multi drug resistance and general development of cancer. It is 
important to emphasize that poor prognosis breast cancer groups, as well as cell 
line models that represent poor prognosis drug resistant tumours, are enriched 
with BCSCs [48].  
Therefore, the multi drug-resistance trait in breast cancer may be related to the 
presence of BCSCs and these cells should be investigated and selectively targeted.  
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1.2 Classification 
1.2.1 Overview  
Classification is one of the ways used to summarize knowledge, as well as a tool to 
identify patterns, traits, and derive predictions. Through classification, knowledge 
is divided into categories of similar characteristics; for example the classification 
of chemical elements by Mendeleyev, or that of animals by Carl Linnaeus. Medicine 
is no exception; categorization of diseases is a central method for diagnosis, 
survival prediction and treatment prescription. Historically, cancers have been 
classified by the organ of origin, and such classification encompasses near 200 
cancer types. Organ-centric classification can be further stratified using 
demographics such as age (childhood leukemia) or cell of origin, meaning the total 
number of cancer types increases dramatically. At one extreme of classification, 
each unique tumour could be classified as a unique disease, but such an approach 
would not aid diagnosis, nor treatment. Rather, classification levels must be set to 
sufficiently differentiate tumours to ensure separation of those that respond 
differently to therapeutics, for example, without resulting in so many 
classifications that the entire system becomes unwieldy. Therefore, a strong, 
repeatable and accurate cancer classification is required to identify common 
patterns and traits, leading to successful disease management and cure. 
1.2.2 Molecular classification 
As previously stated, breast cancer is a heterogeneous group of diseases affecting 
breast tissue. It consists of several unique groups, each exhibiting a distinctive 
molecular portrait, histological properties and clinical behaviour [10]. This 
heterogeneity introduces a significant complexity toward the classification of 
breast cancer, impeding research and the development of effective treatments of 
the disease. Historically, classification of breast cancer was based on histological 
analysis, providing major properties such as tumour grade, stage, location and 
type. Such histological classification led to development of the World Health 
Organization breast cancer descriptor set, made up of at least 18 different 
subtypes [10]. However, the publication of microarray studies for breast cancer 
changed the perception of breast cancer classification, demonstrating the 
limitation of morphological and histological classification systems, as different 
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molecular tumour types were shown to exhibit identical histopathological 
features [49]. The first gene expression profiling experiments revealed existence 
of four different molecular classes (Luminal like, Basal like, Normal, and HER2 
enriched) [49]. Further investigations performed with the aim of improving 
clinical screening have suggested the existence of further groups; however, the 
data supporting these is often contradictory and hence they are not fully 
supported [50, 51]. Figure 5 summarizes the currently accepted molecular types 
of breast cancer. It is well known that histologically identical tumours can have 
different clinical prognosis and therapeutic response: such inconsistencies can be 
explained by the existence of several different molecular classes of breast cancer 
underlying these histologically similar tumours [52]. Therefore, it was suggested 
to replace the traditional classification based on the clinicopathological and 
immunohistological features by the molecular taxonomy [53]. While molecular 
classification overcomes shortcomings of histological classification, it encounters 
its own unique limitations. Due to the lack of consensus and clear definition of 
molecular and immunohistochemical classes, the currently used groups are not 
discussed in detail and instead an overview is given regarding strengths and 
limitations of clinically used methods currently utilized for identification of breast 
cancer groups.  
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Figure 5 – Molecular classification of breast cancers  
Microarray technology was used to acquire gene expression profiles of various breast cancers. A) 
Hierarchical cluster analysis classified breast cancer into several molecular groups based on gene 
expression profile. Image adapted from Perou et al. B) Table compares molecular classes of breast 
cancer. Currently 5 groups are recognized (luminal A and B, normal, HER2 and basal like); new 
groups are emerging, but are currently considered as a subgroups of basal-like tumours, and 
include claudin-low. The normal-like molecular class is argued to be a molecular artefact arising 
due to imperfect techniques. Each class is defined by having unique gene expression patterns, as a 
result contains diverse intra and extracellular networks enabling the use of target therapies [50, 
54-56]. 
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Although it is generally accepted that breast cancer can be classified into 
molecular classes, the exact method of this classification itself is still under debate 
[50]. Intrinsic molecular groups of breast cancer are commonly determined 
through gene expression data (microarray, qPCR etc.) [50, 57]. In order to achieve 
the required detection and classification precision, a robust number of molecular 
classes are required. Currently, the number and types of molecular classes is 
undecided, and no clinically reliable molecular classification tool exists. This lack 
of agreement has largely been driven by different gene expression arrays 
providing different genetic information, leading to array-specific results. For 
example, different microarray platforms contain unique probes, and target unique 
genes, which in turn affect the detection of gene expression. Additionally, as 
discussed above, heterogeneity within each tumour (intratumoural) is common in 
breast cancer. This means that one tumour may in fact belong to several molecular 
classes at the same time. Moreover, this unique tumour composition may suggest 
that each tumour is, in reality, its own molecular class, and should be treated as 
such. While this level of classification is obviously impractical, it does show the 
difficulties with using a higher resolution classification system; it reveals the 
inherent differences between (and within) tumours. Therefore, the complexity 
and heterogeneity of breast cancer can be argued to impede the development of 
reproducible and clinically reliable methods for molecular classification. As a 
result, detailed molecular classification currently adds little to the determination 
of therapeutic treatment and is of limited usage in the clinical setting. However, 
despite this limitation, molecular taxonomy still can aid in decision-making, 
biomarker detection and detection of novel treatment options. Controversially, all 
methods of detection can be correct at the same time, as tumours consists of 
heterogeneous cancer cell populations, with each cancer cell sub-population 
having a progenitor cancer stem cell and being affected by the clonal evolution. 
1.2.3 Methods of molecular classification 
To attempt to breakthrough this impasse, a number of different approaches are 
being used. Firstly, new generation platforms are being used to generate deep-
level omics data, with the aim to identify novel breast cancer molecular groups. 
Secondly, it is becoming clear that rather than shying away from data, it may be 
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necessary to embrace more data. The combination of several different levels of 
information, such as gene expression data, epigenetic landscape and gene 
sequencing data, can enhance molecular classification as each level complements 
and constrains the overall molecular landscape. This will ultimately lead to the 
discovery of new molecular classes that are more comprehensive in their 
classification. 
Single sample predictors (SSP) were developed to aid microarray-based 
classification by comparing expression of a gene for a sample with the average 
gene expression (centroid) for each molecular subtype [50]. Currently there are 
three different SSPs that have been developed: PAM50, Hu’s SSP, and Sorlie’s SSP 
[50]. Obviously, the fact that more than one SSP has been proposed raises a clinical 
issue, as it is unclear which to use. Each of the proposed SSPs has a unique number 
of gene centroids for assignment of breast tumours into one of the five main 
groups (Basal, Luminal A, Luminal B, HER2 and Normal). A comparative study has 
been performed to evaluate the clinical usefulness of these currently available 
SSPs, comparing both the agreement of class assignment and class-specific 
prognostic associations [58]. While basal-type tumours can be consistently 
classified with each of the SSPs, the other intrinsic groups exhibit only fair to 
moderate correlation between SSPs [50]. In addition, HER2 assignment by SSPs 
poorly correlates with clinically determined HER2 positive cases [50, 59]. This 
lack of correlation with intrinsic groups may represent issues with the SSPs, the 
intrinsic classifiers, or more likely both. Molecular grouping performed by SSPs is 
able to categorize tumours into groups with distinctive survival prognosis [50]. 
Although, these are not clinically accurate enough, classification by SSPs does add 
significant prognostic and predictive power to the immunohistochemical 
evaluation [59]. Of the three SSPs, PAM50 is most commonly used, despite the 
acknowledged severe shortcomings of this SSP [60-63]. The PAM50 SSP detects 
five molecular groups, of which one, the normal type class, is considered an 
experimental anomaly [54]. Considerable evidence suggests that this group is an 
experimental anomaly introduced by the contamination of the tumour sample 
with normal tissue cells [64]. Additionally, the inclusion of a normal cell type 
predictor may have biased the other classifications, resulting in Luminal B 
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tumours being presented as Luminal A. This can provide an inaccurate prognostic 
value and suggested therapeutic regimen as Luminal B tumours contain a higher 
proliferation capacity and require a more aggressive chemotherapeutic regimen 
compared to Luminal A tumours [65]. Lastly, the five subtypes employed by 
PAM50 classification are inadequate to fully stratify tumours, as evidence strongly 
supports the existence of more than 5 molecular groups (Figure 5).   
To summarize, there are a few causes impeding accurate classification of breast 
tumours: firstly, not all molecular groups have been identified or established. 
Secondly, the major molecular groups may not be fully distinct, and can be further 
divided into transitional stages [59]. For example, the recent Metabric study 
suggested the existence of 10 intrinsic groups, each exerting a distinct outcome, 
and consisting of group specific genomic aberrations [66, 67]. These suggested 
molecular groups do not correlate with PAM50 classes, the major SSP [66]. 
Thirdly, breast tumours can belong to several molecular groups simultaneously 
due to intratumoural heterogeneity. As a result, classification into intrinsic 
groups, though clinically used, still requires improvement: better class-specific 
molecular markers, clear definition of intrinsic groups and internationally 
accepted guidelines to unify studies [8]. Therefore, in order to overcome the 
shortcomings of molecular classifiers, immunohistochemical methods are still the 
primary determinant of intrinsic molecular groups.  
1.2.3.1 Immunohistochemical approach to identify molecular groups 
Immunohistochemical classification (IHC) is the only clinically reliable alternative 
to microarray-based classification and targets well defined molecular targets such 
as oestrogen receptor (ER), progesterone receptor (PGR) or human epidermal 
growth factor receptor (HER2) [68]. Nonetheless, there are also certain issues 
associated with its usage. Firstly, there are no internationally accepted guidelines 
for the determination of molecular intrinsic groups using IHC methods [8]. 
Therefore, the proposed molecular classifications groups are often study 
subjective (like Luminal B, HER2-, Luminal B HER2+) with the number of 
molecular groups and group specific markers varying between studies [69, 70]. 
Secondly, the lack of defined molecular groups impedes classification (using IHC 
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methods), as different molecular targets are chosen to classify groups, potentially 
leading to misclassification [8].  
1.2.3.2 Summary of the molecular classification 
Due to the limitations of both molecular- and IHC-based methods, their clinical 
usage has not yet been fully exploited for an accurate identification of intrinsic 
molecular breast cancer groups. For example, decisions of breast cancer 
treatment are still based on clinicopathological properties such as age, tumour 
size, histological grade, lymph node metastasis and lymph or vascular invasion. In 
addition, the molecular classifiers of the ER, PGR and HER2 receptors are the 
commonly targeted by the IHC methods [54]. While immunohistochemical 
classification is the main method for identification of breast cancer groups, the 
molecular classification using SSPs into intrinsic molecular classes also can 
considerably aid in decision making of potential therapeutic regimens and risk 
assessment for each patient [71]. Nevertheless, molecular classification of breast 
tumours is only marginally exploited to its full potential, due to lack of consensus. 
While intrinsic molecular subtypes cannot fully be identified using IHC methods 
alone, the PAM50 classification offers only limited clinical value [72]. 
Nevertheless, the rapidly developing technology provides additional insight into 
tumour genetic composition and in the near future the consensus and accurate 
classification methods may be reached. However, currently a combination of IHC 
and molecular classifiers is utilized to identify the most appropriate patient 
specific therapeutic regiment.  
1.2.4 Biochemical classification   
One of the hallmarks of cancer is deregulated metabolism. This has been 
classically described by the Warburg effect, a shift in energy production pathways 
to generate most of the ATP via glycolysis in the presence of oxygen [73]. 
Conversely, a growing body of evidence describes a new phenomenon called the 
reverse Warburg effect, explained by the catabolic symbiosis between the tumour 
and the surrounding stromal cells [74-76].  
The reverse Warburg effect is attained through the close relationship between 
tumour cells and the surrounding fibroblasts; this has been described as 
equivalent to the connection between fast and slow twitch muscles [74]. In muscle 
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cells, fast twitch fibres undergo glycolysis and secrete pyruvate and lactic acid, 
which is consumed by the adjacent slow twitch fibres and utilized through 
oxidative phosphorylation to generate ATP. It has been suggested that cancer cells 
utilize an analogous system to exploit the metabolic capacity of the surrounding 
stromal cells [74]. In this model, tumour cells stress fibroblasts by secreting 
reactive oxygen species (ROS) and interleukins, leading to fibroblast stress and 
chemoattraction of lymphocytes, respectively. These actions engage a destructive 
cycle, by which increased levels of ROS and nitric oxide species are released. As a 
result, the surrounding stromal cells undergo autophagy and catabolism, secreting 
metabolites that are fed into the citric acid cycle of the cancer cells. Through this 
action, it has been observed that some tumours may even increase their 
mitochondrial content [77].  
To investigate the metabolism of triple negative breast cancers (TNBC), a clinical 
study was performed in which the metabolic landscape of 132 tumours and 
surrounding stroma were assessed through tissue microarrays. The expression of 
GLUT2 and CAIX suggested the existence of 4 metabolic tumour phenotypes: 
Warburg, reverse Warburg, mixed oxidative and null [78]. The Warburg metabolic 
phenotype was the most prevalent, while the reverse Warburg phenotype was 
uncommon. However, it should be noted that the employed immunohistochemical 
techniques used were different from similar studies and therefore the 
assignments might not be representative. For example, the study did not include 
Cav-1, a biomarker associated with poor prognosis and a strong indicator of the 
reverse Warburg phenotype [75, 79]. Additionally, the histological grading was 
subjective, and molecular markers were indicated as either present or absent 
rather than by staining strength. As a result, it is appropriate to conclude that the 
Warburg metabolic phenotype constitutes a large proportion of TNBCs, and that 
the proportion of the reverse Warburg phenotype is unclear, although likely to be 
considerably lower.  
Several other studies have been performed to characterize the reverse Warburg 
phenotype, supporting the presence of a subset of poor survival TNBCs employing 
the reverse Warburg effect phenotype [75, 79]. Moreover, the characteristic 
molecular markers of the reverse Warburg effect phenotype correlate with novel 
treatment approaches, such as antioxidants, and drugs inhibiting autophagy, 
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lactate and ketone metabolism or promoting mitochondrial hyperfunction [79, 
80]. In addition with being associated with poor prognosis, the reverse Warburg 
phenotype has been associated with drug resistance; inhibition of the reverse 
Warburg effect has been shown to restore tamoxifen resistance in MCF-7 cell line 
[81]. To add further complexity, another study described a positive effect on 
tumour growth through interaction with glycolytic cancer-associated fibroblasts 
[82].  
The existence of several metabolic breast cancer phenotypes is evident, with the 
reverse Warburg effect attracting an increasing amount of attention. Studies have 
described the reverse Warburg effect, discovered biomarkers, and related it with 
poor prognosis. It has also become increasingly evident that metabolism of breast 
cancer cells plays a central role in carcinogenesis, as well as the maintenance of 
cancer traits. Metabolism is, therefore, an appropriate target for further studies in 
understanding drug resistance and improving treatment options.  
1.2.4.1 Hypoxia and metabolic reprogramming  
The Warburg effect states that cancer cells uses glycolysis as the predominant 
metabolic pathway to generate energy [73]. Upon oxygen deprivation in the 
tumour environment, cancer cells can switch to glycolysis by secreting hypoxia-
inducible factor 1 (HIF-1) which in turn signals in paracrine/autocrine fashion to 
mediate metabolic adaption to compensate shortage of oxygen [83]. However, 
HIF-1 induces metabolic reprogramming not only in response to the decreased 
oxygen availability, but also to the increased ROS production by the mitochondria 
as the increase in ROS production also occurs at the hypoxic condition [83]. 
Research has also shown, that HIF-1 signalling increases the number of BCSCs 
under hypoxic conditions in a concentration dependent manner [84]. It was 
proposed that CSC contain metabolic protection against negative effects of ROS 
[85]. In summary, tumours grow in a hypoxic environment, and a hypoxic 
condition is capable of inducing the metabolic switch regulated by the HIF-1. 
Moreover, the higher HIF-1 concentration not only induces the glycolytic switch, 
but also increases the number of BCSCs.  
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1.2.5 Summary  
Breast cancer is a group of heterogeneous diseases affecting breast tissue. 
Advances in the molecular biology techniques rendered histopathological 
classification system (over 40 histopathological types) obsolete demonstrating 
existence of molecular classes. To complicate the matter further, this molecular 
classification has confirmed that each tumour consists of several cancer cell 
lineages, allowing the same tumour to belong to several classes at the same time. 
Together, these lead to a complex, evolving classification of breast cancer. It 
should be remembered that the purpose of classification is not classification itself, 
but the identification of traits that could be exploited for treatment purposes. 
Therefore, future emphasis should lie on molecular and biochemical traits of each 
tumour rather than assignment of class. Likewise, biomarkers should concentrate 
on identification of tumour traits rather than assignment of a class. This will 
almost certainly result in the expansion of the number of current classification 
markers. For example, triple negative breast cancers as currently classified can 
undertake completely opposite means of energy generation (Warburg vs reverse 
Warburg effects). Likewise, classification of breast tumours as HER2 enriched 
currently aid treatment stratification, it does not contain the molecular resolution 
to allow truly precision medicine, in which the treatment regimen is tailored to 
the individual’s tumour. Finally, it is important to recognize that individual 
tumours consist of several different molecular classes due to intratumoral 
heterogeneity, and that changes of tumour molecular class occur after the 
treatment regimen. Together this leads to a complex, dynamic biological system, 
hindering effective treatment. To this end, novel approaches to understand the 
molecular basis of breast cancer are required.  
1.3 Treatment  
Breast cancer is treated employing surgical resection, radiotherapy and the use of 
pre-operative (neoadjuvant) or post-operative (adjuvant) chemotherapies. The 
recommended therapy, or more usually combination of therapies, depends on the 
properties of the tumour. In the majority of breast cancer cases, surgery is 
employed to remove the primary tumour, with adjuvant chemotherapy used to 
treat the remaining primary tumour cells, plus metastasis. Classical adjuvant 
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therapy involves cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 
combination or the use of antracyclines and taxanes. In this paradigm, the 
chemotherapeutics are non-specific, and hence target only rapidly dividing cells. 
While successful in some cases, this lack of specificity means that a proportion of 
tumours are non-responsive, and the regimen may even select for resistance 
within individual tumours. More recent treatment approaches utilize drugs that 
exploit tumour-specific characteristics, for instance targeting surface receptors. 
At the gross level, such approaches can be classified into three therapeutic groups, 
disregarding the existence of molecular and metabolic groups.  
1.3.1 Hormone-sensitive 
Hormone sensitive breast tumours are oestrogen-signalling dependent; therefore, 
these tumours typically express the oestrogen receptor (ER), progesterone 
receptor (PGR) and endothelial growth factor receptor (EGFR), and often its 
related receptor HER2. Hormone receptor positive cancer constitutes the largest 
proportion of diagnosed breast tumours (approximately 75%). They 
predominantly belong to the Luminal A and Luminal B classifications, with the 
latter being more aggressive and requiring additional treatment. Due to potential 
for targeted therapy against the oestrogen-signalling pathway, the hormone 
sensitive group is associated with the best survival probability and lowest relapse 
rate [86]. 
Endocrine therapy exerts its action by minimizing the proliferative effects of 
oestrogen on oestrogen receptors [87]. This is achieved either through the use of 
anti-oestrogens (e.g. tamoxifen), or by reducing serum and tissue oestrogen 
concentrations by using aromatase inhibitors (e.g. anastrozole) in 
postmenopausal women or ovary ablation in premenopausal women [87]. The ER 
is expressed in around 75% of breast cancers, hence it is a potential target in order 
to reduce cellular proliferation [88]. The third generation AIs such as letrozole, 
anastrozole and exemestane were shown to be very effective and exerted greater 
efficacy than tamoxifen. However, tamoxifen is still a first-line therapy and 
considered the most effective anti-oestrogen due to its high patient tolerability 
[88].  
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1.3.2 HER2 
The human endothelial receptor family consists of four receptors (HER1 or EGFR, 
HER2, HER3 and HER4), which regulate cell growth, survival, and differentiation 
[89]. HER2 is a surface tyrosine kinase receptor that is over-expressed in 
approximately 20-30% of breast cancers [90], providing a growth advantage to 
these cells. Over-expression of HER2 is thus associated with poor prognosis, high 
reoccurrence and mortality rates [90]. 
The monoclonal antibody trastuzumab and the intracellular tyrosine kinase 
inhibitor lapatinib, which target both HER1 and HER2, are the only treatments 
specifically approved for treatment of HER2 positive breast cancers [90]. 
Trastuzumab is recommended as a single agent or in combination with taxols after 
completion of chemotherapy. In cases where trastuzumab therapy is unavailable 
due to either increased risk of cardiotoxicity or the development of resistance, 
lapatinib is prescribed.  
1.3.3 Triple negative 
Triple negative breast cancer (TNBC) is characterized by the lack of expression of 
oestrogen (ER), progesterone (PGR) and HER2 receptors. As such, TNBC lacks 
these specific molecular targets, limiting treatment options, and is usually 
associated with poor prognosis [91]. Eighty per cent of all TNBC tumours belong 
to the basal-like molecular classification and, in many publications, the terms 
basal-like and TNBC are used interchangeably. However, it is important to 
highlight that TNBC is a heterogeneous group consisting of other molecular 
subtypes (e.g. claudin-low, molecular apocrine and, in rare cases, Luminal B), and 
simple classification as basal-like is misleading [55]. Due to the lack of specific 
molecular targets, TNBC are treated with systemic chemotherapy. This can be 
highly effective, but is often associated with the development of a drug resistant 
phenotype, limiting treatment options. For example, taxanes and antimetabolites 
are attractive options for naïve patients, but previous exposures to these agents 
are associated with a high probability of acquired drug resistance [14]. Many 
recurrent metastatic breast cancers develop resistance to cyclophosphamide, 
methotrexate and 5-fluorouracil (CMF), taxanes and antracyclines.  
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It should be noted that although treatment of TNBC remains a challenge, some 
progress is being made. Molecular classification has revealed certain signal 
transduction pathways in TNBC that could potentially be targeted [91]. For 
example, research revealed that TNBC overexpress certain receptors such as 
endothelial growth factor receptor (EGFR), vascular endothelial growth factor 
receptor (VEGFR) and fibroblast growth factor receptor (FBGR) [92]. Therefore, 
several clinical trials have been conducted to evaluate the effectiveness of the 
monoclonal antibody treatments and receptor inhibitors in combination with 
cytotoxic drugs such as carboplatin. While clinical trials have reported increased 
response rates, (10-15%), the overall disease free survival and overall survival did 
not increase [92]. Therefore, novel treatment strategies are desperately required 
to treat TNBC that generally develop a multiple drug resistance trait. 
1.4 Drug resistance   
Despite a wide range of therapeutics available, the current treatment paradigms 
are inadequate to fully treat breast cancer, and to prevent reoccurrence and 
metastasis. One reason for this is that many breast tumours develop multiple drug 
resistance phenotype (MDR), a complicated multifactorial phenotype, which 
usually arises after the initial treatment of tumours with chemotherapy [93]. The 
origin of drug resistant cells is not clear. However, a number of theories have been 
put forward to explain their appearance. The simplest hypothesis of MDR states 
that certain cells acquire genetic changes, allowing them to avoid the cytostatic 
effects of chemotherapy. Such an advantage over chemo-sensitive cells allows 
them to survive the treatment, undergo positive selection, and ultimately 
repopulate tumours with drug resistant cancer cells [93]. Alternative models are 
based on the tumour forming stem cell theory: the first model of MDR 
development proposes that tumour-forming stem cells are naturally resistant to 
chemotherapy. Chemotherapy, therefore, actively selects for a population of cells 
that drive an MDR phenotype. The second model proposes that stem cells do not 
innately possess drug-resistant qualities. Rather, they acquire drug resistance 
through mutations, and pass this to their descendant cells [93]. Current evidence 
suggest that all three theories could be correct, and more experiments are 
required to further delineate the development of MDR, its impact on 
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chemotherapy, and how successful treatments can be developed to mitigate its 
effects. Drug resistance can either be acquired (i.e. arising after contact to the 
chemotherapeutic agents) or be intrinsic (i.e. existing without prior 
chemotherapeutic exposure) [7]. MDR cancer cells can employ a vast array of 
mechanisms to allow them to evade the deleterious effects of chemotherapy: 
reduced drug uptake, increased drug efflux, reduced drug bio-activation, 
increased drug detoxification, increased DNA repair, reduced apoptosis, changes 
in cell cycle regulation or changes in drug target pharmacodynamics (Figure 6) 
[94]. The mechanisms employed to avoid the effects of chemotherapeutic agent 
may depend on the mechanism of action of the drug. For example, treatment with 
DNA-damaging agents such as cisplatin can result in the up-regulation of DNA 
repair mechanisms[95]. However, while certain responses are drug specific, other 
mechanisms are universal, such as the up-regulation of drug efflux mechanisms 
[96]. As these alterations provide resistance to different classes of drugs they play 
a central role in creating the MDR phenotype.  
1.4.1 Drug transporters and drug resistance 
The MDR trait is predominantly propagated by the efflux transporters, which 
pump the cytotoxic drugs out of the intracellular compartment into the blood, and 
hence reducing the intracellular concentration and the resulting exposure [97]. 
The overexpression of ATP-cassette binding proteins (ABC) such as P-
glycoprotein (P-gp), multidrug resistance associated proteins (MRP) and breast 
cancer resistance protein (BCRP) increases cancer cell survival rate and as a 
result, directly correlates with poor survival status and higher mortality rates 
[96].  
The ABC transporter is a superfamily of trans-membrane proteins and consists of 
currently known 48 genes and seven subfamilies, which undertake various 
functions, such as antigen presentation, transport of peptides and lipids across 
membranes (intracellular and plasma) and controlling efflux of a wide range of 
xenobiotics [96]. Due to the protective role (efflux of xenobiotics), ABC 
transporters are highly expressed in the most sensitive cells (blood brain barrier 
and stem cells) [96].  
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The ABC transporters utilize ATP energy to actively expel xenobiotics via the 
extracellular membrane to blood. The process demands high amounts of energy, 
nevertheless, it provides immunity to a range of structurally unrelated cytotoxic 
drugs. Therefore, ABC transporters are viable therapeutic targets.  
  
Figure 6 - Summary of resistance mechanisms utilized by cancer cells.  
Cancer cells utilize several different defence mechanisms to mitigate cytotoxic effects that are elicited by 
chemotherapeutic agents. The mechanisms include expression of detoxifying enzymes, increased anti-oxidant 
enzyme expression, altering expression of molecular targets, substituting molecular targets (changing receptor 
expression), increased capacity to repair DNA, down regulation of proteins involved in apoptosis, changing 
microenvironment, but most importantly over expressing ABC transporters [7]. ABC transporters uses ATP 
energy to actively export xenobiotics to the extracellular space, and this action is the major contributor of multi 
drug resistance. Nevertheless, the metabolism of cancer cells supports the resistance mechanisms, by altering 
expression of signalling molecules, molecular targets, and enzymes involved in defence and drug metabolising 
pathways [7].   
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1.4.1.1 Targeting ABC transporters to overcome MDR trait 
ABC transporters play a central role in the MDR trait; therefore, several inhibitors 
have been developed to sensitize cancer cells to the therapeutic regiments [98]. 
Although the importance of ABC transporters has been known for a long time, 
currently there are no effective therapeutics targeting the efflux transporters that 
could reverse the MDR due to associated toxicity and efflux of drugs via different 
efflux transporters (there are at least 48 ABC transporter genes) [98]. For 
example, the first generation inhibitors (verapamil and cyclosporine A) in 
addition to associated toxicity (exert several pharmacological effects) are also 
subjected to efflux due to being substrates to the P-gp transporter [98]. The 
second generation ABC transporter inhibitors (PSC-833 or VX-710) were 
designed to exert higher specificity in order to reduce the associated toxic effects. 
Although, PSC-833 and VX-710 increased overall sensitivity of cancer cell lines, 
the overall response to the therapeutics did not show therapeutic benefits [99]. 
Third generation inhibitors were designed to contain an even higher affinity for 
the ABC transporters and lower associated toxicity. Despite fewer side effects and 
higher cancer cell sensitization, clinical trials revealed no benefits towards overall 
survival in metastatic cancer patients [100, 101]. The first generation inhibitors 
contain high unspecific toxicity due to lack of specificity, while the second and 
third generation drugs does not resolve the MDR trait.  
In summary, clinical evidence indicates that other mechanisms of MDR are as 
important as overexpression of ABC transporters. Additionally, the high number 
of ABC transporter genes and associated genetic variability may contribute 
towards the lack of response as inhibitors of one receptor may serve as a substrate 
for another.  
1.4.2 Micro RNA and drug resistance 
Despite the fact that plasma membrane transporters are the most studied 
mechanism of MDR, they are not the sole mechanism responsible for it. Of 
particular relevance to this thesis are changes in cell signalling, and the 
subsequent flow of information that leads to alterations in metabolism, flux 
balances, gene expression, protein production and other processes [102, 103]. In 
addition, research has shown that alteration in miRNA expression levels can 
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induce or diminish drug resistance, and as such these represent both an 
interesting mechanistic explanation and potential therapeutic targets [104, 105]. 
As well as being directly involved in regulating the expression of drug resistance 
effector proteins, miRNAs also control enzymes that play key roles in DNA 
methylation [105]. This, in turn, implies that miRNAs can affect a wide range of 
systems through epigenetic regulation. It is important to note that the ATP-
producing pathways of metabolism also affect epigenetic regulation. In fact, there 
is an established link between mitochondrial dysfunction, epigenetic regulation 
and the development of cancer [106]. This is a vast area for discussion; however, 
a comprehensive review is beyond the scope of this report.  
It is becoming increasingly clear that cancer can be viewed as a metabolic disease, 
with subsequent cancerous traits such as drug resistance arising due to deviations 
in metabolism. The downstream effects of signal networks can drive central 
metabolism, and equally metabolic changes can influence the activity of signalling 
networks. Thus, to understand the aetiology of cancer and MDR, as well as 
developing strategies to treat cancer it is important to consider the metabolic 
component of this disease.  
1.5 Systems biology 
1.5.1 Introduction 
As described previously, breast cancer is a spectrum of diseases consisting of 
diverse molecular profiles, comprising genetic, epigenetic and metabolic 
aberrations. These unique aetiologies lead to the need to develop a range of 
therapeutic options, targeting different sub-populations within this disease. To 
fully understand the aberrant states of interacting systems (cell signalling, 
metabolism, epigenetics and so forth) that occur within cancer cells, it is 
important to examine cellular processes as a whole rather than on a case-by-case 
basis. This allows the study of the overall phenotypes that emerge from these 
interactions [107]. For example, multiple alteration in cancer cell biology results 
in metabolic shifts to support unrestricted growth and proliferation: however, the 
emergent phenotypes (e.g. Warburg and reverse Warburg) are characterized by 
significantly differentially deregulated molecular profiles (gene expression, 
genetic mutations, epigenetic landscapes) [108]. In fact, the metabolic shift of 
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cancer cells is so profound that it is considered one of the major cancer traits 
[109]. Systems biology approaches can be used to understand the interactions 
between different molecules, predicting the emergent behaviours of systems 
under both normal and disease conditions. This can help understand the events 
leading to deviations from homeostasis and serve as a basis for the development 
of precision medicine treatment options [110].  
Systems biology is a discipline that integrates mathematics, physics, chemistry, 
biology and computer science in an attempt to investigate biological systems as a 
whole. Successively, genome scale metabolic and signalling models were created, 
followed by the development of various methodologies that ultimately allow the 
recreation, analysis and manipulation of virtual biological systems. In addition, 
the holistic approaches of systems biology allow it to overcome robustness and 
redundancy, the traits that define the biological systems. Robustness is an ability 
to survive perturbations of the biological system (microbe, cell, organism); for 
example, a change in the gene expression levels in response to the availability of 
external metabolites or toxins [111]. Redundancy is the presence of several 
different components (genetic, metabolic) that perform the same function; for 
example, expression of Per1, Per2 and Per3 undertake the same function and 
therefore, the knock-down of one protein does not affect the system [112].  
Technological advances in the 21st century have produced a significant 
technological innovation in the development of high-throughput molecular 
technologies (omics). These have led to the genome-wide characterization of the 
molecular and genetic traits of various cancers [113]. DNA sequencing, plus 
quantitation of transcripts, microRNA, proteins and metabolite levels have 
generated a legacy of extensive data libraries to analyse complex systems, such as 
metabolism, and its deregulation in disease. In addition, improved computational 
capabilities have enabled extensive simulations of metabolism to be possible. As a 
result, various mammalian genome-scale metabolic networks (GSMNs) have been 
reconstructed along with various metabolic modelling methodologies to study 
cancer and mammalian cell metabolism at a genome-wide scale. GSMNs are 
important tools of systems biology, designed to understand relationship between 
genotype and phenotype. This enhances understanding of biochemical 
mechanisms and processes potentially leading to the determination of molecular 
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traits of complex diseases, plus advances in the precision medicine approach to 
disease treatment.  
1.5.2 Using systems biology approach to study metabolism 
Metabolic shifts can be a cause or a consequence of the carcinogenic 
transformation. While the directionality of this relationship may be important for 
determining the potential of metabolic intervention as a therapeutic strategy, it is 
irrelevant for the exploitation of metabolic changes as biomarkers [114]. Due to 
robustness and redundancy of biology, it is important to study metabolism at a 
holistic scale, rather than as a series of isolated systems (e.g. one 
enzyme/metabolite/reaction); systems biology offers tools and means for such 
analysis [114].  
Any metabolic process can be studied using mathematical models. These 
processes can be reduced to the physical interactions of genes, proteins and 
metabolites, all of which can be described by formal mathematical equations 
[115]. For example, the classical Michaelis-Menten equation describes the 
enzyme-catalysed transformation of a substrate to a product. Extending this 
concept, the entire metabolism of a cell can be studied through the coupling of 
such reactions to produce a metabolic network. Finally, if cancer is envisaged as 
an aberrant metabolic phenotype, then it can be studied using modelling 
techniques to examine how it deviates from the ‘normal’ metabolic network [114]. 
However, it is important to first discuss the definition and functions of models that 
can be employed for cancer studies.  
Systems biology models are defined as a set of components (genes, proteins, 
metabolites) that are described by biochemical and physical laws, and combine to 
perform a biological process [112]. Such models serve as a tool to study 
metabolism, test hypotheses, explain biological processes, gather information 
(growth rate, metabolite secretion), predict biological system response to 
perturbations, discover disease biomarkers and, most importantly, establish and 
predict biological truths. In order to serve a purpose and provide reliable 
information, a model needs to be both comprehensive and accurate [116]. 
Consequently, biological models are often data driven in a similar fashion to the 
molecular classification of cancer. Their overall structure and predicted 
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interactions are informed by, and validated through, experimental work, often at 
the omic level [116]. One of the major challenges in systems biology is the creation 
of virtual cells, and their combination to form, ultimately, a virtual human. The 
subsequent text will concentrate on the development of such knowledge-based 
models.  
There are several modelling approaches that could be undertaken in order to 
study metabolism and these approaches are defined by a number of factors, such 
as the available information, computational efficiency and practicality (Figure 7) 
[116, 117].  
 
Knowledge based models can answer different questions and serve different 
purposes [117]. At the gross level they can be divided into quantitative (kinetic) 
and qualitative (structural) models: in the former, all reaction kinetics are 
explicitly defined, while in the latter only the overall process diagram may be 
Figure 7 Comparison of different systems biology modelling approaches.  
More detailed models require large computational power and inversely correlate with possible model size.  
Kinetic models are small in size, however, they are the most powerful, whereas structural models are large in 
size, yet contain little detail. In contrast, constraint based models are large scale, contain moderate amount of 
detail, hence are suitable for large-scale metabolic simulations. 
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defined [117]. This leads to different levels of predictions: for example, a 
quantitative model would predict the rate of metabolite secretion from a cell, 
while a qualitative model would only reveal the potential for this process to occur. 
While it might seem that quantitative models would always be preferable, it 
should be noted that the level of information required to parameterize such 
models is not always available, especially in larger biological systems [118]. In 
these cases, an intermediate approach is often undertaken; constraint based 
modelling, whereby a qualitative model is constrained by a number of 
experimentally derived kinetic parameters [119]. As shown in figure 7, these 
different models can produce quite different insights, and are defined by 
distinctive traits being quantitative or qualitative, stochastic or deterministic, 
discrete or continuous, static or dynamic, statistical or mechanistic [117]. 
Consequently, each model contains strengths and weakness.  
1.5.2.1 Kinetic models  
Kinetic, differential reaction based models are powerful and determine change of 
metabolite concentration over time [118]. However, such models require detailed 
information of each component (metabolite and enzyme) such as concentration, 
kinetic properties, degradation rate, binding constants etc. [118]. Hence, such 
models are often limited by size and are infeasible for large-scale modelling. Due 
to this, kinetic models are usually considered examples of ‘bottom-up’ modelling, 
whereby small-scale models are constructed, validated and then combined to 
form larger models. The high demand for quantitative parameters in kinetic 
models means that their development is limited by the rate of generation of robust 
experimental data [118].  
1.5.2.2 Qualitative models 
In contrast to smaller kinetic models, the qualitative systems biology models are 
primarily topological (structural) and do not require additional information such 
as concentration or kinetic parameters, and therefore can be of large scale [120]. 
The structural models that show connectivity of the components (proteins, 
genes), are the simplest example of qualitative models (metabolic map, protein 
connectivity maps) [120]. However, the qualitative models can extend beyond the 
static investigation of the given system. For example, signalling networks are 
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analysed using Petri-Net formalism and therefore are studied to analyse input-
output relationship (activation of receptor and the resulting gene expressions), 
feedback loops or signal transduction pathways [121]. Such analysis allows us to 
analyse the systems response for various perturbations, for instance, the changes 
in signalling pathways upon inhibition of a receptor. Qualitative models are used 
to understand cellular behaviours, however, as the name suggests, the analysis 
does not provide information that could be quantified and physically measured 
using in vitro experiments (the activation of gene expression does not provide 
quantity of the synthesised mRNA, but rather constitutes a fact).  
1.5.2.3 Constraint based models 
 As mentioned above, a compromise between the truly quantitative and 
qualitative models, and one that is applicable to the study of metabolism, is 
constraint-based modelling (CBM) [119]. These models, including genome scale 
metabolic models (GSMNs, discussed further in section 1.5.4), utilize omics data 
enclosed by set of constraints in order to define biological processes (Table 1).  
Table 1 – Summary of possible constraints used in constraint based modelling techniques. 
Additional constraints may be utilized by different CBM algorithms, such as proliferation rate 
required by PRIME algorithm. Nevertheless, these are the basic constraints that are universally 
applied to each CBM method. 
Constraints are imposed on models to overcome the limitation of a lack of detailed 
kinetic knowledge [119]. Before providing further information, it is important to 
emphasize that CBM models are as powerful as kinetic models, but provide a 
different biological insight. This insight is more targeted at understanding the 
design principles of a system as opposed to predicting exact concentrations of 
Constraint Explanation 
Mass balance Maintains a consistent quantity of metabolites across all occurring reactions. 
The amount of metabolites at the beginning of simulation corresponds to the 
amount at the end. It assumes a steady state of a network. While some 
algorithms allows pseudo-steady state assumptions.  
Thermodynamic Controls the directionality of reactions, constraining irreversible reactions to 
occur only in one direction.  
Capacity Caps the capacity of reaction. Controls the speed or each metabolic process. 
In certain simulations, the capacity of reactions corresponds to protein 
expression levels.  
Molecular  Controls gene-protein-reaction connections, modifies metabolic models to 
correspond to available molecular information, can also control metabolite 
concentrations. Maps reactions to available gene, protein concentration.  
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individual metabolites. A significant advantage of CBM is that it requires biological 
information that is eminently acquirable, such as gene expression levels (or 
presence/absence levels). Cells operate under a myriad of constraints, any 
combination of which can be used to constrain a model. The simplest, but perhaps 
most powerful, constraint is that of stoichiometry. Stoichiometric constraints 
indicate the connectivity of a model, describing relationships between reactions 
and metabolites. For example, in a reaction ABC, metabolite A cannot become 
metabolite C without transitioning through metabolite B. In conjunction to 
stoichiometry, thermodynamic constraints are commonly used in CBM, as they 
define the direction of reactions by being consistent with the Gibbs free energy 
change. The third major constraint applied to CBM is that of conservation. The law 
of mass balance states that mass cannot be created or destroyed, but is converted 
from one form to another. Therefore, the total mass of species within a model must 
remain constant. The final constraint that is commonly used in CBM is setting of 
reaction (flux) rates. By changing the upper and lower bounds of a reaction, it is 
possible to limit the flow of metabolites in the forward and reverse directions, 
respectively. These flux bounds can be set to correspond to experimentally 
derived values, or extrapolated from protein and/or gene expression levels. The 
flux bounds define the rates of each metabolite consumption and production by 
each reaction [119]. Depending on the specifics of individual models, additional 
constraints are implemented, including: spatial, regulatory, environmental, or 
molecular (protein, gene levels). 
1.5.2.4 Metabolic network analysis using constraint based modelling 
Metabolic networks can be functionally analysed using CBM in order to predict 
the metabolic state (landscape) of a system. CBM-based analysis of metabolic 
networks can answer such questions as the predicted maximal cell growth rate, 
the maximal/minimal production rate of metabolites, the maximal/minimal 
consumption of metabolites, maximal ATP production, minimal redox potential, 
the overall metabolic demands of a cell, the set of active reactions responsible for 
a given phenotype, or the essential reactions in the network. These questions are 
addressed by several different methods to examine the CBM; a full discussion of 
these approaches is beyond the scope of this review, and only those relevant to 
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this work are addressed further (Table 4), in addition Table 2 provides a 
simplified description of CBM methods utilized in this study. The interested reader 
is pointed toward reviews by [122] for a wider overview of this topic. CBM 
analysis can be performed using several software packages such as COBRA 
(constraint based reconstruction and analysis) or RAVEN (Reconstruction, 
analysis and visualization of metabolic networks) toolboxes [123, 124].  However, 
in this study our own analysis software, SurreyFBA, has been implemented [125]. 
 
Table 2 - Description CBM analysis algorithms used in this study. 
 FBA- flux balance analysis, FVA- flux variability analysis. The detailed description of algorithms is 
provided in the following publication [126]. 
1.5.2.4.1 Objective function 
An important component of all CBM analysis approaches is the use of an objective 
function, which represents the key task the model is asked to perform. The use of 
objective function is a form of a reverse engineering, and is used to overcome the 
lack of known parameters (growth rate, the rate of metabolite production). 
Therefore, an objective function is used to identify the optimal metabolic solutions 
to perform the stated objective (Figure 8A). In simpler words, the objective 
function is used to identify an unknown semi-quantitative parameter (i.e. growth 
rate) and the associated distribution of metabolic fluxes (rates of the reactions). 
In order to do so, the optimization algorithms (further discussed in section 
1.5.2.4.4) are employed to calculate the most optimal solutions (objective function 
value and rates of the associated active fluxes).  
This objective function could represent a specific biological task (e.g. optimal 
production of a specific metabolite) or be more general (e.g. maximize the 
production of components required for cell growth). Therefore, the objective 
function can be used to explore the metabolic reactions necessary to support a 
Method Biological questions  
FBA  What is the maximum growth rate? Minimal and maximal metabolite 
consumption and excretion rates? 
FVA What are the ranges of all reactions for a given biological system? 
Gene 
essentiality 
How does a deleted gene affect biological system? Synthetic lethality 
investigations. 
Reaction 
essentiality  
Identifies essential reactions and metabolites 
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given phenotype (purpose of an organism or network of interest). As a result, the 
assignment of an objective function is critical in ensuring that CBM predictions are 
relevant to the real biological situation, and represent metabolic processes that 
the organism has to perform. For example, biomass formation can be used for 
cancer models because uncontrolled growth is a major cancer trait, and this 
biomass objective function will be discussed in more detail below.   
Biomass production is one of the major metabolic functions that is applicable for 
bacterial and cancer studies [108, 119]. However, it should be noted that it is not 
applicable for analysis of normal human cells, where the rate of cell division is low. 
The biomass reaction is defined by the ratio of fluxes producing all essential 
metabolites composing a cell. In other words, the fluxes of reactions producing 
essential cellular components such as nucleotides, amino acids, ATP etc. are 
proportionally scaled to the composition of organism of interest. This allows the 
calculation of biomass by converting 1g of total metabolite mass to 1 unit of 
biomass [127]. Therefore, the flux of biomass reaction equals growth rate in units 
of 1/h, while other reactions contain units of mmol/g dry weight/h [127].  
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Figure 8 - Explanation of biomass reaction, objective function and solution space.  
A) The substrates of biomass reaction are the key constituent components of cell mass (AAs – 
amino acids, NTPs – nucleotides, Carbs – carbohydrates and energy (ATP)). Objective function is 
used to identify the highest possible growth rate (biomass reaction flux) and the flux rates of the 
associated metabolic reactions, which support the biomass reaction. The optimisation algorithms 
ensure all constraints are satisfied such as mass balance. B) The optimisation algorithms identify 
all possible metabolic solutions that satisfy the objective function. The allowable solution space 
represents all possible answers to the objective function; however, introduction of various 
constraints narrows the solution space. Flux balance analysis method identifies the particular 
solution, which satisfied all constraints. Once the most optimal growth rate is determined, the flux 
variability analysis can be used to identify the range of fluxes of each reaction. As biological 
systems are robust and redundant, there are more biochemical solutions to solve the particular 
problem – several different distributions of metabolic reactions can support the same growth rate. 
Image depicting solution space adapted from [119]. Sv=0 is more detailed explained in the original 
publication [119]. 
1.5.2.4.2 Flux balance analysis 
Flux balance analysis (FBA) is a computational method widely used in the analysis 
of reconstructed genome-scale biochemical networks such as Recon2 (the major 
human metabolic models are described in section 1.5.4) to explore the optimal 
states of a model for a given objective function [119, 127]. FBA analysis requires 
a specific objective reaction, such as biomass, and predicts the steady state fluxes 
A) 
B) 
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of all reactions generating the maximum possible flux toward the objective 
function (Figure 8B). An extension of this approach is the use of reaction 
essentiality analysis (or reaction knock-out analysis), which predicts the 
contribution of each reaction towards the objective function. Such an approach is 
particularly useful for determining choke-points within a metabolic network, 
which possess a large control over the flux towards the objective function. These 
choke-points may represent ideal therapeutic targets. As well as performing 
knockout analysis, synthetic lethality can be examined through the simultaneous 
knockout of two or more reactions. Synthetic lethality is based upon the 
observation that in most biological systems, two or more pathways are capable of 
producing the same end metabolite (e.g. production of glucose by glycogenolysis 
and gluconeogenesis). This redundancy is an important component of why 
biological systems are robust, as disruption of one pathway can be compensated 
for by another. However, when trying to kill cells during cancer chemotherapy, 
this redundancy can lead to drugs being less than 100% effective, or indeed totally 
ineffective. Synthetic lethality looks to identify these redundant pathways and 
then target all of them through a combination approach. For example, synthetic 
lethality has been proven to successfully identify gene pairs by using 
reconstructed metabolic models of NCI60 cell lines.[128].  
1.5.2.4.3 Flux variability analysis 
Flux variability analysis (FVA) - although related, this approach is fundamentally 
different from FBA in that it does not require an objective function; however, it 
does requires the definition of an optimal state, which is commonly found using 
FBA and hence an objective function [129]. One complication with FBA is that 
there is rarely one solution that is optimal to produce a maximal flux towards the 
objective function [119]. Hence, FBA explores the set of possible solutions and 
provides the most likely solution. FVA can then be used to identify the range of 
fluxes for each reaction that support this optimal state [129]. Hence, this provides 
information not only on the most likely metabolic landscape to optimise for a 
given objective function, but also the variability that can exist in this landscape yet 
still meet the defined solution.  
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1.5.2.4.4 Optimization algorithms 
There are four algorithms employed for CBM calculations, all of which are 
optimization algorithms to compute through the many different permutations to 
find the requested solution [129]. The algorithms were each designed for specific 
methods, and have different requirements with regard to computational power 
[129]. Linear programming (LP) and mixed integer linear program (MILP) are the 
most relevant to this work, and will be discussed in detail below. Quadratic 
programming and non-linear programming are not further discussed.  
LP allows the investigation of metabolic capabilities under fixed constraints, and 
can be used to calculate the maximum and minimum rates of each flux 
participating in the network [129]. In other words, linear programming finds a 
minimum and maximum rate of each reaction within the network that will allow 
the metabolic objective to be met. An important limitation of LP is it operates only 
when all variables are integers, hence the use of gene expression constrain cannot 
be implemented in LP approaches [129].  
MILP algorithm was designed to overcome the shortcomings of LP as it can be 
used with non-integer values [129]. For example, MILP can calculate flux rates 
while also incorporating deterministic values such as gene expression status 
(presence or absence, or high, medium and low expression status). Subsequently, 
the MILP is slower method as it is significantly computationally more expensive 
than LP. 
1.5.3 Summary of constraint based modelling 
Constraint based modelling enables large scale modelling analysis in a semi-
quantitative manner without the requirement of detailed kinetic information. The 
curated genome scale metabolic models represent a stoichiometry constraint 
(connection between reactions and metabolites, a metabolic map), which is used 
to impose mass balance constraint (the reaction products are equal to the 
substrates). Each reaction (flux) is defined by upper and lower flux bounds 
(forward and backward reaction rates). Therefore, the flux bounds define the 
production and consumption rates of each metabolite to satisfy the mass balance 
constraint. As a result, there can be several different distributions of fluxes that 
satisfy the biological objective (e.g. a particular growth rate).  
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The objective function is used to fill the information gaps (e.g. lack of growth rate) 
[119]. For instance, the growth rate is defined as a biomass reaction; therefore the 
flux balance analysis can retrieve the maximum (the most optimal solution) 
growth rate. The FBA analysis identifies the fastest possible biomass reaction rate, 
in a manner that is concordant with all constraints (particularly the mass balance). 
The end result of an FBA analysis is a single solution – the highest flux rate of 
objective function (biomass reaction) and the associated fluxes of each reaction 
[119].  
The newly calculated biomass reaction rate enables FVA analysis, which is used to 
identify all possible metabolic solutions (reaction rates) that can support the most 
optimal growth rate [129].  
Computational algorithms (LP and MILP, also can be others) are used to solve CBM 
methods such as FBA and FVA [129].  
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1.5.4 Genome-scale metabolic models 
In silico metabolic models are based on a network of reactions that represent 
connections between all of the metabolites. The creation of a metabolic network 
is the first part for in silico GSMN modelling. Metabolic networks (stoichiometric 
matrixes) are the main part of the GSMNs and are represented as a stoichiometric 
matrix (S in Figure 9) indicating the relationship between metabolites and 
reactions (Figure 9).  
 
 
Figure 9 - Example of simple metabolic model. 
A) Metabolic model shown visually. B) The metabolic network represented as a stoichiometric 
matrix, which shows the relationship of metabolites and reactions. For example, the very first 
metabolite, glc-D(e) is a substrate in GLCt1 reaction(shown as -1, because it’s the reactant) and 
metabolite glc-D is a product (expressed as 1, because it is a product). The 0 value indicates that 
metabolite does not participate in the given reaction. C) The upper and lower bounds for each 
reaction. The infinity indicates no restriction, while 0 indicates reaction is restricted. UB- upper 
bound, LB- lower bound. Image adapted from [130]. 
 
Modelling metabolism at the genome scale level can significantly expand our 
knowledge of cancerous traits, their underlying metabolic causes and the 
relationship between these traits [131]. GSMNs were initially developed to study 
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the metabolism of bacteria, which were tractable due to their relatively small 
genomes [131]. Since the successful completion of such project, GSMNs have 
become increasingly available for more complex organisms, from yeast to 
mammalian cells. GSMNs are the base platform that allows in silico simulations of 
metabolism to identify biomarkers, drug targets, and understand metabolic 
responses to environmental changes [131].  
The first GSMNs were created to study the metabolism of bacteria and were able 
to predict changes of growth rate in response to different medium and successful 
metabolic targets. The first human generic genome scale metabolic model was 
published in 2007, and was named Recon1 [132]. Since then, major improvements 
in the size and curation of the model have been released (Table 3). Currently there 
are two main metabolic models available, Recon2 and HMR2 [133, 134]. Both are 
generic models representing all potential reactions within a cell, but can be further 
constrained to represent specific cell-types. Both models are not considered ‘final’, 
and are constantly updated; indeed, they were created by merging previously 
created models with the aim to be as comprehensive as possible and encompass 
all know metabolic reactions. Recon2 is currently the most detailed reconstructed 
genome scale metabolic network, consisting of 7,440 reactions, 1,789 genes 
encoding enzymes and 2,626 metabolites encompassed within 8 cellular 
compartments [133]. Recon2 was created by merging five previously developed 
GSMNs: Recon1, HepatoNet1, Edinburgh Human Metabolic Network (EHMN), 
human small intestinal enterocyte model, and acyl carnitine and fatty-acid 
oxidation model [133]. In comparison to Recon2, the HMR 2 model has been 
curated by combining previously five developed models (Recon1, HepatoNet1, 
iHuman1512, iAdipocytes1809, EHMN) with data from several curated metabolic 
databases (KEGG, HumanCyc, REACTOME, Lipids Maps Lipidomics Gateway) 
[134]. The HMR2 model focuses on lipid metabolism and, for example, includes 
reactions simulating lipid droplet formation, while the former network is more 
generic [134]. Arguably, the main difference between Recon2 and HMR2 is 
adaptability; Recon2 is fully open sourced, while HMR2 is designed to be used with 
the COBRA platform using a pre-built algorithm for context specific modelling. As 
a result, the Recon2 model is more widely used despite being smaller in size and 
containing less gene-reaction associations. 
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As generalized reconstructions, both Recon2 and HMR2 represent all 
potentialities within a human cell. In order to create cell-type specific models from 
generic GSMNs, these models must be integrated with various data types such as 
microarray gene expression levels or proteomics to constrain the metabolic 
landscape appropriately (discussed in detail below). These cell-type specific 
metabolic landscapes will aid in the identification of s metabolic pathways that 
create cell-specific traits such as drug resistance, immune response evasion etc. 
[135].  
 
Metabolic 
model 
Genes Reactions Metabolites Publication 
year 
Ref 
Recon1  1,905 3,742 2,766 2007 [132] 
EHMN 2,322 2,823 2,671 2007 [136] 
Recon2  2,194 7,440 5,063 2013 [133] 
HMR2 3,668 8,181 9,311 2014 [134] 
Table 3 - Comparison of currently relevant metabolic models.  
Each newly released model is more comprehensive than its successor. Currently relevant models 
are Recon2 and HMR2 [137]. EHMN – Edinburgh Human Metabolic Network. HMR – human 
metabolic reaction. 
1.5.4.1 Generic genome scale metabolic models 
Generic human GSMNs are a starting point for the generation of context specific 
models. In comparison to bacterial and yeast models, human GSMNs are generic, 
meaning they consist of all know metabolic reactions. While generic networks are 
applicable to unicellular organisms, additional modifications are necessary to 
make human GSMNs context specific (cell, tissue, cancer, patient), as different cells 
contain active metabolic networks tailored to support their functions. In addition, 
this allows the modelling of disease conditions such as cancer where aberrant 
metabolism is an important part of the disease aetiology. An additional difference 
between human and bacterial models is size: As bacterial genomes are smaller, so 
too is the encoded metabolic model, the derived models are also smaller in size 
and require less information to create powerful models. In contrast, the 
proportion of the human genome encoding metabolic functions is considerably 
larger, meaning human GSMNs are significantly larger in size [138]. In addition, 
this increased complexity leads to incomplete level information for enzyme 
kinetics and the concentrations of enzymes and metabolites. Therefore, human 
 47 
GSMNs tend to be constrained based, compared to bacterial models that can be 
either ODE or constraint based [138].  
As the name indicates, constraint-based modelling implies a set of constraints to 
simulate cellular processes, such as provided in Table 2. While kinetic modelling 
offers a single solution, a change of each metabolite over time, the CBM provides 
a solution space, as there can be several solutions for any given objective. The 
solution space depends on the rigidity of constraints and hence their selection is 
critical; if they are too loose the generated solution space is too large and provides 
little information of use; in contrast, if the constraints are very rigid, the desired 
solution space may be so small that the (MI)LP cannot successfully optimise the 
problem, resulting in no useful information. There are no hard-or-fast rules for the 
determination of an optimal set of constraints, and indeed this is an area of 
ongoing debate.  
1.5.4.2 Reconstruction of genome scale metabolic models 
Over the last decade a number of computational and mathematical solutions have 
been published for context specific model building (Table 4). These computational 
algorithms are designed to simulate personalized metabolism to the closest 
physiological resemblances. They must implement model constraints, context-
specific data, and data gaps that will undoubtedly be present. As a result, the 
design of each algorithm is a compromise between practicality and reliability. For 
instance, the modelling algorithm PRIME is able to create powerful context-
specific models; however, to do so it requires proliferation rates, effectively 
limiting the approach to in vitro samples only. Similarly, the tINIT algorithm 
requires definition of metabolic tasks for context-specific model creation, and 
while such definitions may be envisaged for cells and tissues operating under 
normal conditions, the difficulty arises for disease models. Here, the metabolic 
tasks are unknown and, indeed, one aim of the GSMN may be to reveal such tasks. 
In comparison, the iMAT algorithm requires only gene expression or protein 
levels, and can then calculate context-specific metabolic fluxes including 
predictions of features such as post transcriptional regulation. While this model is 
universally applicable and can be used for both in vitro and in vivo samples, as 
well as healthy and disease states, this flexibility comes at the cost of increased 
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computational expense. In this study, the GEBRA algorithm has been used for 
constraint based modelling, which is a development of iMAT that is significantly 
faster. The major difference between iMAT and GEBRA is the number of 
calculations required to generate a solution. iMAT does not require an objective 
function, but must undertake two rounds of MILP optimization for each reaction. 
In contrast, GEBRA requires the definition of a metabolic task, but only requires a 
single MILP calculation for each reaction. As a result, creation of context-specific 
models in Recon2 can be performed in less than 30 minutes using GEBRA, 
compared to approximately nine hours using iMAT. Therefore, GEBRA is more 
suitable for analysis of large-scale datasets such as those created by large cohort 
studies.  
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Algorithm Optimization 
problem 
Objective 
function 
Characteristics  Ref  
iMAT  MILP Not required Constrains reaction fluxes based 
on gene expression data. 
Computationally expensive. Based 
on flux variability analysis.  
[139] 
GIMME LP Required Rebuilds model based on gene 
expression or proteomics data sets. 
[140] 
GIM3E MILP Required Integrates metabolomics and 
transcriptomics data with GSMN. 
Usage with mammalian GSMNs has 
not been demonstrated. Requires 
metabolomics data.  
[141] 
INIT/tINIT MILP Have to define 
metabolic 
tasks.  
Integrates proteomics or genomics 
data with GSMN to reconstruct a 
functional network that fulfills all 
defined metabolic tasks. Requires 
definition of metabolic tasks. 
[142] 
PRIME LP Required Requires proliferation rate of a 
sample and gene expression data 
for construction of personalized 
GSMN. Reaction bounds are 
modified correspondingly to the 
gene expression levels.  
[143] 
MPA MILP Not required Uses gene expression or protein 
levels to calculate probability of 
metabolic reaction occurring for a 
given sample.  
[144] 
mCADRE MILP Not required Builds a model based on gene 
expression data. Is not sample 
specific, as requires gene 
expression data from many 
samples to build a single model.  
[145] 
GEBRA MILP Required Based on FBA analysis, can 
incorporate genomics and 
proteomics data to provide a 
metabolic landscape, a 
personalized context specific 
metabolic models.  
[146] 
Table 4 – Summary of algorithms currently available for constraint based modelling of context 
specific genome scale metabolic models.  
 
1.5.5 Obstacles of context specific genome scale metabolic modelling 
Genome scale metabolic modelling was originally developed to study the 
metabolism of simple, single-celled organisms. As both our biological 
understanding and computational power has increased, these studies have 
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increased to incorporate metabolism of human cells, under both normal and 
disease conditions. The challenge here is that while each human cell is composed 
of an identical genetic makeup, the gene expression driven from this differs 
between cell-types in order to accommodate the specific functions each cell has to 
perform: for example, the metabolic capacity of a hepatocyte is far different from 
the metabolic capacity of white blood cell or from a disease-affected hepatocyte. 
In a similar fashion, each cancer cell expresses a unique gene expression profile, 
which is imprinted upon the same enzymes and metabolic network, leading to a 
different combination of components and altered metabolic capacity. Therefore, 
in order to perform effective whole cell metabolic simulations, molecular (genetic) 
properties have to be accommodated. As it is unrealistic to manually curate these 
context-specific metabolic models, a number of different algorithms have been 
developed for their generation.  
It is important to remember that genome scale metabolic modelling is ruled by the 
same over-riding concept as all other modelling techniques from predicting the 
weather to analysing consumer preferences: ‘Rubbish in = rubbish out‘. In the case 
of GSMNs, the quality of the resultant context-specific GSMN is dependent on the 
quality of GSMN, the data available for personalization and the algorithm utilised. 
For example, not all gene expression data should be considered equally robust for 
the generation of context-specific GSMNs. Gene expression arrays that use poorly 
designed probes provide low quality gene expression data, which in turn, 
irrespective of the GSMN or algorithm used, will result in low quality, inaccurate 
metabolic landscapes. The same holds true for GSMN that is being studied, with 
poorly curated, incomplete networks (e.g. many first generation GSMNs) unlikely 
to provide robust or novel metabolic information.  
In summary, genome scale metabolic models are used to represent the potential 
metabolic network of an organism. The use of specific algorithms allows these 
GSMNs to be tailored to produce context-specific GSMNS, allowing the 
examination of the metabolic capacity of specific cell types or disease states. As a 
result, these qualitative models have the potential to significantly expand our 
knowledge of the functioning of both normal and pathophysiology, and can be 
effectively utilized for the identification of biomarkers and development of novel 
treatments.  
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1.6 Summary of introduction  
The female mammary gland undergoes growth and regression cycles until the 
menopause. To achieve this it uses stem cells that divide and differentiate to create 
breast tissue cells. However, due to this constant cellular proliferation breast 
tissue is susceptible to the development of cancer, with nearly 12% of women 
subject to breast cancer in their lifetime.  
New evidence tightly links breast cancer with cancer stem cells. Cancer stem cells 
are a relatively new concept, and challenge the centuries old idea that cancer 
develops only after acquisition of genetic mutations, irrespective of the 
differentiation status of the cell. The breast cancer stem cell theory states that 
breast cancer develops from mutated (deregulated) breast tissue stem cells or 
partially differentiated cells that have not lost the ability to differentiate and can 
revert back to the stem cell phenotype. As a result, breast cancers are maintained 
by cancer stem cells, with the heterogeneity of tumours sustained by hierarchical 
differentiation and random mutations. Therefore, each cancer is unique and 
progressively grows larger and acquires new traits, usually becoming both drug 
resistant and metastatic over time. Due to intratumoural heterogeneity it is hard 
to classify breast cancers, in fact each tumour can be considered as a unique class. 
Nevertheless, molecular biomarkers should be used for cancerous trait 
identification and guide for the treatment purposes.  
Drug resistance is a molecular trait, maintained by metabolism, and responsible 
for the majority of breast cancer deaths. To mitigate the effects of drug resistance, 
novel study approaches are required to understand the process better and design 
effective treatments. Cancer is increasingly being seen as a metabolic disease, with 
traits such as enhanced cell growth and drug resistance requiring shifts in cellular 
metabolism to support them. This, therefore, also raises the potential for 
metabolism to be an effective therapeutic target to treat cancer. Given the 
complexity of the eukaryotic metabolic network, it is unrealistic to study 
metabolic deregulation using isolated systems, but rather a holistic approach is 
required. System biology offers tools and methods for whole cell genome wide 
metabolic studies with an aim to increase understanding of cancer and finally 
develop means for personalized treatment. 
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1.7 Hypothesis 
Computational modelling techniques translate molecular profiles into functional 
metabolic models, which reveal tumour specific metabolic adaptations that are 
otherwise not highlighted by the traditional analytical methods. We hypothesise 
that analysis of tumour specific metabolic shifts (each tumour is defined by 
unique metabolism) will provide mechanistic insights of cancer traits, such 
as immune response evasion, growth support, energy production and, most 
importantly, drug resistance.  
Aggressive, metastatic, drug resistant breast cancer tumours constitute 10-20% 
of all breast cancer cases. Such tumours should contain distinct metabolic 
adaptations that are the underlying causes of cancerous traits. Therefore, 
performed metabolic analysis should identify such tumours, reveal the 
metabolic shifts, and suggest possible biomarkers as well as treatment 
strategies to develop a cure.  
1.8 Aims and objectives 
 Develop a method for a metabolic model creation that would incorporate 
transcriptomics data with genome scale metabolic models. 
 Up scale the developed method to enable performing the large-scale 
metabolic analysis (over 2,000 clinical and breast cancer cell line 
samples). 
 Explore functional metabolic modelling, by further constricting models  
 Confirm the validity of created models 
 Identify the poor prognosis breast cancer metabolic group 
 Isolate metabolic adaptation unique to the poor prognosis tumours 
 Suggest biomarkers and treatment options 
 Validate the models using in vitro experiments  
 Validate discovery using in vivo experiments 
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2 Materials and methods  
2.1 Materials  
Materials and reagents are provided in Table 5, and antibodies in Table 6. Unless 
otherwise stated all chemical reagents were purchased from Sigma-Aldrich 
(Poole, UK) and were of cell culture or molecular biology grade, as appropriate.  
2.1.1 Reagents 
Material Catalog NO. Supplier 
Protease inhibitor cocktail 
tablets, completeTM, Mini  
11836153001 Roche, Lewes, UK 
PierceTM, Bovine serum albumin 
standard 
23210 Thermo Scientific, IL, USA 
Treatment drugs 
Serotonin hydrochloride  H9523 Sigma-Aldrich, Poole, UK 
Apelin-13 ab141010 Abcam, Cambridge, UK 
DAMGO E7384 Sigma-Aldrich, Poole, UK 
-casomorphin C0783 Sigma-Aldrich, Poole, UK 
DX600 002-26 Phoenix Pharmaceuticals, 
CA, USA 
Carbidopa C1335 Sigma-Aldrich, Poole, UK 
Sorafenib sc-220125 Santa Cruz, Oregon, USA 
DNA/RNAse free water  10977 Invitrogen, Paisley, UK 
Doxorobucin  AB120629 Abcam, Cambridge, UK 
Western blotting 
PreciseTM, Tris-Glycine gels, 8-
16% 
25263 Thermo Scientific, IL, USA 
Nitrocellulose membrane LC2001 Thermo Scientific, IL, USA 
NovexR, Tris-Glycine running 
buffer (10x) 
LC2675 Thermo Scientific, IL, USA 
Novex Tris-Glycine SDS (2x) LC2676 Thermo Scientific, IL, USA 
Dried Milk Tesco product Marvel, Dublin, Ireland 
PageRulerTM Prestained NIR 
Protein Ladder 
26635 Thermo Scientific, IL, USA 
Restore TM Western blot 
stripping buffer 
210569 Thermo Scientific, IL, USA 
Trans-Blot Turbo TM Transfer 
pack 
170-4156 BIO-RAD, Hemel 
Hempstead, UK 
Cell culture 
Trypsin-EDTA solution T4174 Sigma-Aldrich, Poole, UK 
Foetal bovine serum, heat 
inactivated 
10500064 Thermo Scientific, IL, USA 
Phosphate buffered saline P4417 Sigma-Aldrich, Poole, UK 
Trypan Blue Solution, 0.4% 15250061 Thermo Scientific, IL, USA 
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DMEM D6429 Sigma-Aldrich, Poole, UK 
DMEM/F12 11965-118 Invitrogen, Paisley, UK 
EGF 100-15 Peprotech, London, UK 
Hydrocortisone H-0888 Sigma-Aldrich, Poole, UK 
Cholera toxin C-8052 Sigma-Aldrich, Poole, UK 
Insulin I-1882 Sigma-Aldrich, Poole, UK 
Pen/Strep 15070-063 Invitrogen, Paisley, UK 
Horse serum 16050-122 Invitrogen, Paisley, UK 
Commercial kits 
Serotonin ELISA Kit ab133053 Abcam, Cambridge, UK 
DCTM Protein assay  5000111 BIO-RAD, Hemel 
Hempstead, UK 
Cell migration assay, 
-Dish 35mm, low 
80136 Ibidi, Martinsried, Germany 
Table 5 - General reagents and assay kits used in the experiments.  
2.1.2 Antibodies 
All primary antibodies were purchased from Abcam (Cambridge, UK) and all 
secondary antibodies were purchased from Li-COR (Cambdridge, UK), unless 
otherwise stated. Other materials used in Western Blotting experiments are 
provided in Table 5.  
Target Species Optimized 
dilutions 
Catalogue 
number 
Supplier 
ACE-2  Rabbit  1:1000 ab15348 Abcam, Cambridge, UK 
-actin Mouse 1:1000 ab-8226 Abcam, Cambridge, UK 
ERK 1 Rabbit 1:250 sc-94 Santa Cruz, Oregon USA 
p-ERK Mouse  1:200 sc-7383 Santa Cruz, Oregon, USA 
DDC Rabbit 1:250 ab131282 Abcam, Cambridge, UK 
TPH-1 Rabbit 1:1000 HPA022483 Sigma-Aldrich, Poole, UK 
MAO Rabbit 1:1000 ab126751 Abcam, Cambridge, UK 
-opioid receptor Rabbit 1:1000 ab176324), Abcam, Cambridge, UK 
-opioid receptor Rabbit 1:1000 ab137264 Abcam, Cambridge, UK 
-opioid receptor Rabbit 1:1000 ab17934 Abcam, Cambridge, UK 
Anti-rabbit  Goat  1:10000 926-68071 LI-COR, Cambridge, UK 
Anti-mouse Goat 1:10000 926-32210 LI-COR, Cambridge, UK 
Anti-goat Donkey 1:10000 926-32214 LI-COR, Cambridge, UK 
Anti-mouse Donkey 1:10000 926-68072 LI-COR, Cambridge, UK 
Anti-rabbit Goat 1:10000 926-68071 LI-COR, Cambridge, UK 
Table 6 - Antibodies and their optimized concentrations.  
2.1.3 Buffers 
Cell lysis buffer (modified RIPA) – 50mM Tris-HCl, 150mM NaCl, 1% (v/v) NP-
40, 1% (w/v) Sodium deoxycholate, 2mM EDTA, 50mM NaF, pH 7.5, stored at -
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4oC. One complete mini protease inhibitor tablet was added to 10ml of cell lysis 
buffer immediately prior to use.  
 
Transfer buffer – 25mM Tris-Base, 0.2M Glycine, 20% Methanol, pH 8.5.  
 
Blocking buffer with Tween-20– 5% (w/v) non-fat dried milk, 0.1% Tween-20, 
in TBS.  
Blocking buffer – 5% (w/v) non-fat dried milk, in TBS. 
 
10x TBS (Tris-Buffered Saline) – Tris-Base, NaCl, pH 7.5. 
 
TBS – 1 part of 10xTBS and 9 parts of distilled H2O. 
 
TBST – TBS buffer and 0.1% (v/v) of Tween-20. 
 
Running Buffer - NovexR, Tris-Glycine running buffer (10x). The working 1x 
buffer was prepared as per manufacturer’s instructions.  
 
PBS (Phosphate buffer saline) – phosphate buffered saline tablets (Sigma,UK) 
were dissolved in reverse osmosis filtered H2O and subjected to autoclave for 
sterilization. One tablet was used per 250 ml H2O.  
2.1.4 Gene expression data  
 
The Metabric transcriptomic data was obtained from the European genome-
phenome archive (https://www.ebi.ac.uk/ega/home)[66] following approval by 
their Data Access Committee. The dataset consists of two independent subsets: a 
997-sample discovery set, and a 995-sample confirmatory set. In addition, 131 
samples have transcriptome data from normal matched breast tissue samples, 
taken from the cancer unaffected breast. Despite the indication of 141 normal 
breast tissue samples being present in the Metabric dataset, only 131 was 
identified.  
Gene expression data for breast cancer cell lines and primary breast cancer stem 
cells was obtained from the publically available Gene Expression Omnibus (GEO) 
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repository (http://www.ncbi.nlm.nih.gov/geo/)[147] and are further described 
in Table 7. 
Accession no. Description Reference 
GSE41445 Basal gene expression data of MCF-7, MDA-MB-231 and 
MCF10a breast cancer cell lines (in triplicates)  
- 
GSE7513 15 primary breast cancer stem cells replicates and  
15 primary breast cancer cells replicates 
[1] 
GSE24460 2 replicates of MCF-7 breast cancer cell line 
2 replicates of doxorubicin treated MCF-7 breast 
cancer cell line 
[148] 
GSE10281 18 primary pre-treatment breast tumour samples and  
18 primary post letrozole treatment breast tumour 
samples 
[148] 
GSE12777 Basal gene expression of 51 breast cancer cell line (in 
triplicate) 
[149] 
Table 7 - Additional transcriptomic datasets used in the study.  
All datasets use the Affymetrix Human Genome U133 Plus 2.0 Array, and were obtained from the 
GEO repository.  
2.2 Methods  
2.2.1 Cell lines  
The breast tumour cell lines MCF-7 (Catalogue no. 86012803), MDA-MB-231 
(Catalogue no 92020525), and T47D (Catalogue no. 85102201) were purchased 
from the European Collection of Cell Cultures (ECACC). MDA-MB-468 (Catalogue 
no. HTB-132) and MCF10a (Catalogue no. ATCC-CRL-1-317) breast tumour cell 
lines were acquired from the American Type Culture Collection (ATCC). The breast 
cancer cell line SKBR3 was kindly donated by Dr. Helen M. Coley (University of 
Surrey).  
2.2.1.1 MCF-7, SKBR3, MDA-MB-468 and MDA-MB-231 growth medium  
The cell lines were cultured in high glucose Dubecco’s modified eagle medium 
(DMEM, Catalogue no. D6429, Sigma, UK), supplemented with 10% foetal bovine 
serum (FBS), 100 units/ml of penicillin and 0.1mg/ml streptomycin sulphate.  
2.2.1.2 MCF10a growth medium  
The MCF10a cell line was cultured in Dubecco’s modified eagle medium/Ham’s 
F12 (DMEM/F12 1:1 (v/v), Catalogue no. 11965-118, Invitrogen, UK), 
supplemented with 100ng/ml cholera toxin, 0.5 g/ml hydrocortisone, 10g/ml 
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insulin, 20ng/ml epidermal growth factor (EGF), 100g/ml streptomycin, 100 
units/ml penicillin and 5% horse serum.  
2.2.1.3 Cryo-preservation medium  
For long-term storage, cells were preserved in the vapour phase of liquid nitrogen. 
Cryo-preservation medium consisted of 90% normal growth medium and 10% 
DMSO.  
2.2.1.4 Cell culture methods  
2.2.1.4.1 Cultivating cells 
For routine growth, all cell lines were cultivated in T75 vented, filter flasks. The 
medium was replaced every 48 hours, and cells passaged once they had reached 
70-80% confluence, as determined visually by light microscope. Cells were 
passaged at a ratio 1:5 under standard conditions; after aspirating the medium, 
the attached cells were washed twice with pre warmed PBS buffer, followed by 
the addition of 5ml of pre-warmed 1x Trypsin-EDTA solution. Trypsinisation was 
allowed to progress for seven min (15min for MCF10a cell line) at 370C. Once 
detached, cells were gently homogenized using a sterile 10ml pipette to ensure a 
single-cell culture was achieved. The trypsinisation reaction was then stopped by 
addition of 10ml of pre-warmed medium, which both dilutes the trypsin:EDTA 
and moves the pH toward neutral. The cell suspension was transferred to a 50ml 
falcon tubes and centrifuged for 5mins at 300xg. The supernatant was then 
aspirated and the cell pellet resuspended with 10 ml of pre-warmed medium. Two 
millilitres of cell suspension was dispensed into a T75 flask containing 12ml of pre 
warmed medium and transferred to the incubator (370C, 5% CO2). 
2.2.1.4.2 Cell counting 
A cell suspension was prepared as described in the section 2.2.1.4.1. Next, a 50l 
aliquot of this suspension was mixed with trypan blue (1:1 v/v), a vital dye that 
stains dead cells only. The stained cell suspension was subjected to a cell count 
using an improved Neubauer chamber haemocytometer or an Invitrogen 
CountlessTM automated cell counter, according to the manufacturer’s instructions.  
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2.2.1.4.3 Cryopreservation and resurrection of the frozen cells.  
For long-term storage, cells were preserved in the vapour phase of liquid nitrogen. 
A cell suspension was prepared as described in section 2.2.1.4.1, and cell 
concentration determined as described in section 2.2.1.4.2.  The cell suspension 
was centrifuged (5min, 300g), and the resulting cell pellet resuspended in 
cryopreservation medium at a final concentration of 1x106cells/ml. The cell 
suspension (1ml) was dispensed into cryo-vials, transferred to a cryopreservation 
container (Mr. Frosty, Sigma-Aldrich, Poole, UK) and stored for 48 hours at -200C, 
to allow controlled freezing of the cells. After this, the frozen cells were transfer to 
a liquid nitrogen storage vessel.  
For recovery of cell lines from long-term storage, frozen vials containing cell 
suspensions were rapidly defrosted by gentle agitation in a water bath (370C). 
Once defrosted, cells suspensions were transferred to a T25 flask containing 10ml 
of fresh, warm growth medium and incubated for 24-hours in a humidified 
incubator (370C, 5% CO2). After this period, medium was replaced with 12 ml of 
pre-warmed growth medium and cells cultivated as described in section 2.2.1.4.1. 
2.2.2 Preparation of the treatment solutions 
Treatment drugs were dissolved in DNAse/RNAse free H2O (Invitrogen) or 
dimethyl sulfoxide (DMSO) as indicated in Table 8. Stock solutions were prepared 
at 1000x the highest concentration required, as appropriate, and stored at -200C 
for a maximum of 6 months. Cell medium was prepared by diluting stock drug 
solutions into full growth medium. In order to control for, and minimize, the 
influence of the solvent on experiments, solvent volume was constant at 0.5% 
(v/v) of the total treatment medium (0.5l of the stock solution in 99.5l of growth 
medium).  
 
Compound Solvent 
DX600 DMSO 
-casomorphin H2O 
Apelin H2O 
DAMGO H2O 
Carbidopa DMSO 
Sorafenib DMSO 
Serotonin H2O 
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Table 8 - Treatment compounds and solvents.  
Each compound was dissolved in the most appropriate solvent as indicated by the manufacturer.  
2.2.3 Cell migration assay (gap closure assay) 
2.2.3.1 Overview 
The cell migration assay was performed using -Dish 35mm, low dishes (Ibidi, 
Germany). These dishes are composed of a 35mm diameter dish divided into two 
compartments by a silicon insert in the middle. The silicon insert forms a barrier 
around which cells are seeded. Once the seeded cells reach 95-100% confluence, 
the insert is removed, generating a gap: migration into this gap over time can then 
be observed using a light microscope.  
2.2.3.2 Protocol 
The procedure for the cell migration assay was followed according to the 
manufacturer’s instructions. Briefly, a cell suspension (5x105 cells/ml) was 
prepared as indicated in section 2.2.1.4, and 70l (35,000 cells) transferred to 
each compartment. Two millilitres of pre-warmed medium was added and the 
dishes returned to the incubator for the 24 hours (370C, 5% CO2), or until the 
seeded cells reached 95-100% confluence. Next, the inserts were removed and 
1ml of treatment medium applied. The closure of the gap was monitored using a 
light microscope (40x times magnification): cells were imaged every 4 hours, with 
five pictures taken per gap. Gap closure percentage was calculated using the freely 
available software TScratch [150]. 
2.2.4 Cell viability assay (MTT) 
To measure cell viability the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay was used [151]. This assay relies on the 
conversion of MTT (yellow) to its formazan metabolite (purple) by mitochondrial 
NAD(P)H-dependent mitochondrial oxidoreductases. As such, it measures 
mitochondrial activity, a surrogate marker for cell viability. It is important to note 
that this assay measures the cell number, but does not differentiate between cell 
proliferation or cell death.  
To undertake the assay, cell suspensions were prepared at 5x104 cells/ml 
concentration (5000 cells per well), unless otherwise stated. The suspended cells 
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were seeded into 96-well plates and incubated for 24-hours (370C, 5% CO2). Next, 
the medium was aspirated and replaced with 200 L freshly prepared treatment 
medium and returned to the incubator for 24, 48 or 72 hour treatment periods, as 
indicated for individual experiments. For carbidopa treatment, medium was not 
replaced for the duration of the incubation, while for other chemicals the medium 
was replaced daily. At the end of the treatment incubation, the medium was 
aspirated and replaced with 200l of freshly prepared medium containing 
0.2mg/ml MTT solution, and incubated for two hours (370C, 5% CO2). The medium 
was aspirated and the formed formasan crystals dissolved in 100l of 100% 
DMSO. Plates were gently agitated for 30 min to ensure even colour dispersion, 
and the colour intensity measured by using 540nm wavelength.  
2.2.5 Western Blotting 
For general molecular characterisation of cell lines, protein analysis was 
undertaken. As described below, cells were grown under standard conditions, and 
the lysed with modified RIPA buffer. Following quantitation, total cell protein 
extracts were separated by SDS-PAGE. Finally, the desired proteins were 
identified via Western blotting.  
2.2.5.1 Protein extraction (cell lysis)  
Cell lines were seeded in 6-well plates at a concentration of 5x104 cells/ml (50,000 
cells per well), and transferred to an incubator (370C, 5% CO2) for 72 hours. Next, 
the 6-well plates were transferred onto ice, medium aspirated, cells washed twice 
in 2ml of ice cold PBS. After aspirating PBS for the second time, 150μL of cell lysis 
buffer (with protease inhibitors) was added to each well. The cell monolayer was 
removed using a cell scraper and transferred to a 1.5ml Eppendorf tubes, followed 
by the incubation for 30 min at 40C with rotation. Next, cell aggregates were 
broken down using ten gentle plunges with a sterile 22g needle. The cell lysates 
were then centrifuged at 13,000 rpm (15,000g) for 10 min at 40C to remove 
cellular debris. The supernatant was transferred to a fresh Eppendorf tube, and 
protein concentration determined as described below. Protein lysates were stored 
at -200C for a maximum of 12 months.  
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2.2.5.2 Protein quantitation  
Protein concentration was determined using the DCTM Protein assay (BIO-RAD) 
according to the manufacturer’s instructions. This assay is based upon the Lowry 
assay [152], and relies on the interaction between protein and copper under 
alkaline conditions. Following colour development, intensity was measured at 
690nM. Absolute concentrations were generated through interpolation of colour 
intensity compared to bovine serum albumin standards (Pierce) prepared by 
serial dilution in cell lysis buffer prior to the assay. 
2.2.5.3 Protein extract preparation for SDS-PAGE 
Frozen protein lysates were defrosted on ice. Next, the defrosted lysates were 
mixed with -Mercaptoethanol and 2x SDS in the following proportions: 0.45 parts 
of lysate, 0.45 parts of 2x SDS and 0.1 part of -Mercaptoethanol. The prepared 
samples were boiled for 5min at 950C, briefly centrifugated, and stored on ice until 
loading. This ensures that tertiary and secondary structures are denatured, 
allowing separation by peptide chain length alone. 
2.2.5.4 SDS-PAGE  
Prepared protein extracts were loaded onto precast 8-16% Tris-Glycine gels 
(Thermo Scientific); the volume of sample was adjusted to achieve the desired 
protein quantity. In addition, 3 l of protein ladder (Thermo Scientific) was loaded 
into a final lane as a size reference standard. The loaded protein extracts were 
resolved using a BioRad Mini Protean Tetra cell and 1x NovexR running buffer 
(Thermo Scientific) under 45mAmp current for 1-2hours.  
The resolved proteins were transferred to 0.45m pore size nitrocellulose 
membranes (Thermo Scientific) using a BioRad Mini Protean Tetra cell. Proteins 
were transferred at 300mA for 90 min in freshly prepared ice-cold transfer buffer 
(0).  
For DDC, ERK 1/2, p-ERK detection an alternate transfer protocol was used to 
increase concentration of membrane bound proteins. A Trans-Blot Turbo transfer 
pack (BioRad) was used, along with the Trans Blot Turbo transfer system 
(BioRad), according to the manufacturer’s instructions. 
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2.2.5.5 Immuno-detection 
Nitrocellulose membranes were washed with 10ml of TBS buffer and incubated 
with blocking buffer for one hour at room temperature on a roller. Next, 
membranes were washed three times with 10 ml of TBST buffer, followed by 
incubation with primary antibody (Table 6) for 1 hour at room temperature using 
gentle agitation. Once incubation with primary antibody was complete, 
membranes were washed three times with 10 ml of TBST buffer, and exposed to 
the relevant secondary antibody (Table 6) for one hour at room temperature with 
gentle agitation. Finally, membranes were washed two times with 10 ml of TBST 
buffer, and stored in 10ml of TBS buffer prior to imaging.  
Membrane imaging and analysis was performed using an Odyssey Family Imaging 
System (LI-COR, Cambridge, UK), and image analysis performed using the freely 
available ImageStudio Lite software (LI-COR, Cambridge, UK).  
2.2.5.6 Membrane stripping 
To allow detection of multiple proteins on the same membrane, a weakly acidic 
glycine solution is used to strip antibodies from the membrane. Briefly, 
membranes were washed with 10ml TBS buffer for 5 min and incubated with 
10ml of stripping buffer for 30 min at room temperature with gentle agitation. 
Following incubation, the stripping solution (Thermo-Scientific) was removed 
and membranes washed three times with 10ml TBS (5 min, room temperature). 
The stripped membranes are then prepared for blocking and re-probing 
procedures, as described in the section 2.2.5.5. 
2.2.6 ELISA for the quantitation of serotonin concentration in the medium 
2.2.6.1 Medium preparation 
Enzyme-linked immunosorbent assay (ELISA) is an antibody-based technique 
that allows rapid and sensitive quantitation of proteins and peptides. Serotonin 
(5-HT) concentrations were determined in naïve medium and cells, as well as 
following exposure to treatment chemicals. 
2.2.6.2 Serotonin concentration measurement 
The 5-HT concentration of conditioned medium from naïve and treated cells (after 
the 24h incubation period) was measured using the Abcam 5-HT ELISA kit 
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(Abcam, Cambridge, UK) as per manufacturer’s instructions. The developed colour 
intensity was measured at 450nM, and serotonin concentration calculated 
through interpolation from a standard curve.  
2.3 Computational analysis 
Note: The detailed scripts for all analysis are provided as supplementary 
information (computational_analysis_file1.pdf). This section only provides the 
minimum required information for a successful replication of the undertaken 
analysis. 
The computational analysis consisted of three parts. First, pre-processing of the 
raw microarray data was undertaken. This removes and/or normalizes for 
outliers and data inconsistencies that occur due to the technical variance during 
the experimental procedure. As a result, microarray data from different arrays can 
be directly compared and further analysed. Second, differentially expressed genes 
were identified using statistical analysis. Third, microarray data was converted to 
a format compatible with genome scale metabolic modelling, and used to predict 
metabolic landscapes. 
2.3.1 Pre-processing and data normalization  
This study consisted of gene expression data obtained from two different 
microarray platforms (Illumina and Affymetrix). As a result, platform specific data 
pre-processing and normalization methods are detailed.  
Gene expression microarray platforms generate digital images of pixel intensities, 
which represent the gene expression signals. These images are susceptible to the 
errors and artificial variation introduced during the experimental procedure 
(uneven background intensity or other factors). Pre-processing is a term used to 
describe the normalization of the raw data, so it could be further analysed [153]. 
Pre-processing is an important step required for microarray data analysis, which 
addresses between array variability, image pixel intensity artefacts (for example, 
one part of the array shows higher signal than the other) and gene to probe 
summarization effects [154]. Data pre-processing removes data generation errors 
so statistical analysis of samples could be performed. 
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2.3.1.1 Illumina platform - HumanHT-12 v3 Expression BeadChip 
Metabric transcriptomics samples were generated using the Illumina HumanHT-
12 v3 Expression BeadChip platform. Pre-processing and normalization of these 
samples were undertaken using the open-source Bioconductor software in R 
[155]. Data was pre-processed, quantile normalized (Discovery and Validation 
sets were separately quantile normalized) and stored as an ExpressionSetIllumina 
(an extension of an eSet class) object using the beadarray library [156]. Further 
analysis (differential gene expression and genome scale modelling) was 
performed only using data associated with well-annotated, selective probes. 
Annotation and characterization of probes (to good quality and poor quality) was 
derived using the illuminaHumanv3.db library [156].  
2.3.1.1.1 Probe classification to the presence-absence calls 
Probes were classified as expressed (present) or non-expressed (absent) based 
upon their presence-absence call using the calculateDetection function within the 
beadarray library (function compares probes expression value with values of the 
negative control probes) [156]. Function calculateDetection is a method 
developed by Illumina to calculate the detection score for all the beads present on 
the microarray. In short, the summarised bead types (there are several identical 
beads scattered throughout the platform) are ranked based on the intensities and 
the p value is calculated by comparing bead rank against the negative control 
beads (beads made of sequences that do not occur in human) using this formula 
1-R/N, where R represents the rank and N is the mean of the negative control 
beads. The detailed mathematical explanation could be found in this publication 
[157]. 
2.3.1.2 Affymetrix platform - Human Genome U133 Plus 2.0 Array  
All other transcriptomic data sets were generated using the Affymetrix Human 
Genome U133 Plus 2.0 Array (Table 7). Again, pre-processing and normalization 
was undertaken using Bioconductor; specifically, the affy package [155]. 
Normalization was performed using the rma function (affy library), with each data 
set normalized separately (Table 7). Results were stored as an eSet class 
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extension. Detailed scripts are provided in the supplementary information 
computational_analysis_file2.pdf.  
2.3.1.2.1 Probe classification to the presence-absence calls 
Presence-absence probe classification was undertaken using the panp 
(presence/absence/marginal p-values) library, according to the provided 
instructions [158]. The Affymetrix array contains several perfect match (PM) and 
mismatch (MM) probes that monitor detection of each gene. The gene expression 
score is calculated using Wilcoxon signed-rank test. The detailed mathematical 
explanation could be found in this publication [157]. The eSet object for each 
microarray experiment was analysed with the panp function. The pa.calls function 
calculates the gene expression probability and classifies probes into three 
categories: present, absence or a borderline expressed (marginal). In this study, 
both present and marginally present probes were treated as expressed. 
2.3.2 Differential gene expression analysis 
Differential gene expression analysis was performed between the 131 breast 
cancer tissue samples and their relevant matched-normal breast samples (262 
samples in total), and between the poor prognosis metabolic group and the 
remaining tumour samples. All transcriptomic samples belonged to the Metabric 
dataset and were pre-processed, quantile normalized and quality filtered probes 
as described in the section 2.3.1.1. Illumina provides a classification of the probe 
quality based on the sequence of each probe. Certain probes are poorly designed 
and do not perfectly match the target genes. Therefore, these probes are defined 
as a bad quality probes, whereas probes with a perfect sequence to the target gene 
are defined as good quality probes. The filtering procedure allows removal of bad 
quality probes from the further analysis and the remaining good quality probes 
are called filtered probes.  
The differential gene expression analysis has been undertaken using empirical 
Bayes test implemented by the limma package, according to the reference manual 
[158].  
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2.3.3 Creation of the personalised genome scale metabolic models 
To predict metabolic landscapes for each tumour sample (plus matched normal 
breast tissue, where available), a variant of the iMAT (GEBRA) congruency 
approach was undertaken [146].  
GEBRA (gene expression based reaction activity) algorithm uses the categorized 
gene expression data (gene presence/absence calls) as an input method. This 
algorithm utilizes LP and MILP congruency approach to include the maximum 
number of reactions associated with expressed genes and minimum number of 
reactions associated with absent genes in order to identify the metabolic solutions 
that satisfy the defined rate of the objective function. The returned reaction states 
are defined as -1 (reaction is inactive in all metabolic solutions), 0 (in some 
solutions this reaction is active and in others is inactive) and 1 (reaction is active 
in all metabolic solutions). GEBRA algorithm does not generate reaction states for 
each metabolic solution that satisfies predefined constraints (objective function 
rate, stoichiometry, thermodynamics), but rather returns the combined result of 
all possible metabolic solutions. A detailed description of the GERBA algorithm is 
provided in the supplementary information[159], with all analysis scripts 
provided in computational_analysis_file1.pdf.  
The creation of the genome scale metabolic landscape is based on two 
components: the generic genome scale metabolic model (Recon2), and the 
sample-specific gene expression status (Presence/Absence calls). These are 
merged through the computational algorithm GEBRA. Briefly, the algorithm 
searches for tumour-specific GSMN maximally congruent with reaction 
classification based on the Metabric transcriptome data while satisfying 
stoichiometric and thermodynamic constraints of the Recon 2 GSMN. Hence, 
reactions catalysed by proteins with absent gene expression calls should be zero. 
Probes were classified as present or absent as described in the following sections 
(Illumina 2.3.1.1.1, Affymetrix 2.3.1.2.1). Where genes were represented by more 
than one probe the median classification (not expression) was considered: the 
gene was classified as present if half or more probes were classified as expressed 
(the detailed script provided in documentation1.pdf file). The GEBRA algorithm 
was then used to predict the metabolic landscape for each transcriptomic sample 
 67 
using the resulting gene expression classification table and the stoichiometric and 
thermodynamic constraints within Recon2. 
2.3.3.1 Clustering analysis to predict sub-groups of similar metabolic landscapes 
K-means clustering was performed to group the generated metabolic landscapes 
into clusters of similar landscapes using the combined reaction states for each 
sample. K-means clustering was performed using a default Hartigan-Wong 
algorithm as suggested by the kmeans function. K-means clustering divides the set 
into k number of clusters, consisting of n number of features, in such a way that 
the squared Euclidean distance of each feature is closest to the centre of the group 
[160]. Functional reaction states were extracted from each metabolic landscape 
and combined into one table, which was subjected to the K-means clustering 
analysis. Clustering analysis was undertaken for a number of target clusters (2 to 
12), to check the robustness of the derived clusters. 
2.3.3.2 Survival plots 
Kaplan-Meier survival probability plots were created using the spline and survival 
libraries (R statistical programming language) [161, 162]. The Metabric sample 
data was characterized using cluster number, determined in the section above, 
and survival endpoint, provided by the Metabric study. This patient data was then 
subjected to Kaplan-Meier survival analysis (detailed scripts provided in the 
supplementary file discovery_set_protocol.R).  
2.3.3.3 Conversion of the personalized genome scale metabolic models to the sfba 
format 
A specific R script was written (makeSFBA6, documentation1.pdf) to convert 
metabolic landscapes into functional, context specific, genome wide metabolic 
models. The generic GSMN (Recon2) was tailored to represent the metabolic 
landscape, by inhibiting reactions that were inactive within the metabolic 
landscape.  
2.3.3.4 Reaction essentiality analysis 
Reaction essentiality analysis has been performed using a function built into the 
SurreyFBA software [125], using the reconstructed sample-specific genome scale 
metabolic models (2.3.3.3). 
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2.4 Statistical analysis 
Statistical analysis was performed using either GraphPad Prism v6.01 (GraphPad 
Software Inc., La Jolla, USA) or R statistical programming language [162], as 
indicated by the figures representing results. The level of statistical significance 
was set a priori at p < 0.05. Table 9 shows statistical tests used in each analysis.  
Analysis Test Additional information 
K-means clustering K-means Hartigan-Wong algorithm.  
Fig. 12B.  
Hierarchical clustering Agglomerative hierarchical 
clustering 
Ward’s method 
Fig. 38. 
Differentially activated 
reactions 
Signed Wilcoxon rank test Bonferoni adjustment.  
Tbl. 12, tbl. 14, tbl 19. 
Survival Kaplan-Meier Fig. 12, fig. 27A, fig. 30A 
Comparative cluster analysis  Unpaired t-test Fig. 13, fig. 27B, fig. 30B 
Biomass flux rate of normal 
and cancer tissue models 
Paired t test 
Linear regression 
Fig. 17. 
Fig. 18. 
Biomass rate of each cluster One-way ANOVA Fig. 19 
Comparative analysis One way ANOVA Fig. 28 
Cell viability One-way ANOVA Tukey’s multiple comparison 
correction. Fig. 33, fig. 34. 
Gap closure assay Multiple T tests Fig. 29. 
Cell signalling and ELIZA One way ANOVA Dunnet’s multiple comparison 
correction 
Fig. 35, fig. 36. 
Stem cells Chi-squared  Fig. 40. 
Table 9 Statistical analysis tests 
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3  Study cancer by using virtual metabolic models 
3.1 Introduction – Overview, aims and workflow  
Over the last decade, the field of systems biology has seen an exponential growth. 
Technological and experimental advances have made seemingly impossible 
simulations possible: structural eukaryotic metabolic networks were transformed 
from abstract concepts into computational powerhouses [163]. These models 
have the potential to drive the discovery of drug targets, biomarkers and 
metabolic traits [128]. Furthermore, these technologies allow the study of the 
systemic effects of metabolic disturbances.  
This project was built on previous successes in the field of systems biology in an 
attempt to increase our understanding of breast cancer [66, 133]. This will allow 
us to examine the underlying causes of metastasis and drug resistance, and 
potentially suggest novel biomarkers and therapeutic approaches against multi 
drug resistant disease. In addition, our pioneering approach of using virtual 
personalized metabolic models serves as an example of systems biology potential.  
Microarray technology has enriched our understanding of many diseases. 
However, the generated gene expression profiles have not yet been fully exploited, 
due mainly to the analysis methodologies used [164]. This large data legacy has, 
particularly, had limited impact in the area of multi drug resistance cancer, which 
is associated with a high mortality rate. The incorporation of gene expression data 
with genome-scale metabolic networks (GSMNs) by using metabolic simulation 
algorithms, has the potential to provide further mechanistic insight of cancer 
traits [128]. This is because such analyses are constrained further by the 
stoichiometry and thermodynamics inherent to GSMNs. 
Figure 10 outlines the workflow of this chapter. Gene expression data as acquired 
from the Metabric consortium was integrated with the Recon 2 GSMN. Our novel 
algorithm Gene Expression Based Reaction Activity (GEBRA), which is designed 
for large-scale analysis of ~omics data. In addition, gene expression data from 
commonly used breast cancer cell lines were acquired from several different 
studies (Table 7). This allowed a comparison of metabolism between the cell lines, 
as well as between the cell lines and real patient data. This chapter demonstrates 
the application of context-specific metabolic models to increase our 
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understanding of cancer and to offer new insights, biomarkers and therapeutic 
approaches.  
 
This project was performed in consecutive sections, each designed to address a 
particular aim (Table - 10). Systems biology approaches require constant 
validation to ensure the validity of the predictions. Therefore, an initial proof of 
concept study was performed to test the capability of GEBRA algorithm and to 
establish the data analysis pipeline for the large scale modelling approach (2000 
models). The further research was designed to identify the metabolic traits 
associated with an aggressive breast cancer phenotype. Finally, the modelling 
Figure 10 –The workflow of analysis for microarray data.  
Gene expression data (Metabric and cell lines) was initially pre-processed: probe intensities were acquired, and then 
normalized. Next, poor quality probes were removed and the remaining good quality probes classified as expressed 
or not expressed. Finally, each gene was assigned an average expression score, as each gene is represented by more 
than one probe: -1 if less than half of the probes were not expressed and 0 if at least half of the probes were detected). 
GEBRA analysis integrates these gene rules with the Recon 2 GSMN using the congruency approach, in order to the 
metabolic landscape. Analysis of these models increased our understanding of breast cancer; clustering revealed 
metabolic groups, functional analysis described adaptations governed by the determined metabolism, and finally 
additional simulations were performed. KO – knock out (reaction essentiality). 
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approach was used to propose novel treatment interventions against aggressive 
breast cancers. This chapter discuses only the computational results, with the in 
vitro experiments described in chapter 4.  
Aim Hypothesis Approach 
Prove the validity of 
GEBRA algorithm. 
GEBRA algorithm simulates 
metabolic models that reveal 
mechanics of cancer traits, 
normally unattainable by the 
gene expression data alone.  
Identify metabolic differences 
between tumour and matched 
normal breast tissue models. 
Identify the poor 
prognosis metabolic 
breast cancer group. 
Metabolic shift drives and 
sustains cancerous traits. 
Create 997 metabolic 
landscapes using GEBRA 
algorithm and cluster the 
functional reaction states. 
Confirm the validity of 
the identified poor 
survival metabolic 
group. 
The identified group is 
described by the traits common 
to aggressive disease. Also can 
be identified from an 
independent data set. 
Recover and compare the poor 
prognosis cluster from the 
metabolic landscapes of an 
independent data set (995 
patients). Characterize the 
identified group using clinical 
information.  
Reveal the metabolic 
adaptations of the poor 
prognosis group. 
The metabolic adaptations 
provide an evolutionary 
advantage to the cancer cells.  
Compare the poor prognosis 
group to the remaining models. 
Transform the metabolic 
landscapes, generated 
using GEBRA, to the 
functional models SFBA 
models. 
The created SFBA models would 
provide reliable information of 
the growth rate and test 
possible metabolic targets for 
the therapeutic interventions. 
Convert the metabolic 
landscapes to the SFBA models 
and perform FBA, reaction 
knock out analysis (KO). 
Create breast cancer cell 
line models 
Breast cancer cell line models 
should resemble the metabolic 
models, derived from the real 
patients data 
Acquire gene expression data 
for the breast cancer cell lines. 
Generate metabolic landscapes 
and SFBA models, compare the 
results with the real patients 
models.  
Table - 10 summarizes aims, hypothesis and the undertaken approaches. 
3.1.1 Microarray data used in this study  
Within this chapter, gene expression data was used from two sources: patient data 
and breast cancer cell lines. This allowed both the prediction of metabolic 
landscapes from the most comprehensive ~omics study on breast cancer to date, 
but also a comparison of these findings to the current gold-standard cell lines for 
study of breast cancer.  
 72 
3.1.1.1 Breast cancer patient data 
Gene expression data representing real patients was acquired from the Metabric 
study, a comprehensive genomic and transcriptomic study on approximately 
2,000 breast cancer patients, including linked clinical data [66]. A detailed 
description of the data is provided as supplementary information in the original 
Metabric publication. The transcriptomics samples were divided into two 
independent datasets, discovery (997 samples) and confirmatory (995 samples).  
Transcriptional profiling of Metabric samples was performed using the Illumina 
HT-12 v3 platform (Illumina_Human_WG-v3). This microarray platform consists 
of approximately 48,000 probes, with the exact number of probes varying 
between beadarray chips due to their technological design. The quality of these 
probes has been previously evaluated, with annotation updated as necessary 
[165]. This is an important quality control step, as poorly designed probes provide 
sub-optimal information on gene expression status, and may distort the further 
analysis steps. Following this quality control process, approximately 33, 000 
probes were available for mapping to genes present in the Recon2 GSMN. It is 
important to note that the greater number of probes compared to genes is 
expected as there frequently more than one probe per gene. Where such multi-
probe sets are present, an average expression value must be calculated.  
3.1.1.1.1 Gene expression values 
Metabolic analysis, performed in this study, required gene detection values, but 
not expression levels. The expression values of each probe were compared to the 
negative control probe in order to identify probe detection scores. Each gene (one 
gene can be targeted by several probes) was assigned a detection value if the 
detection was present for half or more (50%=<) probes targeting the gene. 
Alternatively, a negative detection value was assigned if more than half of the 
probes (>50%) were classified as absent. We were able to map probe (sets) to 
1,499 genes out of the 1,733 present in the Recon2 (84.5% coverage); these genes 
were classified as expressed (0) or absent (-1) as described above. The remaining 
234 genes that were not covered by the microarray platform were assumed to be 
expressed, as this was felt to be the conservative assumption with a minimal 
change of negative bias during the subsequent metabolic simulations.  
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3.1.1.2 Breast cancer cell line data 
The transcriptomics data representing the breast cancer cell lines were acquired 
from several studies, full details of which are described in chapter 2. For 
uniformity of analysis, each study utilized the Affymetrix GeneChipR Human 
Genome U133 Plus 2.0 array. The Affymetrix array system is different from 
Illumina in several aspects, with technological design being the most significant 
difference. As a result, different scripts and data analysis steps are undertaken, 
with a detailed description provided in chapter 2. The Affymetrix microarray 
platform uses probe sets rather than probes, with a total of 54,676 probe sets 
annotated on the Human Genome U133 Plus 2.0 array. It should be noted that as 
an independent annotation/quality control has not been undertaken, 
incorporation of poorly designed probes might affect the downstream analysis. 
Probe sets were described as present or absent for each given sample, by 
following the published analysis approach [166]. The probe sets summarization 
approach was identical to that undertaken with the Illumina array, and allowed 
1,580 genes out of the 1,733 genes present in Recon 2 to be characterized (91.1 % 
coverage).  
In summary, transcriptomics data from both Illumina and Affymetrix platforms 
were preprocessed in an analogous fashion, with transcripts classified as present 
(expressed) or absent (unexpressed) for each sample. In total, the Illumina and 
Affymetrix platforms defined the status of 84.5% and 91.1% genes in Recon 
2,respectively. These classified gene expression status’ can then be used as an 
input matrix for the creation of personalized metabolic landscapes, using the 
GEBRA algorithm for in silico metabolic modelling.  
3.1.2 Gene expression based reaction activity – GEBRA  
The GEBRA algorithm (also referred as fast iMAT) generates a functional 
metabolic state for a genome scale metabolic network that retains the maximum 
congruency with transcriptomics data. A challenge in the congruency approach is 
that biological systems are dynamic, robust and redundant. Due to this, many 
alternative metabolic states of a GSMN may be identified for a single sample that 
all approach the maximum possible congruency. Therefore, a fast and 
computationally inexpensive optimization solution is required in order to select 
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the most congruent solution. GEBRA is similar to the previously published iMAT 
algorithm [167], delivers a significant reduction in computational cost (80 times 
faster) without compromising the integrity of the results (92% similarity) [139, 
159].  
The computational efficiency of the GEBRA algorithm is because it performs one 
mixed integer linear programming (MILP) optimization for every alternative 
GSMN solution, while iMAT requires two. The optimization step determines 
reaction (flux) rates in the following manner: reactions associated with absent 
genes are newly constrained to match solutions that were acquired during the 
MILP optimization. Further flux rates of reactions lacking a gene rule are 
determined using standard flux variability analysis. The final output of GEBRA in 
silico simulation predicts a functional metabolic landscape (not just structural), 
which satisfies mass balance, stoichiometric, thermodynamic, transcriptomic and 
reaction capacity constraints. The simulated metabolic landscape describes the 
state for each reaction present in the Recon2 genome scale metabolic 
network ; ( 𝑠1, … , 𝑠𝑚) ∈ {−1,0}
𝑚, where and m is the number of metabolic 
reactions in Recon2.  
Before discussing the biological implications of the predicted metabolic 
landscapes, it is important to understand the limitations of any predicted 
metabolic landscape generated by the GEBRA algorithm, or indeed any 
congruency approach solution. Each created transcriptomic specific metabolic 
model consists of over 10,000 reactions; an example of seven output reactions 
from GEBRA is shown in Table 11. The GEBRA algorithm identifies all possible 
metabolic solutions; therefore the state of any individual reaction may differ 
between unique metabolic solutions. To represent this, reactions that are shown 
to vary between different functional states are described as undetermined 
(state:0). In contrast, reactions that are always active or inactive retain a clear 
functional state (state: 1 or -1, respectively). The GEBRA algorithm also calculates 
the possible minimum and maximum reaction rates. These calculated rates 
indicate the bounds of reaction capability: hence, in each metabolic solution, the 
reaction rate would be calculated to be between these bounds. By analysing the 
functional reaction states a clear insight of metabolic adaptations can be revealed, 
as well as a comparison between samples and groups can be performed.  
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In summary, the GEBRA algorithm shapes genome scale metabolic network 
models to exert the highest possible congruency status with transcriptomic data, 
producing a functional context-specific metabolic model. The simulated model is 
also referred as a metabolic landscape, as it is not a dynamic model, but a snapshot 
of metabolism, representing reaction states and flux ranges across all possible 
metabolic simulations. The predicted metabolic landscapes revealed mechanistic 
adaptations unique to the analysed sample, and can be further subjected to 
comparison (e.g. tumours vs normal model and clustering analysis).  
 
3.2 Results  
3.2.1 Analysis of the matched breast cancer and normal tissue samples 
The metabolic shift of cancer cells is a well-documented trait[168]; therefore, 
context-specific cancer models (landscapes) should reveal unique adaptations 
that would be absent in matched normal breast tissue models (landscapes). A 
unique feature of the Metabric dataset is that it contains 131 patient samples that 
contain both tumour tissue and corresponding normal breast tissue, resulting in 
262 personalized metabolic models. This dataset is important because of the 
known heterogeneity in normal tissue, which can mask tumour-specific 
Table 11 - shows an example output file, generated by the GEBRA algorithm.  
Reaction column provides the Recon 2 reaction name and direction; for comparison purposes reversible reactions 
are split into two (forward and backward) states.  As a result, each model contains over 10,000 reactions. The 
slowest and fastest rate columns present minimal and maximal reaction rates as determined using FVA analysis, 
respectively.  The reaction state column presents the functional metabolic reaction state (1: reaction active, 0: 
undetermined, -1: reaction inactive). Gene state represents the molecular constraint, as determined by the gene 
expression state (expressed or absent).  
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adaptations due to the ‘noise’ of the normal tissue. Here, it is possible to compare 
each tumour with a corresponding gene expression profile from matched-normal 
tissue, identifying patient-specific adaptations. Then, these adaptations can be 
compared, with the aim of understanding general adaptations that occur in all 
tumours.  
Once the metabolic landscapes for each breast tumour and its matched-normal 
sample had been created, within-patient differences were revealed by directly 
comparing functional reaction states, Table 12 represents an example of 
comparison analysis. The reaction state score for each tumour can then be 
summed, producing a total score for this reaction: the more positive the number 
(max 131), the more consistently a reaction is predicted to be active, and vice 
versa. Differentially regulated reactions are also named as differentially regulated 
pathways (DAP). Ranking of these total scores reveals their bias toward the 
tumour or normal tissue-specific models; therefore biochemical differences were 
identified. Table 12 provides an example of the most differentially regulated 
metabolic pathways (DAPs) active in breast cancer tumours, but not normal tissue 
models, with the full comparison of over 7440 reactions provided as 
supplementary table S8.  
The ranking approach was only used to sort reactions by their importance to each 
group (tumour or normal tissue). In addition, a Wilcox signed rank test was 
performed to assess statistical significance. This analysis included only variable 
reactions, which were defined by containing at least one different reaction state 
among the 262 models: this equated to 3207 reactions. As a result, 272 reactions 
were shown to exhibit a statistically significant state between tumour and normal 
tissue models (Bonferroni adjusted p value >0.05, supplementary table S8). It is of 
interest to note that from the 7,440 reactions initially searched, only 
approximately 3% were predicted to exhibit a different activity state between 
tumours and matched-normal tissue. This suggests that there are a small core of 
metabolic changes that grant evolutionary advantage to the tumours, and which 
have been identified.  
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Table 12  - shows an example of the metabolic landscapes comparison analysis. 
 Tumour and matched-normal tissue models were separated into two groups. For each model, the functional state of a 
reaction is defined as 1 (active), 0 (undefined) or -1 (inactive) through the GEBRA algorithm. These functional states were 
summed for each group respectively. Next, the difference between the sums for tumour and normal models was calculated 
as a result reaction different index (RANK).  
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Table 13 - shows the DAPs that are the most differentially regulated between tumour and matched-normal samples.  
Mean represent the average activity state for the pathway within the group, with -1 indicating inactive in 100% of the models, and 1 active in 100% of models. 
Difference equals ‘mean others’ – ‘mean poor’, and is used to rank the degree of difference. The statistical difference is assessed through the Wilcoxon signed rank 
text, and adjusted for multiple comparisons. In this case, samples are more commonly active in tumours compared to normal tissues.  
 
 
Reaction Rank Normal 
models 
Tumour 
models 
Bonferroni 
adj. P-value 
Reaction name Subsystem 
R_FKYNH -94 -124 -30 1.70E-28 N-Formyl-L-kynurenine amidohydrolase 
Tryptophan 
metabolism 
R_TRPO2 -94 -124 -30 1.70E-28 L-Tryptophan:oxygen 2,3-oxidoreductase (decyclizing) 
Tryptophan 
metabolism 
R_EX_C02470_LPAREN_e_RPA
REN_ -93 -124 -31 6.12E-28 Xanthurenic acid exchange 
Exchange/demand 
reaction 
R_KYN3OX -93 -124 -31 6.12E-28 kynurenine 3-monooxygenase 
Tryptophan 
metabolism 
R_r1030 -93 -124 -31 6.12E-28 Transport reaction 
Transport, 
extracellular 
R_RE2349C -93 -124 -31 6.12E-28 RE2349 
Tryptophan 
metabolism 
R_ANTHte -92 -124 -32 2.17E-27 Transport of anthranilate 
Transport, 
extracellular 
R_EX_anth_LPAREN_e_RPARE
N_ -92 -124 -32 2.17E-27 Exchange of anthranilate 
Exchange/demand 
reaction 
R_KYN -92 -124 -32 2.17E-27 kynureninase 
Tryptophan 
metabolism 
R_LFORKYNHYD -91 -124 -33 7.60E-27 L-Formylkynurenine hydrolase 
Tryptophan 
metabolism 
R_r0239 -91 -124 -33 7.60E-27 
N-Formylanthranilate amidohydrolase Tryptophan 
metabolism EC:3.5.1.9 
Tryptophan 
metabolism 
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Kynurenine production was shown to be predominantly active in breast cancer 
models, compared to their matched normal controls (Table 12). The comparative 
analysis predicted active kynurenine synthesis (reactions are shown in Figure 11) 
in 101/131 (77%) tumour models, as compared to 6/131 (6%) of the 
corresponding matched normal tissue models. It is of interest to note that this 
differential activity level exists for a number of reactions within the metabolic 
pathways associated with tryptophan metabolism and kynurenine synthesis 
(Figure 11), including tryptophan conversion, further metabolism of the 
metabolites and final excretion to the blood. This is of interest as deregulated 
tryptophan metabolism and increased kynurenine synthesis has been observed to 
take place in tumour models. The significance of kynurenine synthesis has been 
previously documented to play an important part in tumourogenesis, particularly 
immune response evasion [169]. Such data appears to validate this approach to 
detect biologically significant alterations in tumour metabolism. Additionally, the 
kynurenine synthesis could not be identified by the differential gene expression 
analysis by comparing differential gene expression of tumours and matched 
normal tissue samples (supplementary table S7). Hence, the metabolic analysis 
introduces an additional level of transcriptomic data analysis, which increases 
understanding of tumour biology. 
Altered tryptophan metabolism was not the only biological area identified as 
being consistently altered between normal and tumour tissue. Other deregulated 
systems include the amino acid production and metabolism of the extracellular 
matrix (supplementary table S8). In both cases, these systems were more 
commonly active in tumour tissue compared to matched-normal tissue, consistent 
with increased activity. This is logical as deregulation of both metabolic systems 
could be envisaged to promote tumour development; the amino acid synthesis is 
directly related with deregulated growth, whereas increased metabolism of 
extracellular matrix is associated with metastasis.  
In summary, the GEBRA algorithm was demonstrated to successfully create 
metabolic models using transcriptomic data of breast cancers and corresponding 
normal breast tissue cells. The direct comparison of predicted reaction activity 
between these groups revealed metabolic adaptations that allow tumours to 
proliferate, invade and escape immune surveillance. Together, these represent the 
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core alteration in tissue metabolic capacity that promotes tumour survival. Most 
importantly, the performed computational metabolic analysis reveals information 
which cannot be obtained by pure analysis of the transcription datasets. 
Therefore, our method reveals sample (tumour) specific metabolic adaptations 
that maintain cancerous traits (possibly drug resistance). In order to identify such 
possible metabolic adaptations, a large scale analysis of over 2,000 tumour 
samples has been further conducted.  
 
 
Figure 11 - graphical representation of the set of identified reactions active in the breast cancer-specific models (landscapes) 
compared to matched-normal tissue. 
Reactions are presented as their E.C. numbers, with differentially activated reactions highlighted in red. We hypothesise that 
the active production of kynurenine leads to both paracrine and autocrine regulation. First, kynurenine is a key-signalling 
mediator for immune reaction evasion in numerous cancers.  Second, kynurenine is a ligand for the Aryl hydrocarbon receptor 
(AhR), a transcription that upon activation influences genes expression, promoting cell survival and invasion.  Finally, 
anthranilate and xanthurenic acid are terminal metabolites in this pathway, and are secreted into the blood, where they may 
represent important tumour biomarkers. 
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3.2.2 Analysis of 2,000 metabolic models identifies the poor prognosis group 
The next phase of the breast cancer metabolic analysis was to create nearly 2,000 
metabolic models using the remainder of the Metabric transcriptomic dataset. 
Prediction of such a large number of metabolic landscapes for breast cancer, 
coupled with the accompanying clinical data, is an important first step in 
identifying molecular mechanisms associated with the poor prognosis breast 
cancer. Understanding these metabolic adaptations will help predict stratification 
biomarkers and potential therapeutic solutions in order to improve treatment. 
The molecular heterogeneity of breast cancers is well documented, including the 
existence of a poor survival category, which lack therapeutic targets and is often 
associated with multi drug resistance phenotype. This heterogeneity also hinders 
analysis, making it harder to distinguish core alterations that underpin a specific 
phenotype (e.g. poor prognosis). The development of GEBRA, which allows for the 
first time high-throughput analysis of ~omic data in the context of metabolic 
networks, makes possible analysis of sufficient power to generate biologically 
important findings. The aim of the following analysis was to identify and 
characterize metabolic breast cancer group associated with the poor survival. 
The Metabric consortium transcriptomic dataset consists of two independent 
groups, namely the discovery (997 breast tumours) and confirmatory (995) 
datasets. The existence of the independent confirmatory group is essential, as it 
allows repetition of analysis to determine if insights gained from the discovery 
dataset can be replicated – an important first step in validation. The high number 
of tumour samples and presence of two independent transcriptomic datasets 
significantly increases confidence in any findings.  
The discovery set transcriptomic samples were preprocessed and gene 
expression data characterized as previously described (chapter 2). The 
characterized gene expression data (presence/absence calls) was subjected to the 
GEBRA analysis, effectively creating 997 personalised metabolic landscapes. To 
look for commonalities between these predicted landscapes K-means clustering 
was undertaken. This type of clustering was also undertaken in the original 
Metabric study, albeit without the further constraint of a metabolic network, to 
identify the novel breast cancer molecular groups. The initial step is to determine 
the optimal number of clusters to use. In the original Metabric analysis, 10 
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molecular groups were shown to be the most optimal solution within the range 2-
18 groups. Therefore, in this study we also examined a range of potential 
metabolic clusters between 2-12, with 8 clusters showing the most relevant 
clinical response (Figure 12). It is known that breast tumours contain a 
subpopulation of patients with exceptionally poor survival prognosis; therefore 
the identification of the poor survival metabolic group was the key aspect in 
determining optimal number of clusters.  
The clustered samples were subjected to the Kaplan-Meier survival analysis, 
revealing a potential poor prognosis group (cluster 8; p value 0.009).The full 
description of identified 8 metabolic clusters is provided in supplementary table 
21.  
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Figure 12 - K-means clustering method requires manual input of desired cluster count.  
A) Sometimes within group sum of squares approach helps to suggest the optimal number. According to this graph, 
little variation between samples is observed in groups from 5 to 10 clusters. Therefore, in this study, the range of o 
5-10 clusters was examined in terms of survival plots, with 8 clusters showing the most prominent results. B) 
Reaction functional states were subjected to K-means clustering (Hartigan-Wong algorithm). The survival 
probability of each cluster was plotted by using available clinical information. A metabolic cluster associated with 
poor prognosis was identified within both transcriptomic datasets. Survival plots were drawn and statistical 
analysis was performed using Graph pad Prism 6 software.  
 
A) 
 
 84 
Having confirmed the reproducibility of the poor prognosis cluster, it is of interest 
to examine the classical clinical characteristics of these patients before moving 
onto a more in-depth analysis of the identified poor prognosis cluster, which is 
characterized by the traits associated with aggressive breast cancers such as 
younger age and higher grade (Supplementary table 21) . The clinical information 
of the patients and PAM50 classification is provided by the Metabric study [66]. In 
addition, this cluster is composed predominantly of HER2 and Basal intrinsic 
molecular types (PAM50 classification); both molecular types represent 
aggressive breast tumours. In contrast, the remaining metabolic models consisted 
of Luminal A and B tumours that commonly represent curable, less aggressive 
disease with good survival probability. However, the association with clinically 
relevant traits does not solely prove the true existence of the poor prognosis 
cluster. Therefore, the successful validation of the identified metabolic cluster is 
required to be replicated by using an independent transcriptomics dataset. 
In order to check the reproducibility of this poor prognosis clusters, and confirm 
the metabolic phenotype, the confirmatory group of the Metabric study was 
subjected to an identical data analysis. Here, a cluster of metabolic landscapes 
associated with poor patient prognosis was also recovered (Figure 2; p = 0.006). 
Having demonstrated that a poor prognosis cluster can be recovered from two 
independent datasets, we next examined the similarity between these two 
recovered populations. The comparison of the poor prognosis samples belonging 
to the discovery (134 tumours from 997) and confirmatory (108 tumours out of 
995 samples) sets was performed using a non-parametric t-test. There were 2275 
reactions identified as containing a variable state compared to all other tumours, 
in at least one of the datasets (Figure 13). These reactions, essentially, describe 
the key metabolic adaptations predicted to occur in the poor prognosis landscape. 
A Wilcoxon signed rank test was then used to compare these identified reactions 
between the two poor prognosis clusters (recovered from the discovery and 
confirmatory datasets): 2199/2275 reactions (97%) were not significantly 
different, confirming the reproducibility of the poor prognosis metabolic 
landscape. Full details of these reactions are presented as supplementary table S1.  
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Figure 13 Heatmap shows the reaction states of each personalized tumour model present in the discovery dataset. 
 Columns represent 997 tumours, while rows represent the top 500 reactions with highest within row variability. 
The majority of reactions (of 7440 present in Recon2) show little to no variability between tumours; therefore 
statistical analysis has been performed only using the variable reactions. Each reaction exerting a slightest 
variability (>0) within all tumours were further statistically analysed. Red indicates active and blue inactive 
reactions.  Cells represent nine samples of three breast cancer cell lines, just to emphasize the metabolic differences 
from clinical models. 
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3.2.3 Metabolic traits of the poor prognosis cluster  
In order to identify metabolic traits unique to the poor prognosis cluster, further 
analysis of the discovery data set was undertaken. Functional reaction states 
within the poor prognosis cluster (134 patients) were compared against the 
functional reaction states from all other tumour samples (863). As previous, the 
Wilcoxon signed-rank t test was used to identify statistically significant variation 
between these two sample sets: 632 reactions were shown to be differentially 
regulated in the poor prognosis cluster metabolic landscapes (TABLE S2). The 
identified reactions with the greatest difference (the lowest adjusted p-value) 
could be grouped into a relatively small number of metabolic pathways: opioid 
peptide degradation, production of bioactive peptides and amino acid 
degradation, and an extensive extracellular matrix metabolism (Table 15).  
The degradation of milk proteins (casomorphin, beta-casomorphin and apelin 13) 
was shown to be the most differentially regulated system. Our analysis predicts 
79% (106/134) of the poor prognosis tumours possess activity for reactions 
involved in the hydrolysis of the casomorphin milk proteins. By comparison, only 
11% of the ‘other tumour’ models demonstrated activity for these reactions (96 
models out of 863; 11%). Increased degradation of milk proteins will generate 
amino acids, which are an important requirement for increased biomass 
production (equivalent to cell division). Additionally, as these milk proteins are 
opioid peptides, their hydrolysis may negate the established negative effects of 
opioid peptides on tumour growth; this will be experimentally examined and 
further discussed in chapter 4. As the activity of casomorphin metabolism system 
is directly related to the expression of angiotensin converting enzyme 2 (ACE2), 
which is up regulated by the poor survival tumours (adjusted p value=2.5e-61). In 
addition to the hydrolysis of opioid peptides, the excretion of hydrolysis by 
products (N-acetyl-seryl-aspartyl-lysyl-proline peptides) to the blood has been 
shown to occur in 80% of models (108/134). In summary, the active metabolism 
of milk protein opioids in the poor prognosis cluster samples may drive a 
proliferative phenotype by both supplying building blocks for cell division and 
removing a potential cellular brake.  
The second system that is predominantly active in poor prognosis tumours 
involves the metabolism of several amino acids to generate energy in the forms of 
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NADPH and NADH, and the production and secretion of the bioactive peptides 
serotonin and dopaminium (Table 14).  
 
Reaction 
name 
Reaction Description 
Dopaminium production 
EX_34dhph
e 
34dhphe[e] <=>  Dihydroxyphenylalanine is taken up 
from blood 
34DHPHEt 34dhphe[e] <=> 34dhphe[c]  Dihydroxyphenylalanine is taken 
into the cytoplasm 
3HLYTCL    h[c] + 34dhphe[c] => co2[c] + dopa[c]   Dopaminium is produced 
EX_dopa(e) dopa[e] <=>  Dopaminium is excreted 
Energy generation 
TYRCBOX h[c] + tyr_L[c] => co2[c] + tym[c]  L-tyrosine is converted to 
tyraminium 
TYMSULT aps[c] + tym[c] => h[c] + pap[c] + 
tymsf[c]  
Tyraminium is converted to 
adenosine 3,5-bismonophosphate(4-
) 
TYMSFt tymsf[c] => tymsf[e]  Waste Tyramine O-sulfate is 
excreted 
EX_tymsf(e
) 
tymsf[e] <=>  Tyraine o- sulfate is put to blood  
TYROXDAc h2o[c] + o2[c] + tym[c] => h2o2[c] + 
nh4[c] + 4hoxpacd[c]  
Tyraminium is covertated to : (4-
hydroxyphenyl)acetaldehyde 
4HOXPACD
OX_NADP_ 
h2o[c] + nadp[c] + 4hoxpacd[c] <=> 2 
h[c] + nadph[c] + 4hphac[c]  
Hydroxyphenylacetate is produced 
from : (4-
hydroxyphenyl)acetaldehyde. 
NADPH produced?  
HPACtr 4hphac[c] <=> 4hphac[e]  Hydroxyphenylacetate is transferred 
to extracellular space  
EX_4hphac
_LPAREN_
e_RPAREN
_ 
4hphac[e] <=>  4-Hydroxyphenylacetate is excreted 
Serotonin production 
5HLTDL h[c] + 5htrp[c] => co2[c] + srtn[c]  Seratonin is produced  
EX_srtn(e) srtn[e] <=>  Seratonin(1+) is excreted 
Energy generation 
PHYCBOXL h[c] + phe_L[c] => co2[c] + peamn[c]  Phenylalanine is converted to 2-
phenylethanaminium 
PEAMNO h2o[c] + o2[c] + peamn[c] => h2o2[c] + 
nh4[c] + pacald[c]  
Peroxide, amonium and 
phenylacetaldehyde are produced  
r0545 h2o[c] + nad[c] + pacald[c] <=> 2 h[c] + 
nadh[c] + pac[c]  
Phenylacetaldehyde , NADH, and 
phenylacetate are produced 
PACCOAL atp[c] + coa[c] + pac[c] => amp[c] + 
ppi[c] + phaccoa[c]  
phenylacetyl-CoA(4-) is produced, 
ATP is consumed.  
PHACCOA
GLNAC 
gln_L[c] + phaccoa[c] => coa[c] + 
pheacgln[c]  
Glutamine taken to release COA and 
butanoate form 
PHEACGLN
t 
pheacgln[c] <=> pheacgln[e]   Butaoneate excreted 
EX_pheacgl
n 
pheacgln[e] <=>   Butaoneate excreted 
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Table 14 - Metabolism of the amino acids active in poor prognosis group 
Table shows four metabolic groups of amino acid metabolism differentially activated in the poor 
prognosis group. Reactions were retrieved from Recon2 metabolic model. The uptake of 
dihydroxypjenylalanine and subsequent production of dopaminium, followed by the secretion to 
the blood system. The second group of metabolic pathways results in energy production through 
conversion of L-tyrosine to 4-Hydroxyphenylacetate, which is subsequently excreted to the blood. 
The third group synthesise and secrete serotonin to the blood system. The final set of metabolic 
pathways metabolises phenylalanine to produce NADH and subsequently secrete the metabolic 
by-product butanoate into the blood system. 
 
The described reactions (Table 14) were shown to be active in 61% of poor 
prognosis tumours (82/134), compared to only 12% (102/863) of the other 
tumour models. A range of enzymes, notably DOPA decarboxylase (0.46 fold 
change and 3.46E-22 adjusted p-value), several amino oxidases and transporters 
orchestrated the amino acid metabolism reactions (Table 13). In total 30 
differentially activated pathways (DAP), related to amino acid metabolism were 
predicted to be active in the poor prognosis tumours compared to all other 
tumours, thus granting a survival advantage, as the released amino acids are 
consumed to increase the growth rate.  
Another group of differentially regulated pathways, active in the poor prognosis 
group, were those involved in extracellular matrix (ECM) remodelling. In total 4 
groups of DAPs, consisting of 22, 54, 103 and 22 reactions were shown to be 
statistically more likely to be active in the poor survival group, compared to the 
remaining models (supplementary table S3). The largest group, consisting of 103 
DARs (adjusted p=value <2.3e-4) is involved in glycan synthesis, which has been 
previously associated with tumour migration and invasion [170]. Additionally, 
DAPs consisting of 54 and 30 reactions (adjusted p-values p< 7.9e-5, and p<3.9e-
3, respectively) are associated with the remodelling of existing cell surface 
glycans. Finally, the metabolism of chondroitin sulphate (22 differentially 
regulated reactions, adjusted p-value < 1.25e-16) was shown to be the most 
significant set of DAPs. As increased extracellular matrix remodelling plays an 
important role in metastasis, these changes are consistent with the adoption of an 
aggressive tumour phenotype. It should be noted that while we observe more 
tumours in the poor prognosis cluster with active ECM remodelling, the results 
are not absolute, with 32% of other tumours also predicting active ECM 
remodelling (compared to 75% of poor prognosis tumours). This suggests that 
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ECM remodelling also occurs in the remaining models, although the phenotype is 
not as prominent.  
Using GEBRA to predict metabolic landscapes for a large number of breast cancer 
transcriptomes, allows the identification of DARs and DAPs associated with poor 
prognosis. The metabolic systems associated with these DAPs (opioid peptide 
degradation, serotonin production, extracellular matrix remodelling) 
predominantly define the poor prognosis group, and suggest a phenotype that is 
both invasive and aggressive. It should be noted, however, that such prediction 
needs additional experimental confirmation. In order to validate results further a 
set of in vitro experiments were performed to investigate opioid peptide 
degradation and serotonin synthesis systems, and will be discussed further in 
chapter 4.  
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Reaction ID Mean other 
tumours 
Mean poor 
prognosis tumours 
Difference P-value Adjusted p-value Reaction name Subsystem 
R_EX_CE2915_LPAREN_e_RPAREN
_ 
-0.889 -0.206 -0.683 6.75E-74 2.04E-70 beta-casomorphin exchange Exchange/demand reaction 
R_EX_CE2915_LPAREN_e_RPAREN
_ 
-0.889 -0.206 -0.683 6.75E-74 2.04E-70 beta-casomorphin exchange Exchange/demand reaction 
R_EX_CE2916_LPAREN_e_RPAREN
_ 
-0.889 -0.206 -0.683 6.75E-74 2.04E-70 neocasomorphin exchange Exchange/demand reaction 
R_EX_CE2916_LPAREN_e_RPAREN
_ 
-0.889 -0.206 -0.683 6.75E-74 2.04E-70 neocasomorphin exchange Exchange/demand reaction 
R_EX_CE2917_LPAREN_e_RPAREN
_ 
-0.889 -0.206 -0.683 6.75E-74 2.04E-70 apelin-13 exchange Exchange/demand reaction 
R_EX_CE2917_LPAREN_e_RPAREN
_ 
-0.889 -0.206 -0.683 6.75E-74 2.04E-70 apelin-13 exchange Exchange/demand reaction 
R_EX_CE4722_LPAREN_e_RPAREN
_ 
-0.889 -0.206 -0.683 6.75E-74 2.04E-70 beta-casomorphin (1-6) exchange Exchange/demand reaction 
R_EX_CE4722_LPAREN_e_RPAREN
_ 
-0.889 -0.206 -0.683 6.75E-74 2.04E-70 beta-casomorphin (1-6) exchange Exchange/demand reaction 
R_EX_CE4723_LPAREN_e_RPAREN
_ 
-0.889 -0.206 -0.683 6.75E-74 2.04E-70 neocasomorphin (1-5) exchange Exchange/demand reaction 
R_EX_CE4723_LPAREN_e_RPAREN
_ 
-0.889 -0.206 -0.683 6.75E-74 2.04E-70 neocasomorphin (1-5) exchange Exchange/demand reaction 
R_EX_CE4724_LPAREN_e_RPAREN
_ 
-0.889 -0.206 -0.683 6.75E-74 2.04E-70 apelin (1-12) exchange Exchange/demand reaction 
R_EX_CE4724_LPAREN_e_RPAREN
_ 
-0.889 -0.206 -0.683 6.75E-74 2.04E-70 apelin (1-12) exchange Exchange/demand reaction 
R_RE0936E -0.889 -0.206 -0.683 6.75E-74 2.04E-70 RE0936 Miscellaneous 
R_RE0936E -0.889 -0.206 -0.683 6.75E-74 2.04E-70 RE0936 Miscellaneous 
R_RE0937E -0.889 -0.206 -0.683 6.75E-74 2.04E-70 RE0937 Miscellaneous 
R_RE0937E -0.889 -0.206 -0.683 6.75E-74 2.04E-70 RE0937 Miscellaneous 
R_RE0938E -0.889 -0.206 -0.683 6.75E-74 2.04E-70 RE0938 Miscellaneous 
R_RE0938E -0.889 -0.206 -0.683 6.75E-74 2.04E-70 RE0938 Miscellaneous 
R_EX_CE5867_LPAREN_e_RPAREN
_ 
-0.784 -0.191 -0.593 7.91E-44 2.39E-40 N-acetyl-seryl-aspartyl-lysyl-proline exchange Exchange/demand reaction 
R_EX_CE5867_LPAREN_e_RPAREN
_ 
-0.784 -0.191 -0.593 7.91E-44 2.39E-40 N-acetyl-seryl-aspartyl-lysyl-proline exchange Exchange/demand reaction 
R_EX_CE5868_LPAREN_e_RPAREN
_ 
-0.784 -0.191 -0.593 7.91E-44 2.39E-40 N-acetyl-seryl-aspartate exchange Exchange/demand reaction 
R_EX_CE5868_LPAREN_e_RPAREN
_ 
-0.784 -0.191 -0.593 7.91E-44 2.39E-40 N-acetyl-seryl-aspartate exchange Exchange/demand reaction 
R_EX_CE5869_LPAREN_e_RPAREN
_ 
-0.784 -0.191 -0.593 7.91E-44 2.39E-40 lysyl-proline exchange Exchange/demand reaction 
R_EX_CE5869_LPAREN_e_RPAREN
_ 
-0.784 -0.191 -0.593 7.91E-44 2.39E-40 lysyl-proline exchange Exchange/demand reaction 
R_RE2445E -0.784 -0.191 -0.593 7.91E-44 2.39E-40 RE2445 Miscellaneous 
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R_RE2445E -0.784 -0.191 -0.593 7.91E-44 2.39E-40 RE2445 Miscellaneous 
R_3HLYTCL -0.882 -0.389 -0.493 3.79E-42 1.14E-38 3-Hydroxy-L-tyrosine carboxy-lyase Tyrosine metabolism 
R_4HOXPACDOX_NADP_ -0.882 -0.389 -0.493 3.79E-42 1.14E-38 4-Hydroxyphenylacetaldehyde:NADP+ oxidoreductase Tyrosine metabolism 
R_5HLTDL -0.882 -0.389 -0.493 3.79E-42 1.14E-38 5-Hydroxy-L-tryptophan decarboxy-lyase Tryptophan metabolism 
R_EX_4hphac_LPAREN_e_RPAREN
_ 
-0.882 -0.389 -0.493 3.79E-42 1.14E-38 4-Hydroxyphenylacetate exchange Exchange/demand reaction 
R_EX_dopa_LPAREN_e_RPAREN_ -0.882 -0.389 -0.493 3.79E-42 1.14E-38 Dopamine exchange Exchange/demand reaction 
R_EX_pheacgln_LPAREN_e_RPARE
N_ 
-0.882 -0.389 -0.493 3.79E-42 1.14E-38 alpha-N-Phenylacetyl-L-glutamine exchange Exchange/demand reaction 
R_EX_srtn_LPAREN_e_RPAREN_ -0.882 -0.389 -0.493 3.79E-42 1.14E-38 Serotonin exchange Exchange/demand reaction 
R_EX_tymsf_LPAREN_e_RPAREN_ -0.882 -0.389 -0.493 3.79E-42 1.14E-38 Tyramine O-sulfate exchange Exchange/demand reaction 
R_HPACtr -0.882 -0.389 -0.493 3.79E-42 1.14E-38 hydroxyphenylacetate transport via diffusion Transport, extracellular 
R_PACCOAL -0.882 -0.389 -0.493 3.79E-42 1.14E-38 phenylacetate-CoA ligase Phenylalanine metabolism 
R_PEAMNO -0.882 -0.389 -0.493 3.79E-42 1.14E-38 Phenethylamine oxidase Phenylalanine metabolism 
R_PHACCOAGLNAC -0.882 -0.389 -0.493 3.79E-42 1.14E-38 Phenylacetyl-CoA:L-glutamine alpha-N-
phenylacetyltransferase 
Phenylalanine metabolism 
R_PHEACGLNt -0.882 -0.389 -0.493 3.79E-42 1.14E-38 PHEACGLN extracellular transport via diffusion Transport, extracellular 
R_PHYCBOXL -0.882 -0.389 -0.493 3.79E-42 1.14E-38 L-Phenylalanine carboxy-lyase Phenylalanine metabolism 
R_TYMSFt -0.882 -0.389 -0.493 3.79E-42 1.14E-38 Tyramine O-sulfate transport (diffusion) Transport, extracellular 
R_TYMSULT -0.882 -0.389 -0.493 3.79E-42 1.14E-38 Tyramine Sulfotransferase Tyrosine metabolism 
R_TYRCBOX -0.882 -0.389 -0.493 3.79E-42 1.14E-38 L-Tyrosine carboxy-lyase Tyrosine metabolism 
R_TYROXDAc -0.882 -0.389 -0.493 3.79E-42 1.14E-38 Tyramine:oxygen oxidoreductase(deaminating)(  Tyrosine metabolism 
R_EX_34dhphe_LPAREN_e_RPARE
N_ 
-0.881 -0.389 -0.492 8.69E-42 2.62E-38 3,4-Dihydroxy-L-phenylalanine exchange Exchange/demand reaction 
R_EX_lcts_LPAREN_e_RPAREN_ -0.916 -0.473 -0.442 1.64E-41 4.94E-38 Lactose exchange Exchange/demand reaction 
R_LACZe -0.916 -0.473 -0.442 1.64E-41 4.94E-38 b-galactosidase, extracellular Galactose metabolism 
R_34DHPHEt -0.013 -0.008 -0.005 4.50E-41 1.36E-37 3,4-Dihydroxy-L-phenylalanine transport Transport, extracellular 
R_r0547 -0.625 -0.313 -0.312 6.22E-37 1.87E-33 Aldehyde:NADP+ oxidoreductase Phenylalanine 
metabolism EC:1.2.1.5 
Phenylalanine metabolism 
R_HSD17B8r -0.730 -0.221 -0.508 1.92E-30 5.80E-27 17-beta-hydroxysteroid dehydrogenase Steroid metabolism 
R_r0545 -0.566 -0.130 -0.436 1.41E-20 4.26E-17 Phenylacetaldehyde:NAD+ oxidoreductase Phenylalanine 
metabolism / Styrene degradation EC:1.2.1.5 EC:1.2.1.39 
Phenylalanine metabolism 
R_CSAPASEly -0.671 -0.252 -0.419 4.15E-20 1.25E-16 chondroitin sulfate A proteoglycan protease, lysosome ( Chondroitin sulfate degradation 
R_CSBPASEly -0.671 -0.252 -0.419 4.15E-20 1.25E-16 chondroitin sulfate B proteoglycan protease, lysosome ( Chondroitin sulfate degradation 
R_CSPG_Atly -0.671 -0.252 -0.419 4.15E-20 1.25E-16 chondroitin sulfate A transport, extracellular to lysosome Transport, lysosomal 
R_CSPG_Btly -0.671 -0.252 -0.419 4.15E-20 1.25E-16 chondroitin sulfate B transport, extracellular to lysosome Transport, lysosomal 
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R_EX_cspg_a_LPAREN_e_RPAREN_ -0.671 -0.252 -0.419 4.15E-20 1.25E-16 chondroitin sulfate A (GalNAc4S-GlcA) proteoglycan 
exchange 
Exchange/demand reaction 
R_EX_cspg_b_LPAREN_e_RPAREN_ -0.671 -0.252 -0.419 4.15E-20 1.25E-16 chondroitin sulfate B / dermatan sulfate (IdoA2S-
GalNAc4S) proteoglycan exchange 
Exchange/demand reaction 
R_GLCAASE4ly -0.671 -0.252 -0.419 4.15E-20 1.25E-16 beta-glucuronidase, lysosomal Chondroitin sulfate degradation 
R_IDOAASE4ly -0.671 -0.252 -0.419 4.15E-20 1.25E-16 alpha-L-iduronidase, lysosomal Chondroitin sulfate degradation 
Table 15 Metabolic adaptations of the poor prognosis breast cancer group 
Statistical analysis was performed using Wilcoxon singed rank test and Bonferroni corrections. 
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3.2.4 Metabolic landscape modelling for breast cancer cell lines 
In this project three breast cancer cell lines were subjected to metabolic analysis. 
These breast cancer cell lines were chosen as they are classically used to represent 
the major breast tumour types; aggressive, triple negative (MDA-MB-231), 
receptor positive (MCF-7), and normal tissue (MCF10a) [171]. It should be noted 
that while the MCF10a cell line is used as a model of normal tissue, it is not ideal 
due to its transformed status; however, there is a lack of better alternatives to 
MCF10a as a control cell line [172].  
The metabolic landscape for each cell line was predicted using the GEBRA 
algorithm, using the GSE41445 transcriptome samples for each cell line. These 
metabolic landscapes were then subjected to clustering techniques in order to 
identify their relationship to the patient metabolic profiles. The combined 
clustering analysis indicated that the cell lines are predicted to be metabolically 
distinct from patient samples. For example, the aggressive cell line (MDA-MB-231) 
was expected to fall in the same category as the poor survival metabolic cluster. 
However, the K-means clustering separated the cell line models in to their own 
unique cluster, suggesting that the cell lines more closely resemble each other 
than the real patient models. 
The differences in predicted metabolic landscapes between cell lines and patient 
samples may be due to technological bias. Different platforms were used for the 
two studies (Illumina for Metabric and Affymetrix for cell lines). The different 
microarray technology, unique probes and annotation for the respective 
platforms could lead to the simulation of different metabolic profiles. These 
platform-specific technical differences directly affect key parameters such as how 
well is the gene detected, the number of detected genes, and the overlap of gene 
detection (false positive detection, when the same probe targets several unrelated 
genes). As a result, transcriptomic data from Illumina and Affymetrix platforms 
present not only unique metabolic coverage, but also different gene expression 
values (weights), which directly affects the metabolic modelling analysis.  
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3.2.5 Modelling the growth rate and identifying essential reactions  
3.2.5.1 Reconstruction of functional metabolic model 
One issue with using patient samples for computational analysis is that it is 
difficult to validate predictions: it is simply not possible to return to the original 
patients. However, for cell lines, there is a wealth of phenotypic data that can be 
examined to validate computational predictions. Therefore, the breast cancer cell 
lines, if not good representations of patient samples directly, may act as exemplars 
of the predictive power of computational methods. To this end, the metabolic 
landscapes were further examined to predict growth rates and reaction 
essentiality. To allow such analysis, the metabolic landscapes must first be 
converted into sfba (Surrey Flux Balance Analysis) models for additional 
simulation (Figure 16). 
Figure 14  - Creation of functional metabolic model.  
Recon2 is a genome scale metabolic model, which contains the reaction rates and can be further used for 
additional simulations. In contrast, the metabolic landscape created using GEBRA only reveal the functional 
reaction states. The specific scripts were written to tailor the Recon2 GSMN to match the metabolic landscape 
by closing reaction rates for the inactive reactions and leaving unchanged rates for the active. The created sfba 
models were subjected for further analysis.  
Note – sfba (Surrey Flux Balance Analysis) format is used by SurreyFBA software. 
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3.2.5.2 Flux balance analysis  
Flux balance analysis is an optimisation approach that explores the solution space 
for a GSMN. It aims to predict reaction flux values associated with the optimal 
production of a defined ‘objective function’. As previously described, the biomass 
reaction represents a surrogate marker for cell growth, and as such may represent 
a good objective function for tumour cells. In this case, it can be hypothesised that 
models generated from transcriptomic data derived from normal breast tissue 
would have a lower maximal value of biomass (i.e. lower potential growth rate) 
compared to the metabolic landscapes of matched breast tumours. Likewise, a 
higher biomass objective value would be expected for aggressive (e.g. MDA-MB-
231) compared to normal (e.g. MCF10A) cell lines. 
FBA was performed using the transformed metabolic landscapes (sfba models) for 
the 131 pairs of matched tumour and normal tissue pairs. The acquired biomass 
rates were subjected to a paired t-test analysis, with the results indicating that the 
tumour metabolic landscapes have a higher potential biomass rate (p value 
0.0352). However, the statistical significance between tumour and normal tissue 
models alone is not strong enough to conclude that tumour models exert a higher 
biomass reaction rate (Figure 15). The biomass reaction rate is a semi-
quantitative measure; therefore, the small fractional difference in flux rate 
between tumours (mean 476.6 ± 2.220 g/h) and normal tissue models (mean 
469.6 ± 2.887) may be an artefact of the semi-quantitative nature of the analysis 
rather than a true biological effect. To further explore this, a linear regression 
analysis was undertaken (Figure 16): The slope of the linear regression graph was 
calculated to be significantly non-zero (p value 0.014). However, the poor 
goodness of fit value (R2 =0.045) indicates a low confidence in the association. 
Finally, biomass reaction rate was examined in context of the previously identified 
poor prognosis cluster (Figure 18). Again, the results indicated a lack of 
association between the metabolic clusters and the biomass rate. Therefore, it can 
be concluded that the maximum biomass reaction rate does not reveal clinically 
relevant information.  
Given the complex environmental milieu that cells within the body are subject to, 
it is possible that even a rapidly dividing tumour cell is not growing at the maximal 
rate predicted by its metabolic landscape. However, cell lines are selected to 
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represent phenotypic extremes, and are grown under optimal growth conditions; 
under these conditions it is more likely that cells will approach the maximal 
growth rate predicted by the metabolic landscape. When the biomass reaction rate 
was examined for the cell line models the results indicate a significant difference 
between the cell lines (Figure 17); MDA-MB-231 cells have the highest predicted 
maximal biomass rate, with MCF10a and MCF7 cells predicting similar biomass 
flux rates. This appears consistent with the designation of the MDA-MB-231 cell 
line as representing an aggressive phenotype, while MCF-7 cells are seen as less 
aggressive. However, it should be noted that the predicted maximal biomass rate 
do not correlate with the published doubling times for each cell line:, where the 
inverse relationship is seen MCF10a doubling time is 16 hours (NCI-PBCF-1000-
SOP-052814_508), MCF-7 24 hours (NCI-PBCF-HTB22_MCF7_SOP-508.) and MDA-
MB-231 38 hours (NCI-PBCF-HTB26_MDA-MB-231_SOP-508).  
Together these data support that prediction of maximal biomass rate does not 
correlate to actual growth rate, in both clinical samples and experimental models.  
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Mean ± SEM of tumour models 476.6 ± 2.22, n=131 
Mean ± SEM of normal tissue models 469.6 ± 2.89, n=131 
 
Figure 15- Comparison of the predicted biomass reaction rate for the tumour and matched normal 
tissue models.  
A paired t-test reveals a significant difference between the samples (p value = 0.0352), although 
this must be treated with caution due to the significant overlap observed. 
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Figure 16 - linear regression analysis, comparing biomass reaction rate of tumours and matched 
normal tissue models.  
The slope is significantly non-zero (p value 0.014), consistent with a positive association between 
the biomass flux rate in tumours and matched normal tissue. However, this does not confirm the 
hypotheses that tumour models exert higher biomass rate, because the slope is modest (0.2785 ± 
0.01118) and R2 is poor (0.045). 
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Figure 18 - Biomass reaction rates for each of the metabolic clusters identified within the Metabric 
discovery dataset.  
The reconstructed models were subjected to FBA analysis in order to determine the maximum biomass 
reaction rate.  One way ANOVA statistical analysis was performed. 
Figure 17 - Predicted biomass reaction rate for breast cancer cell lines. 
The biomass reaction rate is a semi-quantitative measure, hence should correspond to the relative growth 
rates. However, the actual growth rates as acquired from ATCC represent different doubling times. 
According to the ATCC provided growth rates, the MDA-MB-231 doubling time is 38 hours, MCF-7 24 hours 
and MCF10a 16 hours. Hence an accurate biomass rate results should indicate the highest reaction rate for 
MCF10a cells and slowest for the MDA-MB-231. Biomass reaction rate for each cell line was determined 
from three metabolic models.  
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3.2.5.3 Reaction essentiality analysis 
Reaction essentiality analysis is an approach that identifies metabolic reactions 
that are essential to reach an objective function. In the scenario of cancer 
modelling, where biomass flux is the objective function, these essential reactions 
may represent targets for cytotoxic drugs as blocking these reactions would 
prevent the cell from dividing [128]. In this analysis, the importance of each 
reaction towards the biomass reaction rate is evaluated by calculating the biomass 
objective value when each reaction is fully closed.  
To test the applicability of personalized sfba models as a prediction tool for 
personalized medicine, reaction essentiality analysis was performed. Models 
acquired from transcriptomic analysis of the breast cancer cell lines was used due 
to the possibility of further in vitro validation: this would act as proof-of-concept 
for analysis of personalised metabolic landscapes from the Metabric clinical 
dataset. The effect on biomass reaction rate was examined by disabling each 
reaction sequentially, a total of 7440 FBA simulations for each model. Table 16 
shows selected essential reactions that were predicted to exert detrimental effects 
on the growth rate of breast cancer cell lines (MCF-7, MDA-MB-231), but not the 
cell line representing ‘normal’ breast (MFC10a). Supplementary table S6 provides 
a full list of reactions that reduce the biomass reaction rate, as determined via 
reaction essentiality analysis 
It is interesting to note that the reaction essentiality analysis failed to highlight 
reactions that are currently targeted by cytotoxic drugs, such as 
methylenetetrahydrofolate reductase. A likely explanation for this is that the lack 
of reaction bound constraints results in a large solution space. This means that 
production of metabolites may be redirected via several routes, reducing the 
sensitivity of the reaction essentiality analysis. Nevertheless, the analysis 
identified several reactions with the potential to be druggable targets (Table 16). 
This includes phosphatidylinositol synthase (CDIPT), which has been previously 
implicated as a metabolic target in vitro. Baba et al. demonstrated that the CDIPT 
inhibitor inostamycin exerts cytostatic effects on oral squamous cell carcinoma 
cell lines [173]. Unfortunately, inostomycin is no longer commercially available, 
limiting the ability to test its impact on breast cancer cell lines. In addition to 
CDIPT, several other targets were selected as being potential druggable targets to 
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reduce the growth rate in breast cancer cell lines. Unfortunately, the absence of 
specific pharmacological inhibitors hindered the ability to undertake in vitro 
validation. A small interfering RNA approach was designed to be performed at the 
end of the study, however due to the time constraint these experiments were not 
concluded.  
 
 MCF10a MCF-7 MDA-MB-231 
SMS Death Death Death 
CLS Death Death Death 
CDS No effect Death Death 
CDIPT 
 
No effect Death Death 
r1116 No effect Biomass reduction by 35% Biomass reduction by 
35% 
Table 16 represent the selected reactions, specifically targeting cell lines. Reactions such as SMS 
and CLS produces the key constituent metabolites, that are present in the biomass reaction, hence 
the inhibition of reactions is shown to prevent biomass formation. On the other hand reactions 
such as CDS and CDIPT are cell line specific, hence could be further in vitro validated.  
CDS - phosphatidate cytidylyltransferase, CDIPT - CDP-diacylglycerol-inositol 3-
phosphatidyltransferase, r1116 - ATP Exporter (ATP-E) Mcd4 TCDB:9.A.6.1.1, SMS - 
Sphingomyelin synthase, CLS - cardiolipin synthase.  
 
In summary, reaction essentiality analysis was able to identify some reactions 
whose inhibition may reduce the cell growth rate. However, overall the predictive 
ability demonstrated a low sensitivity, most likely due to a lack of physiologically 
relevant reaction flux rate constraints in the Recon2 metabolic network.  
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3.3 Discussion  
This project was designed to explore the metabolic adaptations that occur during 
breast cancer by using personalized metabolic models as a tool. Analysis of patient 
specific metabolic models can reveal patient specific metabolic adaptabilities that 
can serve as biomarkers and potential targets for the therapeutic intervention. 
Metabolic modelling was performed initially to compare tumour and matched 
normal tissue models, which are a subset of the Metabric dataset. The rationale 
behind this approach is that it allows determination of how cancer metabolism 
differs from the tissue of origin, excluding any confounding from heterogeneity in 
normal breast tissue [174]. The ability to identify physiologically relevant 
metabolic differences unique to the tumour models will not only provide novel 
biological insights, but supports the utility of the computational approach (the in 
vitro validation is discussed in the next chapter).  
Active tryptophan production, plus the related metabolite kynurenine production, 
was the most commonly differentially regulated metabolic system between the 
predicted tumour and matched-normal metabolic landscapes. Consistent with this 
prediction, the uptake of tryptophan and subsequent production and excretion of 
kynurenine has been previously demonstrated to occur in breast cancer cell lines 
(MCF-7 and MDA-MB-231) [175]. In addition, Lyon et al. reported elevated 
kynurenine plasma concentrations in breast cancer patients compared to the 
healthy individuals [176]. This evidence strongly supports that breast tumours 
undergo a metabolic shift to increased kynurenine synthesis, which has been 
suggested to result in immune response evasion [169]. Kynurenine is a ligand for 
aryl hydrocarbon receptor (AhR), activation of which has both genomic and non-
genomic effects. One of the proposed mechanisms indicates that activation of AhR 
promotes generation of the immune response suppressors T regulatory cells 
[177]. In addition to immune evasion the activation of AhR within cancer cells 
leads to upregulation of genes inducing proliferation and migration [169]. 
Therefore the synthesis of kynurenine and the subsequent transport to the 
extracellular space regulates cancer cells gene expression pattern, as well as 
influencing immune cells, leading to suppression of immune response, and 
increased evasion [178]. The recovery of a breast cancer-specific metabolic 
adaptation (kynurenine synthesis) that has been previously validated both in vitro 
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and through clinical studies is a strong validation of the computational approach, 
demonstrating it can recover known metabolic/phenotypic shifts that occur 
during breast cancer.  
Active metabolism of chondroitin sulphate, a component of the extracellular 
matrix, was also identified as being differentially activated in tumour tissue [179, 
180]. The metabolism of chondroitin sulphate has been associated with metastasis 
in aggressive breast tumours [180]. Increased ECM metabolism allows tumour 
cells to escape the primary site and establish secondary tumours in distant 
locations (metastases) [181]. The recovery of a second well-established 
metabolic/phenotypic shift in breast cancer further supports the use of our 
computational approach to identify the metabolic landscape of tumour cells and 
predict the emergent biological phenotype.  
We have demonstrated that the GEBRA algorithm captures metabolic differences 
between tumours and matched normal tissue models. The performed analysis 
revealed tumour specific metabolic adaptations that increase cancer survival and 
promote an aggressive tumour phenotype. Most importantly, the highlighted 
metabolic adaptations were not recovered by traditional differential gene 
expression analysis. This supports metabolic landscape prediction as a 
complimentary technique to leverage new information from omic level analysis of 
cancer.  
The next step undertook analysis of the transcriptomics data of the entire 2,000 
primary breast tumour Metabric dataset. This large dataset, coupled with clinical 
and survival data, should allow the recovery of metabolic traits associated with 
poor and/or enhanced survival. Such information could potentially serve as a 
basis for the personalized therapeutic interventions.  
A small proportion of breast tumours are associated with poor patient survival, 
and possess aggressive, metastatic phenotypes [91]. While these represent only 
10-20% of all breast cancers, they are responsible for the majority of breast cancer 
related deaths. Evidence demonstrates that the metabolism of aggressive tumours 
is different from the more benign counterparts, although this has not been 
undertaken on a whole-genome level to date [79, 182, 183]. The most commonly 
observed metabolic differences associated with poor prognosis within data 
should drive clustering, deriving poor prognosis clusters that can be examined in 
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more detail. To this end, K-Means clustering was undertaken to identify samples 
associated with low survival probability.  
A major challenge in clustering approaches is the discriminative power and 
reproducibility of the derived clusters. Analysis of the Metabric dataset addresses 
these two issues; first, the Metabric dataset represents the largest, most 
comprehensive study to date. In the current analysis the median size of the 
derived clusters was 119 patient samples, with the smallest consisting of 68 
samples. Second, the Metabric dataset is divided into two groups, the discovery 
and confirmatory datasets, which consist of 997 and 995 samples, respectively. 
This means that clustering analysis can be undertaken on two, large, independent 
datasets, increasing the robustness of any findings. The analysis of the 
confirmatory dataset replicated the results of the discovery dataset, establishing 
the validity of the poor survival group. This group compromised 13.4% of the 
discovery models and 10.8% of the confirmatory set (130  and 108 patient 
samples), which is consistent with the reported proportion of aggressive tumours 
in the wider patient population. Additionally, both poor prognosis clusters 
retained traits associated with aggressive drug resistant breast cancer tumours, 
such as higher grade, younger onset, and belonging to the basal intrinsic molecular 
type. Moreover, the majority of samples belonging to the poor prognosis cluster 
are also associated with poor survival by the original molecular clustering, 
performed by the Metabric study. The identification of the poor prognosis patients 
using two different approaches is a positive result, each study (ours and Metabric) 
reveals unique information about the aggressive breast tumours. The Metabric 
study shows molecular (gene expression) differences, whereas our study 
uncovers the metabolic differences. Most importantly, the revealed information of 
poor prognosis breast cancer patients does not overlap between the studies, but 
rather complement each other.  
Clinical data strongly supports that the recovered poor prognosis group 
represents an aggressive disease. Further analysis of the identified poor prognosis 
metabolic models highlighted metabolic mechanisms that grant a survival 
advantage to these tumours compared to all other tumours: these mechanisms, 
plus in vitro validation, are expanded in chapter 4.  
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Uncontrolled division is one the main cancer traits [109]. Therefore, cancer cells 
have an optimised metabolism, which supports the uncontrolled growth rate 
[109]. The use of the biomass reaction as an objective function represents cellular 
growth [184]. Therefore, the optimisation of metabolic network by using a 
biomass reaction as an objective function is a suitable method to reveal the 
metabolic adaptations, which support the hallmark of uncontrolled division [119]. 
GEBRA algorithm generates the metabolic landscapes, which in turn reveals the 
metabolism of each individual tumour. However, in order to perform additional 
simulations, the metabolic landscapes were transformed into functional models. 
The GEBRA algorithm constricts the generic genome scale metabolic model using 
gene expression data, and in return provides activity state and range of flux rate 
for each reaction. Such information was used to further constrain sample specific 
genome scale metabolic models, for additional analysis such as flux balance and 
reaction essentiality.  
The flux balance analysis calculated the maximum possible growth rate (biomass 
rate) for each model [119]. Theoretically, models with the highest biomass rate 
would be capable of dividing at the fastest rate, and would represent more 
aggressive tumours. To examine this assumption, two correlations were 
investigated. In the first, the predicted biomass rate for tumours were compared 
to their matched-normal tissue, with the hypothesis that biomass flux would be 
higher in tumour tissues. In the second analysis, biomass rate was predicted for 
several breast cancer cell lines, and compared to the phenotype and doubling time 
for these cell lines. Analysis of the Metabric pair-matched samples revealed no 
associations. 
 We concluded that the calculated biomass rate did not correlate with the 
aggressiveness status, nor did it provide reliable information of the cell division 
rate. Additionally, models with higher biomass reaction rate were not associated 
with unique prognosis status. The explanation for the inaccurate biomass reaction 
rate can be attributed to the relaxed reaction rates that are present in the Recon2. 
The absence of physiologically relevant reaction flux rates in the GSMN is the main 
reason that impacted FBA analysis results. Acknowledging this drawback of 
flexible reaction rates, the created models were further investigated with reaction 
essentiality analysis.  
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The validation of systems biology results is a difficult process, due to complexity 
of biological systems, which is not captured even by the most comprehensive 
models [185]. In most of the cases, clinical systems biology models cannot be 
validated, therefore it is a common practice to perform validation of the emerging 
properties by using cancer cell lines [185]. 
Reaction essentiality analysis reveals the effect each reaction exerts on the 
producibility of a given objective function: this allows identification of those 
reactions that are ‘essential’ to reach the objective function [186]. Within the 
current project, biomass is used as the objective function, reflecting the basic 
requirement of tumour cells to replicate. The principle of reaction essentiality 
analysis is that the growth rate (biomass reaction rate) is determined using FBA 
when each reaction within the GSMN is inhibited. In this project, metabolic 
landscapes predicted for three breast cancer cell lines were subjected to reaction 
essentiality analysis. These models represent aggressive tumours (MDA-MB-231), 
good prognosis tumours (MCF-7), and a ’normal’ breast cell line (MCF10a). The 
reaction essentiality analysis revealed only a few reactions predicted to affect 
biomass objective value to a significant degree. This is perhaps unsurprising given 
the known robustness of biological systems, where alternative routes can be 
utilised if one pathway is inhibited [187]. However, it should be noted that the 
models failed to predict key reactions targeted by known cytotoxic drugs, 
suggesting that the reconstructed models are too flexible and allow non-realistic 
alternate metabolic routes to occur. Such a flexible network could result due to 
reaction bounds being unconstrained within the GSMN, as previously described. 
Nevertheless, our approach was able to identify pathways crucial for MCF-7 and 
MDA-MB-231 growth, but not the ‘normal’ MCF10a cell line.  
The reaction essentiality analysis predicted that inhibition of reactions (CDS and 
CDIPT), involved in phosphatidyl-1D-myo-inositol (PI) synthesis, would not affect 
the viability of MCF10a cells, but would exert detrimental effects on MCF-7 and 
MDA-MB-231 cell lines (Figure 19).  
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Figure 19 – Essential metabolic reactions.  
CDS and CDIPT produce CDP-diacylglycerol, which is further converted into cardiolipin.  
CDS - phosphatidate cytidylyltransferase, CDIPT - CDP-diacylglycerol-inositol 3-
phosphatidyltransferase, CLS - cardiolipin synthase 
 
PI is an integral component of the membrane and an important constituent of 
intracellular signalling pathways (Akt) [188]. As can be seen from Figure 19, PI 
and diacylglycerol are associated with further metabolism to form cardiolipin, 
which is a constituent of the biomass reaction. Therefore, limitation of PI and cdp-
diacylglycerol is predicted to have a detrimental effect on cell growth. It is unlikely 
that CDS or CDIPT represent viable pharmacological targets for the treatment of 
cancer due to their central role in phospholipid synthesis [189]. Inhibition of these 
enzymes would almost certainly lead to an unacceptable high adverse effect 
profile due to the essential role of phospholipids in mammalian biology, in 
particular inhibition of cardiolipin synthesis is associated with various 
pathological effects [190, 191]. However, their identification does raise the 
possibility of targeting cardiolipin synthesis instead. This would remove the 
potential issue of reduced phospholipid synthesis, but would still cause 
mitochondrial membrane instability as cardiolipin is an important membrane 
component [192]. Research has indicated that reduction of the cardiolipin 
synthesis rate causes apoptosis in the MDA-MB-231 cell line [193]. While this 
supports the importance of cardiolipin in breast cancer cell line growth, further 
validation is required to confirm such results. In addition to studying more breast 
cancer cell lines, it would be important to examine the effect on MCF10A cells; as 
these are supposed to reflect normal tissue and are predicted not to have 
detrimental effects on cell growth through inhibition of CDS or CDIPT. There are 
no known cardiolipin synthase inhibitors or modulators currently available, 
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meaning that any subsequent experiments would have to be performed using 
alternative methods, such as inhibition of RNA production by using small 
interfering RNA (siRNA).  
The metabolic analysis described in this chapter successfully integrates 
transcriptomics data with genome scale metabolic networks. The created 
metabolic landscapes capture known biological features of cancer, supporting 
their utility in detecting possible novel treatment options.  
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4 In vitro validation of the computational results 
4.1 Introduction 
This chapter describes the in vitro validation of the metabolic traits specific to the 
poor prognosis cluster that were identified in chapter 3. Specifically, the potential 
role of the opioid peptide degradation and serotonin production pathways were 
examined. These pathways were predicted to be predominantly active in 
individuals within the poor prognosis cluster, but inactive within other patient 
tumour samples. This leads to the prediction that these pathways are 
discriminatory for poor prognosis tumours, but does not determine if they are 
causative or consequential of this phenotype. As these are computational 
predictions, as opposed to a proven metabolic phenotype, it is important to 
undertake further validation in breast cancer cell lines to confirm these 
predictions. In addition, this may shed further light on whether the predicted 
metabolic changes are able to drive a pro-proliferative, pro-survival phenotype or 
not.  
4.2 Prediction 1 - the degradation of the opioid peptides promotes cancer 
growth 
The opioid peptides are defined as short sequences of amino acids that bind to and 
activate the opioid receptors [194]. The use of exogenous opioid receptor agonists 
such as morphine are widely known for their analgesia and euphoria causing 
effects, marking them both as potent therapeutic agents and potential drugs of 
abuse. It should be noted that the physiological responses to opioids are much 
wider, and include sedation, constipation, and respiratory collapse [195]. This is 
consistent with the observation that endogenously produced opioid receptor 
agonists (peptides) modulate multiple cellular processes that impact on a range 
of physiological functions. Of particular interest in the context of this thesis is the 
fact that opioid receptors activation has been reported to modulate cyclic AMP 
(cAMP) concentration, which can regulate cell cycle progression[196]. Despite 
being widely discussed, the implications of this for the role of opioid peptides in 
cancer progression and/or treatment is unclear; however, the weight of evidence 
supports a role for opioid peptides as anti-tumourigenic agents (further discussed 
in section 4.2.1.2.).   
 110 
Based upon the current literature, a proposed model for the anti-proliferative, 
anti-tumourogenic effects of opioid peptides in breast cancer is presented in 
Figure 20. Within breast tissue the casomorphin milk peptides are produced 
[197]. These molecules are opioid receptor agonists, potentially causing local 
activation of mu and kappa opioid receptors[198]. Activation of opioid receptors 
is known to inhibit the conversion of AMP to the signalling molecular cAMP via the 
enzyme adenyl cyclase [199, 200]. cAMP is able to stimulate proliferation through 
a PKA-mediated cascade resulting in ERK1/2 activation[200]. Therefore, opioid 
agonists such as the casomorphins are seen as anti-proliferative as they inhibit 
initiation of this pathway. The metabolic landscapes associated with poor patient 
prognosis are associated with active casomorphin degradation when compared to 
all other tumours. This is predicted to reduce the local concentration of 
casomorphins, removing the opioid receptor-mediated inhibition of cAMP 
production, and resulting in a pro-proliferative signalling cascade.   
The computational analysis described in Chapter 3 identified the hydrolytic 
angiotensin-converting enzyme 2 (ACE2) as playing a central role in opioid 
peptide degradation. Therefore, further investigations were conducted to 
examine the effects of opioid peptides, and the inhibition of the ACE2, on breast 
cancer cell lines. The following paragraphs describe the opioid peptide regulation 
system in more detail, and provide the objectives for this series of in vitro 
experiments.  
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4.2.1.1 Opioid receptors 
 
 Figure 20 depict the proposed opioid peptide involvement in breast cancer.  
The activation by the opioid peptides (-casomorphin, neocasomorphin) inhibits PKA signalling, which  
in turn reduces the proliferation rate. The computational analysis has identified the degradation of 
opioid peptides to occur in the poor prognosis metabolic breast cancer group. The ACE2 enzyme 
orchestrates the process of the hydrolysis by freeing the amino acids, which are further incorporated to 
the biomass reaction. Moreover, the remaining peptides can be detected within blood, and serve as the 
potential biomarkers. Although, the signalling network has not been identified by our modelling 
approach, it serves as a logical explanation towards the possible mechanism of action the poor prognosis 
metabolic group evolved to increase its tumourigenicity. 
 
 112 
Opioid receptors belong to the superfamily of G protein-coupled receptors 
(GPCRs) and are classified into 3 groups: kappa (; KOR), mu (μ; MOR) and delta 
(δ; DOR) opioid receptors [201]. Opioid receptors share 60% amino acid 
similarity, with the greatest region of variance being the N-terminus and 
extracellular loops [201]. The encoded receptors transduce signals in a similar 
fashion, regardless of their classification, and regulate the same range of effectors. 
These include adenylyl cyclase (AC), phospholipase C (PLC), ERK1/2 and the Ca2+ 
and K+ channels [201]. 
Opioid receptors not only share signal transduction pathways across the family, 
but also cross talk with other receptors, including the Oestrogen receptor (ER), 
epidermal growth factor receptor (EGFR), α2-adrenergic, cannabinoid 1 receptor 
(CB1), chemokine CCR5 receptors and adenosine receptors [202-205]. It is likely 
that the exact biological response to opioid receptor activation depends not only 
on the expression of the opioid receptor subtypes, but also the 
expression/activation status of all these interconnected signalling pathways. An 
example of such cross-talk is shown in (Figure 21), whereby the action of opioid 
receptor activation may lead to differing effects dependent on the status of ER and 
EGFR activation, a scenario that is particularly pertinent in breast cancer. 
Additionally, opioid receptors interact with a wide range of co-regulator proteins 
(opioid receptor interacting proteins), which result in both the trans activation of 
opioid receptors as well their interaction with other receptor classes [206]. Due 
to these complex interactions, the emergent biological phenotype following 
activation of the opioid receptor signalling pathway is difficult to predict and 
almost certainly context-specific (Figure 21).  
In summary, opioid receptors regulate a wide range of cellular processes and have 
been experimentally demonstrated to act as both tumour promoting and 
inhibiting agents (section 4.2.1.2). While the signal transduction primaraly occurs 
via inhibition of the adenylyl cyclase, the activation status of a range of other 
receptors may modulate or negate this effect, altering the emergent biological 
phenotype.  
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Figure 21 shows opioid receptor signalling. 
 The activation of opioid receptors (OR) inhibits adenylyl cyclase (AC) activity, which results in the reduced 
signalling of the PKA. However, the activation of OR also co-actives endothelial growth factor receptor (EGFR) 
which leads to activation of the ERK signalling. Additionally, activation of EGFR leads to increased synthesis of 
the prostaglandin 2 (PGE2), which in turn binds to and activates prostaglandin E2 (EP) receptor leading to the 
subsequent activation of the AC. This figure serves as an example to emphasize the complexity of the opioid 
receptor signalling, because OR interact with a range of other receptors. Therefore the signal transduction may 
transcendence the expression of OR and depend on the expression of opioid receptor interacting proteins and 
co-activated receptors.  As this example indicates, the activation of opioid receptors may activate and inhibit 
adenylyl cyclase activity at the same time.  
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4.2.1.2 Opioid receptors and their relationship with cancer  
Deregulated metabolism and signalling are characteristics common to all cancers. 
As opioid receptors transmit signals via pathways utilised in many biological 
processes (PKA, AC, Akt, ERK), it is therefore not surprising that deregulated 
opioid receptor signalling has been linked to cancer [207]. As shown in Table 17, 
the experimental evidence is mixed, supporting both pro- and anti-tumourogenic 
effects of opioid receptor activation. This conflicting data is most likely explained 
by the known cross-talk between opioid receptors and other receptors, as well as 
the pharmacology of the individual agonists (i.e. dose, exposure, selectivity). For 
example, high dose, chronic exposure of morphine inhibits tumour growth, while 
low concentration, daily exposure exerts tumour promoting effects [208]. 
 
Pro Tumorigenic effects Anti tumorigenic effects 
Morphine promotes growth of 
MDA-MB-231 cells in mouse 
models [209].  
Morphine inhibits tumour growth of MDA-
MB-231 and MCF-7 cell lines in null mouse 
models [210].  
Nalaxone inhibits Oestrogen 
receptor signalling in MCF-7 cells 
[211]. 
Chronic morphine treatment prevents 
growth of breast cancer BT474 cells [212]. 
Nalaxone inhibits proliferation of 
MCF-7 cell line [211].  
At high concentrations (>10μM) morphine 
inhibits adenocarcinoma growth [213]. 
Morphine and DAMGO increase 
proliferation rate of the lung 
cancer cells[214]. 
Opioid peptides (-casomorphins) and 
opioid alkaloids (DAMGO) reduce cell 
viability in prostate cancer cell lines 
(0.01nM-10μM concentration) [215].  
MOR expression is associated 
with worse survival in prostate 
cancers [216]. 
Opioid receptor agonists reduces breast 
cancer cell line (T47D) rate of 
proliferation [215, 217].  
Metastatic lung cancers over 
express MOR receptor [218]. 
Opioid peptide (DADLE, 10-100nM), 
reduce breast cancer cell line (MCF-7) 
growth rate [219].  
Breast cancer patients containing 
non-functional MOR receptor 
allele exerted the lower mortality 
rate [220]. 
Opioid peptides (-casomorphins and -
caseins) reduces T47D cell growth 
0.01nM-10μM concentration) [221] 
Table 17 shows evidence of opioid recptor involvement in cancer promoting and ihibiting events. 
Naloxone is MOR receptor antagonists, morphine and DAMGO are MOR receptor agnoists. 
Numerous studies has shown that activation of opioid receptors can promote, inhibit or exert no 
effect upon activation.  
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4.2.1.3 The role of angiotensin converting enzyme II (ACE2) in opioid metabolism 
ACE2 is a C-terminus carboxypeptidase, meaning that it removes an amino acid 
from the C terminus of proteins/peptides. Its primary function is the catalytic 
inactivation of the vasoconstrictive peptide angiotensin II (Ang II) [222]. Due to 
interest in the renin-angiotensin system, ACE2 has received considerable 
attention [223]. As a result, additional ACE2 substrates have been identified, 
demonstrating that ACE2 has wide substrate specificity, being able to hydrolyse 
11 peptides (out of 126 tested peptides) [224]. While ACE2 exerts the highest 
binding affinity toward angiotensin II (Kcat/Km = 1.9 × 106 m−1s−1), it also has 
considerable catalytic activity toward a number of other endogenous peptides: 
apelin 1-13 (Kcat/Km= 2.1 × 106 m −1s−1), dynorphin A 1-13 (Kcat/Km =3.1 × 106 
m −1 s−1), neocasomorphin, and -casomorphin (Kcat/Km ≥ 1 × 105 m −1 s−1)[224]. 
Due to the wide biological effects of these target peptides, the biological impact of 
ACE2 is not confined to regulation of the cardiovascular system, but plays an 
important role in normal kidney function, as well as pathological conditions such 
as diabetes and cancer [223, 225].  
4.2.1.3.1 ACE2 and cancer  
Lower ACE2 levels are associated with a number of cancers, including pancreatic 
ductal carcinomas, renal tumours and skin adenocarcinomas [5, 226-228]. In 
addition, a higher ACE2 expression level has been predicted to be a positive 
survival factor in primary laryngeal cancers [229]. Overexpression of ACE2 has 
been shown to attenuate metastasis in lung cancers [225], and to inhibit 
proliferation, invasion and angiogenesis of non-small-cell lung carcinoma cells 
[230]. It should be noted that a few reports support the opposite association, with 
overexpression of ACE2 suggested as a prognostic factor for the metaplastic 
gastric cancers [231]. 
Together, these clinical data support a negative association between ACE2 
expression and tumour development, with low ACE2 levels a good prognosis 
biomarker.  
4.2.1.3.2 Pharmacological Inhibition of ACE2  
ACE2 is a carboxypeptidase with 40% identity and 61% similarity to its 
orthologue, angiotensin-converting enzyme (ACE) [222]. However, ACE2 is 
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defined by the unique substrate specificity and has no pharmacological response 
to ACE inhibitors [222]. This has led to the development of pharmacological 
inhibitors specific to ACE2, such as DX600 [225, 232]. DX600 is a high affinity 
peptide inhibitor characterized by a low inhibition equilibrium constant value 
(2.8nM), that acts through both competitive and non-competitive modes of action 
[233]. Moreover, DX600 is ACE2 specific and does not inhibit ACE [233]. Research 
has shown that DX600 is a stable inhibitor that does not lose activity even after 
20h incubation at room temperature [233]. It should be noted, however, that no 
stability studies for time points beyond this, or at 37 C, have been undertaken. As 
expected based upon its Kd value, a 1μM concentration of DX600 has been shown 
to fully inhibit human ACE2 in transfected Neuro-2a cells (a mouse neuroblastoma 
cell line) [234]. To summarize, the DX600 is a stable, specific ACE2 inhibitor with 
good stability at room temperature, and is capable of fully and selectively 
inhibiting human ACE2.  
4.2.1.4 Hypothesis and objectives for prediction 1  
Within the breast, the mammary glands synthesize milk proteins that fragment 
into peptides, including the bioactive opioid peptides (i.e. caseins and 
casomorphins) [235]. This may activate the opioid receptor-signalling network 
both at the local and systemic levels. Within breast tissue, the peptidase ACE2 acts 
to inactivate these opioid peptides, reducing their biological impact and allowing 
the incorporation of hydrolysed amino acids into biomass.  
We have demonstrated that there is an association between active casomorphin 
degradation within breast tumours and poor patient prognosis. Given the role of 
opioid receptor activation in inhibiting cell proliferation, we hypothesise that this 
increased degradation of casomorphins causes the lifting of an opioid-dependent 
cellular brake, allowing tumours to proliferate more rapidly.  
To examine this hypothesis a set of in vitro experiments has been designed to 
characterise the role of opioid peptides and ACE2 in breast cancer cells. 
4.2.1.4.1 Objectives: 
 Verify the expression of molecular targets (opioid receptors and ACE2) in 
the breast cancer cell lines.  
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 Investigate the potential effects opioid peptides may exert to the breast 
cancer cell lines.  
 Investigate the role of ACE2 expression in the breast cancer cells alone 
and in relationship with opioid peptides. 
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4.3 Results – opioid peptides and breast cancer  
In chapter 3, active opioid peptide degradation was identified as a differentially 
activated pathway within the poor survival metabolic cluster. To further examine 
this, a Kaplan-Meier plot was constructed comparing the survival of patients with 
tumours demonstrating active opioid peptide degradation compared to all other 
tumours, results were also replicated using a confirmatory dataset (Error! 
eference source not found.A). It can be seen that active opioid peptide 
degradation alone is able to serve as a stratification marker for poor prognosis 
tumours. As the reactions associated with opioid peptide degradation are 
catalysed solely by ACE2, it is logical to assume that its expression would be 
elevated in these poor prognosis tumours. Examination of the Metabric transcript 
data demonstrated that tumours within the poor prognosis cluster exhibited 
statistically significantly higher ACE2 transcript levels compared to all other 
tumours (Figure 26B).  
4.3.1 Expression of ACE2 and opioid receptors in breast cancer cell lines 
Prior to examining the response of breast cancer cell lines to opioid peptides, the 
expression of opioid receptors and ACE2 was characterised for each cell line. A 
range of breast cancer cell lines was cultivated under standard conditions, lysed 
and opioid receptor and ACE2 expression identified by Western blotting (Error! 
eference source not found.). Our analysis identified three breast cancer cell lines 
that express detectable levels of ACE2 (SKBR3, MCF-7 and T47D), while MCF10a 
and MDA-MB-231 cell lines did not posses detectable levels of ACE2 protein. All 
cell lines expressed at least one opioid receptor, with the exception of SKBR3, 
which was negative for KOR, DOR and MOR. In summary, MCF7a and T467D 
represent cell lines expressing ACE2 and members of all three opioid receptor 
classes, albeit at differing levels. SKBR3 cells are opioid receptor positive and 
ACE2 negative, while MCF10a and MDA-MB-231 are opioid receptor negative and 
ACE2 positive. As such, this range of cell lines allows the examination of both the 
complete signalling pathway, and its component parts on the biological response 
to opioid stimulation.  
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Figure 23 - ACE2 serves as a biomarker of poor prognosis. 
 A) Kaplan-Meier plot compares the survival probability of all patients with the active opioid peptide 
degradation pathways against the remaining patients from the Metabric Discovery dataset. The activity of 
opioid degradation pathways has been determined using GEBRA algorithm (chapter 3) and used to divide 
dataset (997 samples) into the two group: 198 patients with active opioid degradation pathways and the 
remaining 796 patients, p-value < 0.0001 B) Graph shows a comparison of ACE2 enzyme expression 
between patients with active opioid peptide degradation pathways and the remaining patients, statistical 
significance has been determined using a T test, p-value <0.0001.   
 
Figure 22 – Western blot analysis of ACE2 systems molecular targets 
Western blotting analysis identified the molecular targets present in the breast cancer cell lines. The cell 
lines were cultivated in T25 containers until 75% confluence was reached, then subjected to the cell lysis, 
protein quantitation and Western blotting techniques. Each lane contained 45μg of the cell lysate. 
 120 
4.3.2 The impact of opioids on breast cancer cell viability  
The MTT assay is a simple colourimetirc assay to examine the activity of 
mitochondria in cells (chapter 2). As such, it provides readout on the number of 
viable cells, under the assumption that the chemical agent does not cause an 
alteration in the number of mitochondrial per cell (e.g. mitophagy). MTT assays 
were undertaken to investigate the effects of opioid agonists -casomorphin and 
apelin-13 on breast cancer cell viability.  
MCF-7, SKRB3 and T47D cell lines were exposed to -casomorphin and apelin 
across a range of concentrations (1nM-10M) using two different media (serum 
supplemented and serum free). Cells were incubated for 24h, 48h or 72h, with the 
treatment medium being replaced every 24h. As can be seen in Error! Reference 
ource not found., no significant change in cell viability was observed under any 
of these treatment paradigms. This indicates that under the treatment conditions 
used, the opioid peptides were neither pro-proliferative or cytotoxic 
One possible reason for the lack of proliferative effect could be that degradation 
of the opioid peptides by ACE2 was so rapid that an effective concentration could 
not be maintained. The MDA-MB-231 cell line should have allowed examination 
of this scenario, being opioid receptor positive but ACE2 negative, but as a second 
control the ACE2 inhibitor DX600 was used. Treatment of all cell lines with 
casomorphins in the presence of 1M DX600, compared to an IC50 of 0.09M 
[234], had no significant impact on cell viability (Error! Reference source not 
ound.). Similar results were observed when lower concentrations of DX600 were 
used, down to 0.03M (data not shown)  
A second possible explanation for a lack of response is that the applied 
endogenous ligands did not have sufficient potency to elicit an increase in cell 
viability. To examine this, the potent, specific MOR agonist DAMGO was used 
[236]. Once again, no significant impact on cell viability in any cell line was 
observed (Error! Reference source not found.).  
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4.3.3 Gap closure assay 
To corroborate the lack of proliferation observed with the MTT assay, a second 
assay was used. The gap closure assay measures cell migration rate, which directly 
correlates with aggressiveness. The gap closure assay was performed on the MCF-
7 cell line as it contains all of the components of the opioid signalling system under 
investigation, and was therefore the cell system most likely to respond. As can be 
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Figure 24 – Cell viability assay in response to the opioid peptides and DX600.   
Cells were incubated for the 72 hours with treatment medium changed daily.  Each treatment medium contained 
1M of the indicated drug. -cas - -casomorphin, DX600 – ACE2 inhibitor, Damgo – MOR agonist, Apelin – apelin 
receptor agonist. Graphs shows results of average three independent repeats. No statistical significance was 
observed using one way ANOVA.  
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seen from Error! Reference source not found., a significant gap closure was 
bserved in control cells over the 48-hour observation period, consistent with 
published literature. However, none of the treatments has a significant impact on 
the rate  
of gap closure under the tested conditions.  
Together, these data are consistent with the opioid hypothesis being incorrect. We 
can find no evidence that increased ACE2 expression has a positive effect on cell 
viability through enhanced stimulation of opioid-mediated proliferation. This 
would suggest that active ACE2 expression is consequential, but not causative, of 
the poor prognosis phenotype. 
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Figure 25 - Gap closure assay of MCF-7 cell line 
A) The representative pictures of the gap closure assay at the beginning and the end of the experiment. 
Total five pictures were taken by the treatment condition. Experiments were designed as described in 
chapter 2. B) Graph represents the results of average results of three independent repeats conducted using 
MCF-7 cell line. The results show no statistical significance using one way ANOVA test.   
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4.4 Prediction 2: Over-expression of serotonin drives a proliferative 
phenotype in breast tumours associated with poor patient prognosis 
Serotonin (5-hydroxytryptamine, 5-HT) is a ubiquitous neurotransmitter 
controlling both the central (CNS) and peripheral (PNS) nervous systems. As such, 
it is central to the regulation of various physiological functions, including 
perception of mood, digestion, lactation and development of the mammary glands 
[237, 238]. 5-HT is an important homeostatic regulator of the mammary glands, 
controlling a range of physiological and cellular processes: lactation, calcium 
absorption, maintenance of epithelial cells, apoptosis, cell shedding. This 
regulation is achieved through a paracrine-autocrine system that acts via seven 
classes of serotonergic receptors (4.4.1.2)[237, 239, 240]. Due to the wide role in 
regulation of cellular process in the mammary glands as well as other peripheral 
organs, it is not surprising that deregulated 5-HT metabolism has been implicated 
in breast cancer (4.4.1.3).  
The computational analysis of 2,000 breast tumour transcriptomic samples 
predicted that active 5-HT synthesis and transport was a trait associated with 
poor patient prognosis (chapter 3). Figure 26 presents a proposed mechanism for 
how breast cancers with active 5-HT production would gain a survival and 
proliferative advantage. Under normal conditions, 5-HT regulates cellular 
functions within the mammary gland epithelium cells. Active production of 
serotonin could result in increased local and paracrine actions, through activation 
of 5-HT receptors within the breast tissue. This would result in activation of cAMP 
formation, which signals for cellular proliferation through a PKA-dependent 
mechanism.  
In order to confirm the computational prediction, a set of experiments was 
designed to examine the effects of 5-HT on breast cancer cell lines (section 
4.4.1.4). The following paragraphs describe the serotonin system in more detail, 
and provide the objectives for this series of in vitro experiments.  
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Figure 26 Serotonin acts as a signalling molecule to promote tumour growth. Under healthy conditions serotonin 
maintains the homeostasis of the mammary gland in an autocrine-paracrine fashion via seven classes of serotonergic 
receptors. However, the dysregulated serotonin metabolism could acts as a mitogen, promoting growth via activation of 
ERK signalling pathway. 
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4.4.1.1 Metabolism of 5-HT  
Serotonin (5-Hydroxytryptamine, 5-HT) is a monoamine synthesized from L-
tryptophan in two enzymatic reactions catalysed by tryptophan hydroxylase 
(TPH) and DOPA-decarboxylase (DDC), respectively (Figure 27)[241].  
 
 
Figure 27 shows 5-HT metabolism in the cytoplasm of the epithelium cells. 
Monoamine oxidase A (MAO-A) and ALDH degrade 5-HT to 5-hydroxyindolacetic acid (5-HIAA), 
while mainly the DDC is responsible for the plasma 5-HIAA concentrations. Evidence suggests that 
high 5-HIAA plasma concentrations are associated with higher-grade tumours. 5-HIAA is excreted 
with urine. Serotonin synthesis is a 2-step process catalysed by TPH and DDC. Besides taking part 
in 5-HT synthesis, recent study identified DDC as androgen receptor activator in the prostate 
cancer cells [241, 242] 
 
Two forms of TPH have been identified: peripherally expressed TPH1 and 
neuronal TPH2 [243]. This reflects that the major sites of serotonin synthesis are 
the neurons, peripheral endothelial cells (mammary glands), platelets and 
intestinal track [242]. The intestinal and platelet-related synthesis of 5-HT 
maintains the blood 5-HT concentration in the range 0.5-44μg/L, or 2nM-200nM 
[244]. In addition, midgut carcinoid tumours have been reported to increase 
plasma 5-HT concentration [244]. The contribution towards plasma 5-HT 
concentration of production via the mammary epithelium has not been 
established. Elevated plasma concentrations of 5-HT have been previously linked 
to breast and prostate cancers: for example, a recent studies reported a positive 
correlation between higher plasma 5-HT levels and aggressive breast and prostate 
cancer statuses [245, 246]. 
Based upon these observations, it has been proposed to use plasma serotonin 
levels as prostate and breast tumours biomarker, with higher plasma 5-HT 
significantly correlating with stage, life expectancy and metastatic potential [247].  
4.4.1.2 Signalling of serotonin and cancer 
In the development of the mammary glands, 5-HT acts as an autocrine-paracrine 
regulator via activation of the serotonergic receptors to mediate normal breast 
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tissue development and function [243]. 5-HT can activate seven types of 
serotonergic receptors (5-HT1-7), all of which are G protein coupled receptors 
(GPCR) with the exception of the 5-HT3 class, which are ionotropic receptors 
(Table 18) [248]. The epithelium of breast tissue expresses a range of 5-HT 
receptors (5-HT1d,, 5-HT2b, 5-HT3a, 5-HT7), with 5-HT7 being of particular 
importance in ensuring development and function of mammary glands [237, 249, 
250]. With regard to breast cancer cell lines, there exists sparse, often conflicting 
data regarding the expression of 5-HT receptors. While 5-HT7 was demonstrated 
to be the most important receptor for healthy mammary gland epithelium cells, 
the 5-HT2 class has been suggested to play a major role in breast cancer cells [242, 
249, 250]. For example, in MCF-7 cells, activation of 5-HT2a receptor by 5-HT has 
been reported to drive the proliferative response; however, the expression of 5-
HT2a was not confirmed by a subsequent study [249, 250]. Breast cancer cell lines 
express various 5-HT receptors, with class, subtype and even expression levels 
being cell-line specific [250]. Therefore, the response on an individual cell line to 
5-HT stimulation (apoptosis, increased growth, or no response) is almost certainly 
influenced by the 5-HT receptor expression profile [237, 250, 251].  
 
Receptor Class Receptor type Signal transduction 
5-HT1A,1B,1D,1E,1F Gi/Go  Inhibits AC, stimulates ERK 
5-HT2A,2B,2C Gq/Gq  Activates PLC, PKC, PLA2, ERK 
5-HT3 Ion channel Increase Na2+/Ca2+ 
concentration 
5-HT4 Gs Activates AC, PKA 
5-HT5A,5B Gi/Go  Inhibits AC 
5-HT6 Gs Activates AC, PKA 
5-HT7 Gs  Activates AC, PKA, ERK 
Table 18 summarizes 5-HT receptors. There is a large redundancy in terms of signal transduction 
among all types of 5-HT receptors. Additionally, cancer cells may transduce 5-HT mediated 
signalling in a different way from breast epithelium cells. As higher 5-HT concentration stimulates 
apoptosis and cell death in untransformed or primary breast cells, while exert growth stimulatory 
effects in cancerous cells [242, 248, 250]. 
4.4.1.3 5-HT as a tumour growth factor 
5-HT has been shown to exhibit a complex mode of action in vitro. Dependent on 
concentration, serotonin can either stimulate or inhibit the growth rate of breast 
cancer cell lines (Table 19). It should be noted that to achieve growth inhibition, 
supraphysiological levels are required, suggesting that the normal action of 
 128 
serotonin is pro-proliferative. This observation has been reproduced more 
generally in other cell lines, as well as in animal models, affecting tumours such as 
prostate, bladder, small-cell lung carcinoma, colorectal carcinoma, cholangio 
carcinoma, choriocarcinoma and hepatocellular carcinoma [242, 252-254]. Drugs 
that affect 5-HT concentration indirectly have also been implicated in promoting 
metastatic behaviour in breast cancer cell lines [255]. For example, inhibition of 
monoamine A oxidase (MAO-A), the enzyme responsible for degradation of 
serotonin, by clorgyline has been demonstrated to alter growth, migration, 
invasion and adhesion in MCF-7 and MDA-MB-231 cell lines [255].   
 
Cell line Effect Concentrations 
pHMEC Inhibitor 500μM, 750μM, 1mM, 25mM 
MCF-10a Inhibitor 100μM, 500μM, 750μM, 1mM, 25mM 
T47D Stimulator 50μM, 100μM, 500μM 
Inhibitor 1mM, 25mM 
MDA-MB-231 Stimulator 0.5μM, 5μM, 50μM, 100μM, 500μM 
Inhibitor 1mM, 25mM 
MCF-7 Stimulator 1.25μM, 2.5μM, 5μM, 10μM, 20μM 
Table 19 summarizes 5-HT action as a growth regulator in various breast cancer cell lines. At 
physiological concentrations 5-HT promotes cancer growth and at supraphysiological 
concentrations acts as an inhibitor [241, 249, 250]. 
 
The evidence above strongly supports a role for serotonin as a tumour-promoting 
agent. While supraphysiological concentrations may lead to growth inhibition, 
biologically realistic levels are associated with a pro-proliferative phenotype, both 
in vitro and in vivo. Within this biologically realistic range, elevated plasma 
concentrations has been associated with poor prognosis, higher grade tumours. In 
addition, evidence exists for an association between use of serotoninergic 
antidepressants and a higher breast cancer relapse rate [4]. Although, a different 
meta-analysis revealed no association between the use of SSRIs and the increased 
risk of breast cancer [256]. SSRIs act to alter local levels of serotonin through 
blockade of cellular uptake and degradation. Their use might, therefore, be 
expected to drive a serotonin-mediated pro-proliferative phenotype, and be 
associated with increased rates of breast cancer. Several explanations exist that 
may explain this lack of agreement: first, SSRIs may activate a negative feedback, 
reducing local serotonin production in the breast, meaning no net change in local 
serotonin concentrations; second the enhanced proliferative effect may act only 
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as a promoter of extant tumours, rather than increasing their initiation; third, our 
study suggests only a subpopulation of tumours (~20%) have active serotonin 
production [257]. As a result, SSRIs could increase the risk in only a subgroup of 
the breast cancer patients, which could be masked in a meta-analysis using 
heterogeneous study populations. The use of SSRIs such as fluoxetine has been 
observed to exert synergistic effects with anti-cancer drugs. [258]. However, these 
effects are mediated through modulation of drug-metabolizing enzyme activity 
and not through 5-HT signalling pathways. 
To summarize, serotonin has been show to act as a mitogenic factor for various 
cancer cell lines as well as normal cells at physiological levels. A number of studies 
investigating the role of 5-HT in the regulation of breast cancer cell lines strongly 
support serotonin as a mitogen and tumour promoting agent in breast cancer, 
leading to increased growth rate and mesenchymal to epithelial conversion rate 
(i.e. a cancer stem cell molecular profile, which is associated with aggressiveness, 
metastasis and drug resistance). 
4.4.1.4 Objectives 
In order to validate the computational results acquired in chapter 3 a set of in vitro 
experiments were performed to investigate the affect of 5-HT on breast cancer cell 
lines (MCF-7, MDA-MB-231, SKBR3, MDA-MB-231). The validation process 
included:  
 Validation of the molecular targets (receptors and key metabolic 
enzymes), 
 Cell viability in response to stimulation with 5-HT and inhibition of DDC 
enzyme 
 Analysis of 5-HT concentration in response to the inhibition of DDC 
 Involvement of ERK signalling in response to 5-HT stimulation.   
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4.5 Results - serotonin production  
In chapter 2, active serotonin synthesis was revealed as a trait associated with the 
poor survival metabolic group. Further analysis revealed that active 5-HT 
synthesis is associated with lower survival probability (in both Discovery and 
Confirmatory sets), when active 5-HT synthesis was evaluated on its own (Figure 
30A). DOPA decarboxylase (DDC) is responsible for final step in the production of 
5-HT, and when those tumours with active 5-HT synthesis (180 samples) were 
compared with the remaining tumours (817) DDC transcript level was seen to be 
significantly enhanced (Figure 30B).  
 
 
 
  
B) A) 
0 100 200 300
50
60
70
80
90
100
Months 
S
u
rv
iv
a
l 
 (
%
)
Metabric Discovery Dataset
Patients with active 
serotonin synthesis
Patients with inactive serotonin 
synthesis
Active serotonin synthesis The remaining patients
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
DDC expression
E
x
p
re
s
s
io
n
 u
n
it
s
 l
o
g
2
 t
ra
n
s
fo
rm
e
d
****
Figure 28  – 5-HT serves as a poor prognosis biomarker.  
The serotonin synthesis pathways have been determined using GEBRA as discussed in chapter 3. The figure 
compares all patients with active serotonin synthesis, not only the poor prognosis group. Statistical 
analysis has been performed using GraphPad Prism 6. A) Patients with active 5-HT synthesis (180 patients) 
contain lower survival probability and overexpress DDC compared to the remaining patients (817) of the 
Metabric Discovery dataset., p value = 0.0153. B) DDC expression value was determined using DDC probe 
expression values, t test p value <0.0001. The detailed acquisition of gene expression values, are provided 
in chapter 2.  
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4.5.1 Expression of Tph1/2 and DDC in breast cancer cell lines 
As shown in Figure 27, TPH1/2 is responsible for the conversion of tryptophan to 
5-hydroxytryptophan, while DDC further metabolises 5-hydroxytryptophan to 
serotonin. The expression of TPH1/2 and DDC was examined at the protein level 
in a range of breast cancer cell lines (Figure 31). Western blot analysis confirmed 
that MDA-MB-231, SKBR3, MCF-7 and MDA-MB-468 cell lines all expressed 
TPH1/2 and DDC. It should be noted that the expression level of both DDC and 
TPH1/2 varies between cell lines, both in absolute and relative terms. The 
neuroblastoma cell line SH-SY5Y was included as a positive control for expression 
of both DDC and TPH1/2. 
 
  
. 
 
Figure 29 - Western blot validation of TPH1/2 and DDC in the tested breast cancer cell lines.  
SHSY5Y is a cell line derived from the neuroblastoma and was used as a positive control for 
TPH1/2 and DDC detection, 25g of total protein has been loaded as a positive control. Each other 
lane contained 45g of total protein.  The method is described in chapter 2 
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4.5.1.1  Serotonergic system in breast cancer cell lines    
 
Serotonin may activate a range of serotonin receptors, consisting of seven classes 
and multiple subtypes (Table 18). A full proteomic analysis of these receptors is 
beyond the scope of this thesis, and would be technically challenging due to lack 
of antibody specificity. Therefore, transcriptomics data from 51 breast cancer cell 
lines was analysed. As can be seen in Figure 30, all cell lines express at least one 
5-HT receptor subtype, with the majority having significant expression levels of 
multiple transcripts. Once again, the absolute and relative expression levels vary 
by cell line.  
These data support that all breast cancer cell lines express a combination of 
serotonin receptors, plus the synthetic enzymes DDC and TPH1/2. Hence, the 
breast cancer cell lines used in the current study should contain all the molecular 
components to allow examine the impact of serotonin of cell viability. 
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4.5.1.2 Serotonin receptors 
 
 
 
Figure 30-  Heatmap of 5-HT receptor expression in 51 breast cancer cell line.  
Gene expression analysis has been preprocessed and normalized as described in chapter 2. Graph represents the 
expression values (log2 transformed) of the annotated probe sets (a receptor can be represented by several probe sets, 
like HTR6). Note value of 6 is approximate value were probe is considered not to be detected by statistical comparison 
with negative control probes. Receptor expression values were acquired using data set GSE12777 (Table 7).  
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4.5.2 Serotonin selectively promotes cell viability in breast cancer cell lines 
A great deal of evidence supports the mitogenic action of 5-HT towards a range of 
cancer cell lines. In order to examine the potential mitogenic effects of 5-HT on the 
four breast cancer cell lines used in this study (MDA-MB-468, MCF7, SKBR3, MDA-
MB-231), an MTT assay was performed. Cells were incubated with various 5-HT 
concentrations in serum-supplemented medium for 72 hours, and then cell 
viability measured. As shown in Figure 31, 5-HT was able to significantly increase 
cell viability in two of the four cell lines tested: MDA-MB-468 and MCF-7. In 
addition, SKBR3 cells demonstrated a significant trend for increasing cell viability 
with concentration, although the individual points failed to reach significance. In 
MDA-MB-231 cells, no significant impact on cell viability was observed at any 5-
HT concentration tested.  
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 Figure 31 – 5-HT acts as a mitogen in dose response manner.  
Figure represent average values of three independent experiments. MTT assays have been performed as 
described in chapter 2. Total 5000 cells have been incubated for 72h period, treatment medium has been 
changed every 24h. One way ANOVA statistical analysis has been performed.  
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4.5.3 Inhibition of the DDC reduces cell viability  
The importance of endogenous 5-HT production on cell turnover was also 
investigated. Carbidopa was used as a selective inhibitor of DDC, the second 
enzyme responsible for 5-HT synthesis from tryptophan. Carbidopa has a 
reported cell line specific IC50 values of 12-29 M[259]. Therefore, Carbidopa 
concentrations were used that corresponded to the previously reported IC50, plus 
equivalent of the highest therapeutic dose (4x IC50). As can be seen from Figure 
32, the cell viability of all four-breast cancer cell lines was decreased by carbidopa 
in a concentration dependent manner. These data are consistent with endogenous 
production of 5-HT, followed by paracrine and/or autocrine activation of 5-HT 
receptors, being an important contributor to the cell division rate in all four-cell 
lines. Importantly, it also demonstrates that these pathways are functional in each 
cell line.   
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Figure 32 - Inhibition of DDC with carbidopa reduces the cell viability.   
Results represents average values of three independent experiments, 5,000 cells were incubated with carbidopa 
for 72h period without changing the treatment medium, MTT assays have been performed in the chapter 2. One 
way ANOVA statistical analysis has been performed. 
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4.5.4 Characterising the downstream effects of 5-HT receptor activation. 
Having demonstrated that serotonin was able to exert a positive growth effect on 
all breast cancer cell lines tested, the mechanism of action of this effect was 
examined. Serotonin receptors transmit their signal via several secondary 
messenger systems, most notably ERK (Table 18). The phosphorylation of ERK 
was examined following 5-HT stimulation in the breast cancer cell lines. SKBR3, 
MCF-7 and MDA-MB-231 breast cancer cell lines were incubated with different 5-
HT concentrations for a period of 24h, subjected to the cell lysis and subsequent 
Western blotting experiments to determine status of components of the ERK 
signal transduction pathway. The analysis revealed an increased ERK 
phosphorylation in response to the 5-HT simulation to occur in MCF-7 and SKBR3 
cell lines, but not MDA-MB-231 (Figure 33). These data are consistent with the 
observed effect of serotonin on cell line viability. 
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Figure 33 – Serotonin actives ERK signalling pathway in a dose depended manner.  
Total 30 g of cellular lysates have been loaded into each lane. the detailed protocol is decribed in chapter 
2. The densitomtery analysis has been performed using ImageStudioLite software, statistical analyis has 
been performed using GraphPad Prism 6 software. Anova teste P value *  < 0.05. 
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4.5.5 ELISA 
As serotonin acts at both the autocrine and paracrine level, it is possible that the 
experimental treatments would impact on medium concentrations of serotonin. 
ELISA experiments were performed to investigate the concentration of 5-HT in 
conditioned cell culture medium following exposure to either carbidopa or 
serotonin (Figure 34). The level of serotonin in control conditioned medium was 
approximately 2.5ng/ml, compared to a limit of detection of 0.5ng/ml for the 
ELISA system. Supplementation of medium with 5-HT showed the expected 
increase in 5-HT concentration, however inhibition of DDC by carbidopa did not 
lead to any reduction in 5-HT medium concentration.    
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Figure 34 - Serotonin concentration in the medium under different treament conditions.  
Figure represents average results of three independent experiments.  Carbidopa was dissolved in DMSO, 
therefore a second control treatment has been prepared to account effects of the DMSO to the 
concentration of the 5-HT. Detailed protocol is provided in chapter 2. Calibration curve is in the 
supplementary information section (Figure 41). One way ANOVA statistical analysis has been performed. 
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4.6 Discussion 
4.6.1 Introduction 
Serotonin synthesis and opioid peptide degradation are the two major metabolic 
traits that differentiate the poor prognosis metabolic breast cancer group from all 
other tumours. However, such analysis does not determine if the observed 
differences are causative or consequential of this aggressive phenotype. To 
examine this, in vitro experimentation must be undertaken. Such investigations 
are very important because many breast cancer patients are prescribed 
medications that activate opioid receptors and/or increase serum serotonin 
concentration to elevate the symptoms of pain and depression, respectively [260]. 
If activation of either of these signalling pathways is causative of an aggressive 
tumour phenotype, then it is possible that therapy with opioids or SSRIs may 
actually decrease the prognosis for a percentage of patients. Meta-analysis on the 
association between opioids/SSRIs use and relapse-free time in breast cancer 
patients are conflicting, with both positive and negative associations reported 
[260-263]. One explanation for this conflicting data is the lack of stratification of 
patient populations within the clinical studies underlying the meta-analyses. The 
prediction from Chapter 3 describes a scenario where only a fraction of patients 
(~20%) would be potentially at risk, leading to confounding in analysis that are 
not sufficiently powered for sub-population analysis.  
The ultimate aim of these studies is to use the personalized digital metabolic 
models to provide insight into metabolism specific to each tumour. This would 
allow these models to serve as a basis to stratify patients and generate precision 
therapeutic advice. To examine the potential for this, we examined two test cases, 
using in vitro examination to validate the computational predictions.  
4.6.2 Opioid peptide degradation 
Angiotensin-converting enzyme 2 (ACE2) is central to the opioid degradation 
pathway. Western blotting analysis identified MCF-7, T47D and SKBR3 cell lines 
to be ACE2 positive. In addition, MCF-7 and T47D cell lines expressed all three 
subtypes of opioid receptor, namely KOR, MOR and DOR. The expression of ACE2 
did not correlate with the expression of the opioid receptors in breast cancer cell 
lines; for example, the SKBR3 cell line did not express opioid receptors, while 
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MCF10a and MDA-MB-231 cell lines were shown to express DOR and KOR. The 
lack of correlation was observed within Discovery set patient samples, as no 
statistical difference was recovered for MOR and KOR receptors expression within 
metabolic clusters, however poor prognosis cluster overexpressed ACE2 enzyme 
(DOR was not represented by good quality probes, therefore its expression 
pattern was not investigated). The lack of correlation between ACE2 and opioid 
receptor expression indicates that ACE2 may exert another role other than the 
hydrolysis of the opioid peptides, or that the opioid peptides may not be potent 
enough to influence the development of breast cancer. 
The viability of the breast cancer cell lines was not affected by stimulation with -
casomorphin, DAMGO (synthetic opioid peptide), Apelin peptides or the ACE2 
inhibitor DX600. The tested concentrations encompassed the previously reported 
doses (1nm-1M), plus a maximal concentration of 1M ensuring full activation 
of the opioid receptors and to account for any loss of peptide due to stability issues 
[215, 221, 264].  
Finally, the ability to influence cell motility was tested using a cell migration assay 
with the MCF-7 cell line. The MCF-7 cell line was chosen due to its expression of 
ACE2 and opioid receptors, as well as exhibiting the fastest growth rate among the 
three breast cancer cell lines. Nevertheless, the cell migration rate was not 
affected by stimulation with opioid peptides (-casomorphin, DAMGO), nor by 
inhibition of the ACE2 activity.  
To conclude, ACE2 expression was shown to be associated with lower survival 
probability using the Metabric clinical data in both Discovery and Confirmatory 
datasets. In vitro analysis did not reveal any effect of opioid peptides and ACE2 
inhibition on breast cancer cell line expression. A number of explanations may 
exist for this apparently conflicting data. First, fundamental differences between 
real tumours and cancer cell lines may exist, masking any response. While the 
expression of the immediate molecular species involved in opioid signalling were 
determined, this does not exclude the action of other, untested, factors that may 
differ between cell lines and in vivo. Second, as breast tumours are complex, multi-
cell type growths, it is possible that opioid act on parts of the tumour not 
represented by the breast cancer cell lines. For example, ACE2 expression is 
crucial to regulate tumoural vascular system, as the main ACE2 function is 
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regulation of angiotensin signalling. Third, ACE2 expression may be an indirect 
marker of a poor prognosis tumour, and biologically unimportant. In this case, the 
altered activity status would be consequential and not causative of the poor 
prognosis phenotype.  
4.6.3 Serotonin synthesis 
Active serotonin synthesis was shown to be associated with lower survival 
probability using the Metabric clinical data (997 patients and 995 patients of 
Confirmatory dataset). This effect was reproduced in vitro, where serotonin was 
shown to positively impact breast cancer cell line viability via the ERK signalling 
pathway. Serotonin signalling is an innate and crucial regulatory part of the 
mammary gland. Various published studies, including our gene expression 
analysis, have demonstrated that serotonin receptor expression is common to at 
least 51 different breast cancer cell lines. Additionally, the tested breast cancer 
cell lines (MCF-7, MDA-MB-231, MDA-MB-468, SKBR3) were both DDC and TPH1 
positive, suggesting that they are able to synthesise 5-HT. As the investigated 
cancer cell lines express serotonin receptors plus the enzymes central to 
serotonin synthesis, it is logical to presume that serotonin mediated signalling 
could be beneficial to the survival of breast cancer cells. 
The cell viability analysis indicated that serotonin supplementation selectively 
increases the cell growth in a concentration dependent manner in MCF-7, MDA-
MB-468 and SKBR3 cell lines, but not the MDA-MB-231. This may suggest that 
MDA-MB-231 cells are unresponsive to serotonin, suggesting an additional factor 
other than the proteins examined is lacking in these cells. To examine if serotonin 
signalling was functional in MDA-MB-231 cells an alternate approach was taken. 
Inhibition of DDC, a key serotonin synthesis enzyme, was used to inhibit the 
endogenous production of serotonin. In this case, a statistically significant 
decrease in cell viability was observed, suggesting that endogenous serotonin was 
contributing to proliferation of all cell lines tested. Statistically significant 
reduction in cell viability was observed with 25M carbidopa, the highest realistic 
physiological concentration. Moreover, a 4-fold higher concentration of carbidopa 
(100M) elicited a remarkably reduced viability of MDA-MB-468 cells (63.7%, 2.2 
Std. error of mean), in contrast only a mild reduction was been observed in MCF-
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7, MDA-MB-231 and SKBR3 cell lines. This would be consistent with serotonin 
having a positive effect on viability for all cell lines examined. However, in the case 
of MDA-MB-231 cells, addition of exogenous serotonin did not have any effect, 
suggesting that the system may be saturated already. Given the status of MDA-MB-
231 cells as representing an aggressive breast tumour, activation of serotonin 
signalling through enhanced endogenous production would not be inconsistent. 
Cell line specific effects could arise due to unique 5-HT receptors expression 
pattern and DDC and TPH1/2 enzyme expression levels. Such effects would need 
to be more thoroughly examined to fully understand the implications of these 
differences. 
On the contrary, while serotonin was shown to increase cell viability for the tested 
cell lines, the inhibition of DDC activity may exert unspecific cytotoxic effects, 
considering the fact that 5-HT supplementation did not increased cell growth in 
MDA-MB-231 cell line, but inhibition of DDC resulted in statistically significant cell 
viability levels at both tested concentrations (25M -91.1%, 1.1 Std. error of mean, 
100M – 83.26%, 1.6 Std. error of mean). Although our results indicated, that the 
higher concentration of carbidopa significantly reduced cell growth, the effects are 
likely to originate from unspecific toxicity (an increase in reactive oxygen species) 
[265]. Additionally, the observed results are not concordant with the literature, as 
the previous study indicated for carbidopa to exert no effects at 100M 
concentration to MCF-7 cell line, while our study indicated statistically significant 
reduction in cell viability [259].   
The ELISA experiments were conducted to examine the impact of DDC inhibition 
on endogenous serotonin synthesis. Although, the supplemented 5-HT 
concentration was detected as expected, no impact of DDC treatment on medium 
5-HT concentration could be detected. This is likely due to a lack of sensitivity in 
the method. The ELISA assay kit should detect 5-HT concentrations as low as 
0.5ng/ml, however the manufacturer indicated sample specific sensitivities. For 
example, only 91% of 5-HT at 5ng/ml concentration is recovered from plasma 
sample, as indicated in the ELISA kit datasheet (ab133053). This means that the 
assay was operating near the limit of quantitation (3*LOD = 1.5ng/ml), and small 
changes may be obscured. Second, the cell:medium ratio may be too high to detect 
changes in the local 5-HT production upon inhibition of DDC. For a plating density 
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of 5000 cells/well, and an average eukaryotic cell volume of 2pL, this leads to a 
cell volume of approximately 10nL. The medium volume was 200 L, meaning a 
dilution of 20000 fold for any produced serotonin, most likely moving below the 
limit of detection. Third, liquid dynamics alter at the interface between cells and 
liquid, both in vitro and in vivo. This results in a slow diffusing compartment of 
medium in direct contact with the cells, compared to the more dynamic main bulk 
of the medium. This means that serotonin released in to the medium may reside 
mainly in this slowly diffusing compartment where it can exert its 
autocrine/paracrine effects, but further reducing the concentration that can be 
measured in the main body of the medium. Together, these suggest that the used 
ELISA kit was not sensitive enough to investigate changes in 5-HT concentrations 
upon inhibition of DDC enzyme.  
The performed cell signalling experiments indicated a concentration-dependent 
increase of ERK phosphorylation, which could underlie the mitogenic effects 
exerted by the serotonin. It should be noted that this does not exclude the 
possibility that other signalling pathways might be activated as well. Serotonin not 
only exert signal via activation of 5-HT receptors, but also induce expression of 
other signalling molecules (such as parathyroid hormone), which may relay a 
further signal [240]. Hence, it may not be enough to examine the effects of 
serotonin excluding directly related signalling pathways (Table 18). If these 
secondary pathways were not active in MDA-MB-231 cells then this would explain 
why they did not respond to exogenous serotonin.  
In conclusion, our study is concordant with a great number of publications that 
indicate the mitogenic effects of serotonin. We have demonstrated that exogenous 
serotonin activates ERK1/2 phosphorylation, but cannot exclude the role of other 
pathways in the proliferative effect.  
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5 Metabolic modelling of breast cancer stem cells    
5.1 Introduction 
The breast cancer stem cell (BCSC) theory postulates that tumours contain a small 
population of highly aggressive cancer cells that are the main reason for the 
development of a multi-drug resistance trait and cancer relapse [266]. As such, 
these cells represent a highly attractive target for therapy, as their destruction 
could significantly reduce the aggressive nature of tumours, improving patient 
prognosis [93]. Cancer stem cells are so named due to their high resemblance to 
normal stem cells [267]. As a result, only a few molecular differences have been 
identified between cancer and normal stem cells, limiting the ability to 
therapeutically target these cells. The analysis undertaken in this chapter was 
designed to identify the potential metabolic adaptations unique to the BCSC, which 
could be subsequently exploited as potential therapeutic targets.   
Using the same approach as chapter 3, transcriptomics data was integrated with 
a genome scale metabolic network, with the aim of revealing tumour specific 
metabolic adaptations that underline breast cancer stem cell development. 
Despite for the cancer stem cells being a relatively new theory (the first breast 
cancer stem cells were isolated in 2003), there are already freely available breast 
cancer stem cell specific transcriptomics datasets that can be used for this 
approach [268].  
5.1.1 Isolation of breast cancer stem cells 
A key determinant of successful characterisation of cancer stem cells is the ability 
to isolate this cell population at sufficient purity and concentration to allow 
downstream analysis. Research has identified that BCSCs exert a CD44+/CD24- 
molecular phenotype, and are present in breast tumours at very low numbers (like 
the normal stem cells, more detailed review is provided in the general 
introduction 1.1.4). Therefore, there is a need to enrich BCSC samples in order to 
generate sufficient material to perform gene expression profiling using a micro-
array technology.   
Breast cancer stem cells can be isolated from the primary tumours by two 
methods: the first method isolates BCSCs from the general breast cancer cell 
population by using the fluorescence-activated cell sorting (FACS) technique, 
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selecting for the CD44+ and CD24- cells [1]. The second method enriches the 
isolated breast cancer cell population with BCSCs, by cultivating isolated primary 
breast cancer cells in vitro in non-adherent conditions, which allows to form 
mammospheres (cellular spherical clumps) [1, 269] Only BCSC appear to be able 
to form mammospheres, meaning their formation results in enrichment of the cell 
population with breast cancer stem cells [1, 269].  
5.2 Transcriptomic datasets used to generate metabolic landscapes of BCSCs 
Three transcriptomics datasets were used in the current study, each with its own 
advantages and disadvantages. By using three distinct transcriptomic datasets, it 
was hoped that common metabolic adaptations would be identified, while 
experiment-specific variation (biological or technological) would be minimised. 
The datasets are described in Figure 35, and summarized below:  
The first dataset (GSE7513) consisted of 15 biological samples which were subject 
to microarray analysis either unsorted (i.e. predominantly not BCSC), or following 
FACS isolation of CD44+/CD24- cells (i.e. predominantly BCSC) [1].  
The second dataset (GSE7515) consisted of 11 biological samples representing 
primary breast cancer cells (i.e. predominantly not BCSC), and 14 mammosphere 
cell samples (i.e. predominantly BCSC), the samples were derived from 16 
patients, with matched primary cells and mammospheres available for 10 patients 
[1]. 
The third study (GSE10281) comprised of 36 matched biological samples. The first 
18 were primary breast cancer cells acquired prior to letrozole chemotherapy (i.e. 
predominantly not BCSC), and the second 18 samples were isolated post 
chemotherapy and used FACS isolation of CD44+/CD24- cells to enrich for BCSC 
[1].  
5.3 Objectives and methods  
The main objective of this analysis was the identification of metabolic traits, 
unique to breast cancer stem cells. Gene expression analysis was performed in the 
original published studies, and was not repeated in the current study. To achieve 
the task, metabolic models were created for each sample using the GEBRA 
algorithm. Next, the predicted metabolic profiles were compared both within each 
study and across studies to identify unique metabolic traits. The two-fold 
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comparison was performed to increase confidence in the identified metabolic 
adaptations.  
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Figure 35  - BCSCs workflow 
Several gene expression data sets have been analysed to identify traits unique to the BCSC. The primary 
breast cancer samples were acquired from the women participating in the clinical trial as described in the 
related publication [1].   
The GEBRA models were created for each sample; the created metabolic landscapes were analysed to list 
the metabolic adaptations unique to the BCSC.  
GSE7513 gene expression data set consists of 15 primary breast cancer samples, which were flow sorted 
into two groups (CD44+/CD24- and the remaining primary breast cancer cells [1].   
GSE7515 gene expression data set consists of 11 primary breast cancer samples and 15 flow sorted 
(CD44+/CD24-) mamosphere samples. The mamospheres were formed from the primary breast cancer 
cells (as described more detailed here [1]). 
GSE10281 gene expression data set consists of 18 primary breast cancer sample pairs with 18 primary 
samples acquired before the treatment with letrozole and 18 after the letrozole treatment [1].  
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5.4 Results  
Generation of sample-specific predicted metabolic landscapes from the breast 
cancer stem cell transcriptomic data was performed using the previously 
established pipeline as discussed in chapter 3, with detailed scripts provided in 
chapter 2. 
In order to evaluate metabolic similarities/differences, the generated metabolic 
landscapes were clustered using Ward’s hierarchical clustering method (Figure 
36). According to the clustering results, samples from the letrozole treatment 
dataset formed a unique group. The primary breast cancer cells from GSE7013 
and GSE7015 studies clustered together, while BCSCs formed two unique clusters, 
one predominantly enriched with FACS sorted BCSCs and the second enriched 
with BCSCs from the mamospheres.  
 
  
Figure 36 - Hierarchical clustering of BCSCs datasets. 
The dendogram was generated using Ward’s method and is comprised of metabolic landscapes that were 
generated using three gene expression datasets (GSE7013, GSE7015 and GSE10281). The clustering was 
performed using the top 500 most variable reactions (based on reaction states between the metabolic 
landscapes). M stands for mamosphere.  
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Further analysis has been performed to highlight the statistically significant 
reactions (Wilcoxon signed rank test, supplementary table S9), unique to the 
breast cancer stem cells of each dataset (primary BCSC vs primary breast cancer 
cells, mamosphere breast cancer stem cells vs primary breast cancer cells, pre-
treatment primary breast cancer cells vs post-treatment primary breast cancer 
cells). The primary BCSCs models differed by 353 metabolic reactions from the 
primary breast cancer cells (GSE7013 study), while breast cancer cells of the 
mamosphere origin differed by 187 metabolic reactions (GSE7015 study). In 
contrast, the pre-treatment and post letrozole treatment models differed by only 
74 metabolic adaptations. Once the statistically differential reactions have been 
listed for the BCSCs of each dataset, the common metabolic adaptations were 
identified (Figure 37). BCSCs from study GSE7512 (primary tumour-derived) and 
study GSE7515 (mamosphere-derived) showed 35 common metabolic 
adaptations. This represents 9% and 15% of the BCSC-unique metabolic traits 
from study GSE7513 and GSE7515, respectively: These reactions are listed in 
Table 20.  
The letrozole treatment group showed little resemblance to the isolated cancer 
stem cells. Study GSE10218 produce only a small number of metabolic similarities 
with the other two studies, four and 12 reaction for GSE7512 and GSE7515, 
respectively. This is perhaps not surprising as the study design is significantly 
different, including both BCSC isolation and drug exposure. Due to this, data from 
this study was no longer considered.  
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Primary breast 
cancer stem cells 
Mamosphere breast 
cancer stem cells 
Post letrozole treatment breast cancer cells  
Figure 37 - Venn diagram shows similarity between the BCSC 
Metabolic reactions unique to the breast cancer stem cells have been identified. Venn diagram was 
generated to identify metabolic reactions unique to the breast cancer cells across all three studies.  
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Table 20 summarizes the identified metabolic adaptations common to the BCSC. 
Reaction status indicates reaction state within the BCSC, the statistical analysis has been 
performed using Wilcoxon signed rank test as described in chapter 2. Adjusted p value shows a 
statistical comparison for each group.  
  
Reaction Status Adjusted p value Name 
  GSE7513 GSE7515 
 
CDIPTr (-) Active 0.002198901 0.03599796 phosphatidylinositol synthase (Homo sapiens) 
EX_pglyc_hs_LPAREN_e_RPAREN_ (-) Active 0.016858238 0.015419303 phosphatidylglycerol (homo sapiens) exchange 
PGLYCt (+) Active 0.016858238 0.015419303 phosphatidylglycerol transport 
PGS (+) Active 0.00069965 0.022073579 Prostaglandin G/H synthase 
RE3273C (-) Active 0.002198901 0.03599796 RE3273 
CDIPTr (+) Inactive 0.002198901 0.03599796 phosphatidylinositol synthase (Homo sapiens) 
CDS (+) Inactive 0.006321839 0.005904227 phosphatidate cytidylyltransferase 
DCK1n (-) Inactive 0.025327687 0.00016826 Deoxycytidine kinase, nuclear (ATP) 
DCK1n (+) Inactive 0.025327687 0.00016826 Deoxycytidine kinase, nuclear (ATP) 
DCK2n (-) Inactive 0.025327687 0.00016826 Deoxycytidine kinase, nuclear (UTP) 
DCK2n (+) Inactive 0.025327687 0.00016826 Deoxycytidine kinase, nuclear (UTP) 
DNDPt44m (+) Inactive 0.002509272 0.01493808 dTTP transport via ATP antiport 
DNDPt45m (+) Inactive 0.002509272 0.01493808 dTTP transport via ADP antiport 
DNDPt46m (+) Inactive 0.002509272 0.01493808 dTTP transport via dUDP antiport 
DNDPt47m (+) Inactive 0.002509272 0.01493808 dTTP transport via dTDP antiport 
DNDPt48m (+) Inactive 0.002509272 0.01493808 dTTP transport via dGDP antiport 
DNDPt49m (+) Inactive 0.002509272 0.01493808 dTTP transport via dADP antiport 
DNDPt50m (+) Inactive 0.002509272 0.01493808 dTTP transport via dCDP antiport 
DTTPtm (+) Inactive 0.002509272 0.01493808 transport of dTTP into mitochondria 
EX_fru_LPAREN_e_RPAREN_ (+) Inactive 0.016858238 0.000809717 exchange reaction for D-Fructose 
EX_pglyc_hs_LPAREN_e_RPAREN_ (+) Inactive 0.016858238 0.015419303 phosphatidylglycerol (homo sapiens) exchange 
EX_spc_hs_LPAREN_e_RPAREN_ (+) Inactive 0.00777506 0.014349172 sphingosylphosphorylcholine (homo sapiens) exchange 
GLYCtm (+) Inactive 0.025327687 0.00016826 glycerol transport 
MI145PP (+) Inactive 0.006321839 0.005221093 inositol-1,4,5-trisphosphate 5-phosphatase 
MI14P4P (+) Inactive 0.006321839 0.005221093 inositol-1,4-bisphosphate 4-phosphatase 
MI1PP (+) Inactive 0.003698151 0.005221093 myo-inositol 1-phosphatase 
NDPK7m (+) Inactive 0.02093953 0.01493808 nucleoside-diphosphate kinase (ATP:dCDP), mitochondrial 
PGLYCt (-) Inactive 0.016858238 0.015419303 phosphatidylglycerol transport 
PGPP_hs (+) Inactive 0.016858238 0.015419303 Phosphatidylglycerol phosphate phosphatase (homo sapiens) 
PGPPT (+) Inactive 0.016858238 0.015419303 phosphatidyl-CMP: glycerophosphate phosphatidyltransferase 
PI45PLC (+) Inactive 0.006321839 0.005221093 phosphatidylinositol 4,5-bisphosphate phospholipase C 
PI4PLC (+) Inactive 0.006321839 0.005221093 phosphatidylinositol 4-phosphate phospholipase C 
PIPLC (+) Inactive 0.006321839 0.005221093 phosphatidylinositol phospholipase C 
SPHMDAc (+) Inactive 0.00777506 0.014349172 sphingomyelin deacylase 
SPC_HSt (+) Inactive  0.00777506 0.014349172 sphingosylphosphorylcholine transport (diffusion) 
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5.4.1 Characteristics of the breast cancer stem cells  
The performed analysis has revealed 35 metabolic adaptations unique to the 
breast cancer stem cells (Table 20). However, only the top two were further 
investigated: the production of prostaglandin H2 by the prostaglandin synthase 
(PGS, EC 1.14.99.11) and conversion of 1-phosphatidyl-myoinositol to inositol and 
diacyl-glycerol by the phosphatidyl inositol synthase (CDIPT, EC 2.7.8.11).  
The contingency statistical analysis has revealed that the both metabolic 
adaptations are statistically significant between the BCSC and the remaining 
primary breast cancer cells (Figure 38). 
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Figure 38 shows reaction status count for BCSC and non-stem primary breast cancer cells.  
The performed chi-squared statistical analysis has indicated the significant difference for the both 
reactions (PGS p-value <0.0001 and CDIPT p-value 0.0315).  
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5.5 Discussion  
The computational analysis in this chapter investigated the metabolism of breast 
cancer stem cells, with the aim of identifying common metabolic adaptations. 
BCSCs derived directly from primary tumour cells and enriched via mamospheres 
shared a total of 35 unique metabolic adaptations. In contrast, the letrozole-
treatment dataset showed little overlap with either dataset, and was excluded 
from further analysis. The quality of gene expression data has a significant impact 
on the quality of this approach, as does the purity of the cell populations studied. 
In the current chapter, the GE10218 is confounded by a lack of BCSCs isolation in 
the ‘before treatment’ samples, and by drug effects in the ‘post therapy’ isolated 
BCSCs. Both GSE7513 and GSE7515 have the advantage of matched samples for 
total primary and BCSC isolated populations. However, it should be bore in mind 
that these processes are not 100% successful, and hence results may be 
confounded by contamination with non-stem breast cancer cells, leading to false 
negative results. Nevertheless, the performed two-tier comparison was made to 
confirm metabolic adaptations unique to the BCSCs, which lead to identification of 
two metabolic pathways occurring predominantly in the BCSCs but not in the 
primary breast cancer cells.  
5.5.1.1 Prostaglandin synthase and the breast cancer stem cells  
The synthesis of prostaglandin H2, a precursor of all prostaglandins, was 
identified to be active in BCSC compared to its comparator primary cell 
populations (Figure 39). Prostaglandins are important mediators of inflammation 
processes, both following acute damage and as part of the ongoing protection of 
tissues such as the kidney and gastrointestinal tract. Importantly, research has 
demonstrated that prostaglandins may promote tumour growth through a 
multitude of mechanisms: inhibition of apoptosis and stimulation of cell growth, 
angiogenesis, motility, and metastasis (mainly PGE2) [270]. 
The activity of prostaglandin synthase (COX-2) has been implicated in the 
development of carcinogenesis by a large number of studies [270]. Higher 
expression of prostaglandin synthase has been associated with a lower survival 
probability for breast cancer patients, with 40% of invasive breast carcinomas 
overexpressing COX-2, when compared with pre-invasive tumours.  
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Overexpression of COX-2 in breast tumours not only correlates with an aggressive 
disease status, but is usually associated with the multiple drug resistance trait 
[270]. For example, Rong et al. demonstrated that doxorubicin resistant breast 
cancer cells produce significantly higher levels of PGE2 than their drug-sensitive 
progenitors [271]. Such studies do not address the cause of causality, but a 
recently published study supports a causal role: Saha et al. demonstrated that 
inhibition of prostaglandin synthase prevents breast cancer cells from developing 
a multiple drug resistance trait [272].  
Our study has predicted that breast cancer stem cells maintain metabolically 
active pathways coordinated by PGS, but that this feature is lost when BCSC 
differentiate to form primary breast cancer cells. One hypothesis regarding the 
development of multiple drug resistance trait is that the killing of primary breast 
cancer cells through chemotherapy drives BCSC differentiation, including their 
active PGS-associated metabolism. This could lead to an increase in the number of 
drug resistant primary cancer cells. It is important to note that additional studies 
would be required to confirm PGS involvement in breast cancer stem cells. In 
addition, it is unclear the why primary tumour cells do not have active PGS 
metabolism, and why this should persist upon differentiation of BCSCs.  
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Figure 39 represents prostaglandin synthase mode of action.  
Prostaglandin synthases (COX-1 and COX-2) synthesise prostaglandin H2, which is a precursor for 
all the prostaglandins. The prostaglandin synthases are activated by various signalling molecules, 
including various growth factors. The specific prostaglandin synthases convert PGH2 into the 
individual prostaglaninds, which in turn bind and activate the respective receptors. Prostaglandin 
E2 has been implicated to take a major role in aiding cancer by promoting cell growth, survival, 
motility, metastatis, imune reaction invasion via activation of four receptors.  
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5.5.1.2 CDIPT 
The second identified metabolic adaptation of BCSCs was increased CDP-
diacylglycerol production from phosphatidyl inositol (PI), which is catalysed by 
phosphatidyl synthase (Figure 40) [2]. CDP-diacylglycerol may serve as a 
precursor of cardiolipin synthesis, which is a component of the biomass reaction. 
This would suggest that BCSCs have a metabolic adaptation that allows them to 
contribute more cardiolipin toward biomass, providing a greater proliferative 
capacity. Additionally, various studies emphasize PI importance in synthesis of 
inositol bi phosphate (PIP2) and subsequent involvement in mitogenic signalling 
pathways, which are often hijacked by cancer cells to increase the proliferation 
rate [2, 273, 274]. In contrast to the PIP2 synthesis, our study suggests a reverse 
reaction takes place (cardiolipin synthesis) in the breast cancer stem cells. 
Nevertheless, the inhibition of CDIPT should elicit the same desired response – 
reduced viability of cancer cells. The published studies, has associated the CDIPT 
activity with various cancers and suggested inhibition as a possible therapeutic 
route [18, 173].  
Figure 40 The CDIPT (CDP-diacylglycerol-inositol 3-phosphatidyltransferase) reaction is catalysed by 
phosphatidyl synthase. It is a reversible reaction that generates phosphatidyl inositol, which is part of 
central signalling pathways regulating cell growth. The reaction precursor CDP-Diacylglycerol is also a 
precursor for cardiolipin, which is a constituent of the biomass reaction [2]. 
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Under normal conditions, phosphatidyl synthase produces phosphatidyl inositol, 
an important signalling molecule involved in the regulation of cell growth [18]. 
Therefore, overexpression of phosphatidyl synthase (and the associated CDIPT 
reaction) might be expected to drive a proliferative phenotype. Consistent with 
this, elevated phosphatidyl synthase levels have been reported in head and neck 
carcinomas [18, 275]. Research showed that inhibition of CDIPT by inostomycin 
induces apoptosis in several cancer cell lines (small lung, oral carcinomas) and 
reduces metaloprotease secretion in tongue carcinoma cell line [18, 159, 173, 276, 
277], suggesting CDIPT is a potential therapeutic target. This is supported by the 
finding that inhibition of CDIPT by inostomycin has been shown to elicit cytostatic 
effects to squamous carcinomas [18, 278]. Additionally, it was proposed for a 
possible use of inostomycin as a co-therapeutic agent in treating tumours [279]. 
The CDIPT reaction is important metabolic target for several cancer types and the 
reaction inhibition was shown to elicit cytostatic effects.  
The breast cancer stem cells were predicted to maintain an active state of CDIPT 
when compared with non-stem primary breast cancer cells. This would be 
consistent with a stem cell phenotype that with an enhanced pro-survival, pro-
proliferative phenotype. Nevertheless, further research would be required to 
investigate the inhibitory effects of inostomycin in treating breast cancer patients.  
5.6 Summary 
Through computational metabolic analysis, personalized metabolic landscapes of 
breast cancer stem cells were generated. These BCSC landscapes were then 
compared to metabolic models generated from primary non-stem breast cancer 
cells, with the aim of identifying unique metabolic traits for BCSCs. Of the 591 
differentially activated reactions identified from two, high quality, studies 35 
reactions were consistent between the two data sets. This represents only 6% of 
all differentially activated reactions, which suggests a low level of similarity 
between the BCSCs in the two studies. However, this number will almost certainly 
be an underestimation due to both biological and technological factors that 
confound the analysis. Regardless, these common differentially regulated 
reactions may provide novel biological insights into BCSCs. 
 157 
Two major metabolic differences utilized by BCSCs were selected for further 
study, being active PGS and CDIPT pathways. As seen in previous chapters, the 
integration of transcriptomic data with a genome scale metabolic network 
revealed adaptations that had not been previously identified using differential 
gene expression analysis alone, indicating the novelty of our study [1]. This further 
supports the use type of computational analysis to leverage novel biological 
information from omic level experimental data, including the large legacy of data 
already generated [128]. Active prostaglandin synthase has been associated with 
drug resistance and cancers from various tissues. In addition, there is increasing 
interest in it as a therapeutic target to treat breast cancers [280]. Clinical studies 
to establish a clear benefit of Aspirin (PGS inhibitor) as part of a combination 
therapy for breast cancer have been undertaken, but the results are conflicting 
[281-285]. It is important to note that the analysis here suggests active PGS in 
BCSC, but not primary breast cancer cells. Hence, aspirin will only target a small, 
but vital, part of the whole tumour population, and indeed may only be effective 
in tumours with an active BCSC population. This may explain the mixed results 
currently in the literature, which lead to confounded meta-analyses [286]. We 
would predict that inhibition of PGS will impact on the metabolic viability of BCSC, 
either causing them to enter apoptosis directly, or make them more susceptible to 
standard chemotherapeutics. Reduction of the BCSC pool within a tumour is likely 
to lead to a less aggressive tumour with a reduced predisposition toward multiple 
drug resistance. To test this hypothesis, initial studies should be undertaken in 
vitro to confirm the impact of aspirin-containing combinations on BCSC. Providing 
these are positive, they would motivate more targeted (non)clinical studies to 
examine the impact in the more complex environment of a whole tumour.  
In contrast to PGS, the CDIPT reaction is not associated with the development of 
drug resistance, likewise, the additional study is required to investigate the effects 
inhibition may exert to the breast cancer stem cells. Additionally, our study 
indicates the reverse reaction, which is most likely physiologically impossible, 
therefore no further discussion regarding CDIPT is further provided [2].   
In summary, the performed analysis successfully identified two metabolic 
adaptations that could be transferred to the clinical setting and potentially reduce 
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development of multi-drug resistance trait and the associate mortality rate for the 
breast cancer patients[159]. 
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6 Final discussion 
6.1 Summary  
Systems biology is a relatively new field that enables the study of biological 
systems in a holistic manner. Systems biology can be seen as being composed of 
two sub-disciplines: experimental systems biology is the measurement of 
biological systems at the systems level; computational systems biology is the 
interpretation of this data at the systems level in order to gain novel biological 
insights. In reality, these two sub-disciplines are inextricably linked, with 
experimental data being used both to inform and validate computational models, 
with the latter then providing hypotheses for experimental testing. The 
technology and methods for both sub-disciplines are constantly, and 
exponentially, developing, producing data that is both more complex and more 
informative. The successful studies of bacterial modelling laid the foundations of 
the discipline, and in the last decade these have begun to be translated to the study 
of mammalian models. This project used a pioneering approach to integrate high 
content experimental data with genome scale metabolic networks, allowing the 
analysis of transcriptomic data from over 2,000 primary breast tumours, 92 
breast cancer stem cell samples and three breast cancer cell lines.  
This study identified a group of breast cancer patients whose metabolic 
landscapes were associated with poor survival probability, and confirmed this in 
an independent dataset. This poor prognosis phenotype was defined by a 
relatively small number of metabolic adaptations, including active opioid peptides 
degradation (milk peptides) and active serotonin production. Evidence suggests 
that both traits might promote tumour growth and survival abilities; therefore, 
both adaptations were further investigated using various in vitro assays. While the 
opioid peptide system was not associated with increased cell growth, serotonin 
synthesis was shown to promote tumour growth and act as a mitogen. This 
demonstrates the identification of novel biological insights that can be validated 
in vitro. Such work should motivate further examination of these adaptations, with 
the aim of developing novel stratification biomarkers and/or therapeutic options 
for this subset of aggressive tumours that account for the majority of breast 
cancer-related deaths.  
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The final part of the metabolic analysis was performed to investigate metabolism 
of BCSCs, as research has associated these cells with the development of both drug 
resistance and aggressive phenotype in breast tumours. The metabolic analysis 
identified unique metabolic traits of BCSCs, of which prostaglandin production 
was the most interesting. Literature evidence associates active prostaglandin 
signalling with the process of carcinogenesis, where it may impact both tumour 
cell growth directly and indirectly through activation of cell proliferation and 
angiogenesis, respectively. Further validation is now required to confirm the 
activation of PGS in BCSC, determine the biological effect of this, and if it 
represents a viable therapeutic target. Finally, the field of BCSC is rapidly 
emerging, and the relationship between BCSC and primary tumour cells needs to 
be fully characterised.   
In this thesis, a pipeline has been established to allow the high-throughput 
analysis of gene expression data in the context of genome scale metabolic 
modelling. Our project has demonstrated that metabolic analysis can provide 
novel biological insights not available from traditional over-representation 
approaches, and has a strong potential as a tool for the development of precision 
medicine.   
6.2 BCSCs and drug resistance  
The initial goals of this project were twofold: to gain insights into the biology 
underlying poor prognosis breast cancer; and, to gain insights into the 
development of drug resistance in breast cancer. The first goal was addressed 
through analysis of the Metabric samples. However, as there was no clinical 
information regarding the drug resistance within patient’s clinical details this data 
set could not be used to address the second goal. Therefore, analysis of breast 
cancer stem cells was performed, as stem cells exhibit hallmarks of the multi drug 
resistance trait. From this analysis, the potential role of prostaglandins in BCSC 
biology was revealed. 
6.2.1 Prostaglandins and breast cancer stem cells  
The biology of prostaglandins in general, and PGE2 specifically is complex and a 
full review is beyond the scope of this thesis: a more complete overview is 
provided by [287]. Research has demonstrated that PGE2 promotes angiogenesis, 
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survival, motility, proliferation and invasiveness [280]. Therefore, it is not 
surprising, that overexpression of prostaglandin synthase has been associated 
with poor clinical prognosis [280].  
Previous work has demonstrated that mesenchymal-type cancer stem cells 
contain higher prostaglandin synthase levels than non-stem cancer cells 
(information about the functional cancer stem cells types is provided in section 
1.1.4.1) [280]. This is thought to drive elevated PGE2 concentrations in the tumour 
microenvironment, leading to a proliferative, pro-survival phenotype [280]. Our 
study supports this data, predicting active PGS in BCSC. Moreover, we predict that 
PGS is non-active in other breast cancer cells, meaning that prostaglandin 
concentrations within the tumour are likely to be driven via the BCSCs. Our 
discovery is concordant with current literature, it has been reported the breast 
cancer stem cells utilize prostaglandin synthase pathway to stimulate breast 
cancer development [288]. Additionally, prostaglandin synthase/PGE2 pathway 
has been shown to increase development of colorectal cancer stem cells, resulting 
in a higher metastasis rate [289]. Prostaglandin signalling (PGE2) is likely to be 
associated with development and maintenance of cancer stem cells via activation 
of B-catenin (CSCs specific pathway) and be directly associated with development 
of drug resistance trait [280, 290] Additionally, a recent publication demonstrated 
that COX-2 induces development of breast cancer stem cells via activation of 
Akt/PIR3/NOTCH, WNT pathways [291]. The detailed mechanism of how COX-2 
promotes cancer stem cell development is beyond this study, however more 
detailed information can be found in the references provided above.  
We have identified prostaglandin synthase as an important metabolic pathway for 
the breast cancer stem cells and our discovery is concordant with the current 
literature, which indicates involvement of prostaglandin synthase and PGE2 
signalling in maintaining tumourigenicity of breast cancer stem cells.  
6.2.2 Prostaglandin synthase and drug resistance 
 Prostaglandin synthase activity is not unique to BCSCs, but also an important trait 
of cancer stem cells of different origin (colon, glioma, liver, bladder and possible 
other cancers), and evidence indicates the importance of PGE2 in CSC biology[289, 
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291-295]. This has led to several studies and clinical trials to investigate the effects 
of prostaglandin synthase inhibition on tumour biology.  
Inhibition of prostaglandin synthase has been shown to both reduce the risk of 
developing, and mitigating the effects of, the multiple drug resistance trait in 
certain cancers. For example, inhibition of prostaglandin synthase abolished drug 
resistance in bladder cancers (gemcitinib and cis-platin)[295]. Moreover, various 
clinical trials (including breast cancer patients) have demonstrated benefits of 
prostaglandin synthase inhibition, including a reduced cancer risk and improved 
prognosis [296, 297].  
PGE2 has been reported to up-regulate BCRP (efflux transporter) in placental cells 
(drug efflux is one of the main functions of placental cells) [298]. Therefore, the 
possible explanation would be that inhibition of prostaglandin synthase reduces 
PGE2 levels, which in turn causes down-regulation of drug efflux transporters, as 
well as reduces CSCs population. There is a possibility for prostaglandin synthase 
to be involved in the maintenance of multidrug resistance trait in metastatic and 
hardly curable breast cancers, however further validation is needed to establish 
such statement.  
6.2.3 The major limitations of BCSC analysis  
Perhaps the most important potential limitation of BCSC biology is their lack of 
characterisation. Standard approaches (CD44+, CD25- FACS sorting and 
mamosphere enrichment) will not produce 100% pure populations, and may have 
bias toward BCSC sub-populations. As such, downstream analysis must 
acknowledge potential sample bias due to contamination with non-stem cancer 
stem cells or selection of BCSC sub-populations. This will affect the gene 
expression profile generated, and thus the metabolic landscape prediction.   
A limitation of the current study is the number and design of the available 
transcriptomics data. Of the three studies examined, one was discarded due to 
marked differences in protocol. The other two studies shared overlap in study 
design, most importantly comparing primary breast tumours with matched 
samples enriched for BCSCs. They did, however, use different approaches to 
generate the BCSC populations, which might have introduced technological bias. 
In addition, they were both performed using the Affymetrix microarray platform: 
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the Affymetrix platform classification of expressed and non-expressed genes is 
sub-optmial as each gene is represented by several probes, which may give 
different present/absent calls, and each probe may target several genes, 
complicating interpretation. By preference, data acquired with newer 
technologies should be used, as this will reduce the potential for technological 
bias. This could include the Illumina platform, as used in  RNAseq. By using data 
from two independent studies, confidence in the identified metabolic adaptations 
was increased, mitigating some of these limitations. However, such an approach 
limits the number of BCSC-specific metabolic adaptations that were identified.  
6.3 Strengths and limitations of metabolic modelling 
An ideal personalized metabolic model should provide robust biological insights 
in to the metabolic reactions (metabolic landscape) specific to the sample. This 
will allow prediction of objective reaction rates (e.g. biomass formation rate, 
individual reaction rates, FBA modelling), plus the identification of rate-limiting 
reactions (e.g. cytotoxic targets, reaction essentiality analysis). Such 
comprehensive models would be a great aid as a medical tool, helping to predict 
response to know therapeutics or suggest sample-specific combination therapies 
(i.e. synthetic lethality). Most importantly, such a modelling approach would be 
clinically practical and help to realise the aim of precision medicine. While the 
models generated in the current thesis begin to address some of these aims, they 
are not able to answer all of the questions listed above due to both biological and 
technological considerations.   
6.3.1 Novelty of the modelling approach  
The undertaken modelling approach provided a new tier of analysis for gene 
expression data. We have captured metabolic information of individual tumours, 
which was not revealed by gene expression analysis.  
The poor prognosis breast cancer group, albeit similar to the Metabric poor 
prognosis (~50%), revealed metabolic traits that were not captured by the 
differential gene expression data analysis. The poor prognosis group couldn’t be 
recovered by using same clustering approach with metabolic gene expression 
values (gene present in the Recon2 GSMN). Moreover, our poor prognosis group 
revealed metabolic traits, that were not recovered by the Metabric analysis [159]. 
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Additionally, the BCSCs modelling analysis revealed metabolic traits, which were 
overlooked by the gene expression analysis of the initial study [1].  
While we acknowledge the drawback of sensitivity (we recovered less metabolic 
traits, than anticipated), nevertheless, the undertaken modelling approach 
provides metabolic information, which cannot be retrieved by the differential 
gene expression approach.   
6.3.2 Absence of information within GSMN 
Genome scale metabolic networks are designed to capture the total metabolic 
network of a system. For organisms with small genomes, such as many 
prokaryotes, this can be achieved. The annotation of the genome, plus 
experimental knowledge of metabolic reactions allows a coverage approaching 
100%. In contrast, for eukaryotes the size of the network is much larger, and 
despite the extensive biochemical characterisation that has been undertaken for 
human metabolism it is unlikely that network coverage is 100%. This means that 
reactions will be missing, potentially leading to incorrect model predictions. 
Furthermore, the increase in network size also increases the risk of error in 
network annotation, which will again introduce bias. It is thus important that 
human GSMNs are subject to constant refinement and expansion, coupled with 
rigorous curation.  
A second general limitation of GSMNs is the lack of information regarding reaction 
kinetic information and concentration of enzymes and metabolites. This is a 
deliberate choice in the construction of GSMNs, where network complexity and 
connectivity is prioritised over quantitative detail. This is because the level of 
quantitative detail is simply not known for inclusion in large-scale models. Rather, 
these values are replaced with assumptions such as arbitrary reaction rates, which 
will inevitably distort results to some degree.  
Within a GSMN, all reaction rate bounds are set as equal, usually being constrained 
by directionality only (i.e. unidirectional or reversible). Due to the high network 
connectivity and lack of constraint on internal reaction bounds, this produces a 
very flexible network with many solutions to maximise any given objective 
function, many of which will not occur in real biology. One solution to this is to add 
additional biological constraints where known. Here, the exchange reactions at 
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the boundary of the GSMN were constrained to reflect nutrient supply in vivo 
[299]. It should be noted that this is a binary constraint, with reactions set as open 
or closed based upon nutrient availability. A further refinement of this would be 
to use quantitative measurement of nutrient uptake, allowing a more robust 
constraint of nutrient supply. Jain et al. have recently measured the consumption 
production rates of 219 metabolites across the NCI-60 cancer cell line collection 
[300]. Although this has the limitation that the study used transformed cell lines, 
it does provide the most comprehensive set of quantitative data that could be used 
to constrain exchange sets for a GSMN.  
A flexible network design does not only impact on the prediction of objective 
values such as biomass. Approaches such as reaction essentiality analysis rely on 
determining potential alternate routes by which metabolites can be produced or 
consumed. The more flexible a network, the more likely that a biologically 
infeasible solution will be provided, increasing the false negative rate. This not 
only motivates further (quantitative) constraint of GSMNs, but emphasises the 
need for experimental confirmation of predictions. The choice of objective 
function can also have an impact on predictions, as was see in the example of 
cardiolipin synthase. As this enzyme produces metabolites that contribute to the 
biomass reaction it was highlighted as essential. This highlights the need for 
careful consideration of the objective function, as it can have a significant impact 
on the computational predictions. Biomass appears a logical choice for rapidly 
growing tumour cells, but there is not enough empirical evidence at present to 
determine if this is a correct assumption.  
To summarize, current computational approaches are limited by a lack of 
biological data on reaction rates and substance quantities. Without these data to 
constrain GSMN-based models the solution space is increased, meaning that FBA 
and reaction essentiality analysis have a high false positive/negative rate. 
Generation of context-specific metabolic landscapes is less affected by this issue 
and has an improved probability to reveal unique metabolic differences, despite a 
lack of sensitivity. In all cases, the biological limitations mean that subsequent 
experimental validation is vital for any computational predictions. 
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6.4 Future work  
Future work should primarily investigate the use of SSRIs in breast cancer 
patients and expand on the metabolic analysis of the breast cancer stem cells. 
Several studies have been performed to investigate the association between the 
use of SSRIs and the related breast cancer risk [260-263]. These studies have 
reported mixed results, ranging from no risk to an increased risk. The fact that 
such studies has been performed, indicates an interest from clinicians, and the 
desire to understand any potential increase in risk. Our research indicates that 
only a subset of breast cancer patients may be at risk; therefore, any clinical study 
would need to be correctly powered to allow analysis of this group of poor 
prognosis patients. It is important to perform correct patient stratification in 
studies to investigate the relationship between SSRIs and increased breast cancer 
risk (relapse rate, development of drug resistance, and response to the therapy). 
This raises the question as to what stratification biomarker should be used. 
Further mining of the data presented in this thesis could reveal a biomarker panel 
most appropriate for successful stratification. One potential confounder is that 
depression in itself may increase the risk of breast cancer. Therefore, studies 
should ideally include appropriate controls, including patient groups with 
depression being successfully treated with drugs other than SSRIs.  
The second tier of the future work should be performed using the breast cancer 
stem cells to investigate importance of prostaglandin synthase. The metabolic 
analysis should be repeated using isolated breast cancer stem cells, and new 
transcriptomic platforms or next generation sequencing. Additionally, it would be 
informative to compare BCSC to normal breast stem cells as well as normal 
tumour cells. This would reveal cancer stem cell specific adaptations and would 
lead to improved therapeutic approach. The multi-drug resistant cancer cells 
exert the same protective mechanisms as normal stem cells [301]; therefore, 
research should focus on the breast cancer stem cell analysis, in order to finally 
design an effective, patient specific therapeutic strategy.  
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7 Supplementary information  
 
 
 
 
 
 
Figure 41 Calibration curve of the ELISA experiments.  
Standards were prepared as per manufactures instruction (chapter2).  
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Cluster Cluster size Tumour size 
(mm) 
Age (years) Grade 1 (%) Grade 2 (%) Grade 3 (%) NPI status 
1 89 27.53 (16.05) 61 (12) 15% 48% 37% 3.84 (1.08) 
2 197 24.85 (15.34) 60 (12) 9% 53% 38% 3.94 (1.07) 
3 129 28.86 (20.80) 59 (13) 12% 33% 56% 4.28 (1.15) 
4 183 26.37( 12.54) 64 (12) 7% 51% 43% 4.05 (1.03) 
5 116 25.95 (10.72) 60 (12) 4% 41% 54% 4.13 (0.97) 
6 69 22.98 (9.42) 60 (10) 4% 51% 45% 4.12 (1.01) 
7 83 25.44 (11.86) 57 (12) 7% 33% 60% 4.17 (1.07) 
8 131 28.29 (19.15) 56 (13) 1% 17% 82% 4.64 (0.97) 
Table 21 Characterization of the Discovery set metabolic clusters 
Tables provides clinical characteristics of eight metabolic clusters. Cluster size – total number of patients in each cluster, tumour size 
shows mean and standard deviation (SD) in mm, age shows means and SD, grade shows proportion of samples belonging to each grade 
in %, Nottingham prognostic index (NPI) status shows is described by mean and SD
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